National Institute on Aging
National Institutes of Health 		NIA Home
Research Programs
Intramural
Bibliography
Dan L. Longo, M.D., F.A.C.P.

  1. Longo, D., Kwan, C., Cherrick, H., and Apirion, D.: Escherichia coli strains with modified RNase II activity: isolation and properties. Molec. Gen. Genetics 110: 54-60, 1971.

  2. Corte, G., Schlessinger, D., Longo, D., and Venkov, P.: Transformation of 17S to 16S ribosomal RNA using ribonuclease II of Escherichia coli. J. Molec. Biol. 60: 325-338, 1971.

  3. Venkov, P., Schlessinger, D., and Longo, D.: Inhibition of ribonuclease II of Escherichia coli by sodium ions, adenosine-5'-triphosphate, and transfer ribonucleic acid. J. Bacteriol. 108: 601-603, 1971.

  4. Longo, D.L.: Mechanisms of renal disease. An audiovisual educational tool to introduce the genitourinary system in a course in systemic pathology. University of Missouri-Columbia Educational Resources Group, 1974.

  5. Longo, D.L. and Herbert, V.: Radioassay for serum and red cell folate. J. Lab. Clin. Med. 87: 138-151, 1976.[Abs]

  6. Longo, D.L., Senhauser, D.A., Taylor, D.D., and Lucas, F.V.: University of Missouri-Columbia School of Medicine Postsophomore Pathology Fellowship Program. J. Med. Education 51: 340-342, 1976.

  7. Mease, A.D., Longo, D.L., and Hakami, N.: Sicklemia and unexpected death in sickle cell trait: observations of five cases. Military Med. 141: 470-473, 1976.

  8. Colman, N., Longo, D.L., and Herbert, V.: Folate radioassay and crude milk binder. Blood 48: 626-627, 1976.

  9. Grim, C.E., Keitzer, W.F., Esterly, J.A., and Longo, D.L.: The inappropriate secretion of aldosterone associated with adrenal hyperplasia. University of Michigan Med. J. 42: 54-59, 1976.

  10. Longo, D.L.: Hypokalemia in leukemia. Blood 50: 749, 1977.

  11. Longo, D.L. and Larsen, P.R.: Evaluation of suspected thyroid dysfunction. Comprehensive Therapy 3: #ll, l6-22, 1977.

  12. Longo, D.L., Esterly, J.A., Grim, C.E., and Keitzer, W.F.: Pathology of the adrenal gland in refractory low-renin hypertension. Arch. Pathol. Lab. Med. 102: 322-327, 1978.[Abs]

  13. Das, K.C., Herbert, V., Colman, N., and Longo, D.L.: Unmasking covert folate deficiency in iron-deficient subjects with neutrophil hypersegmentation: dU suppression tests on lymphocytes and bone marrow. Br. J. Haematol. 39: 357-375, 1978.

  14. Longo, D.L., Whang-Peng, J., Jaffe, E., Triche, T.J., and Young, R.C.: Myeloproliferative syndromes: a unique presentation of chronic myelogenous leukemia (CML) as a primary tumor of bone. Blood 52: 793-801, 1978.[Abs]

  15. Brereton, H.D., Young, R.C., Longo, D.L., Kirkland, L.R., Berard, C.W., Jaffe, E.S., DeVita, V.T., and Johnson, R.E.: A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non-Hodgkin's lymphoma. Cancer 43: 2227-2231, 1979.[Abs]

  16. Longo, D.L. and Young, R.C.: Cosmetic talc and ovarian cancer. Lancet ii: 349-351, 1979. Letter, ii, 1009-1012, 1979.

  17. Longo, D.L. and Witherspoon, J.M.: Focal neurologic symptoms in hypercalcemia. Neurology 30: 200-201, 1980.[Abs]

  18. Kirkland, T.N., Sieckmann, D.G., Longo, D.L., and Mosier, D.E.: Cellular requirements for antigen presentation in the induction of a thymus-independent antibody response in vitro. J. Immunol. 124: 1721-1726, 1980.[Abs]

  19. Longo, D.L. and Young, R.C.: Ovarian cancer: current treatment and new prospects. In van Ossterom, A. and Muggia, F.M. (Eds.): Therapeutic Progress in Ovarian Cancer, Testicular Cancer and the Sarcomas. The Hague, Martinus Nijhoff Publishers, 1980, pp. 61-75.

  20. Longo, D.L., Schilsky, R.L., Blei, L., Cano, R., Johnston, G.S., and Young, R.C.: Gallium-67 scanning: limited usefulness in staging patients with non-Hodgkin's lymphoma. Am. J. Med. 68: 695-700, 1980. [Abs]

  21. Longo, D.L. and Schwartz, R.H.: Gene complementation: neither Ir-GL gene need be present in the proliferative T cell to generate an immune response to poly (Glu55Lys36Phe9)n. J. Exp. Med. 151: 1452-1467, 1980.[Abs]

  22. Longo, D.L.: More on lithium and leukemia. N. Engl. J. Med. 303: 283, 1980.

  23. Longo, D.L. and Schwartz, R.H.: T-cell specificity for H-2 and Ir gene phenotype correlates with the phenotype of thymic antigen-presenting cells. Nature 287: 44-46, 1980.[Abs]

  24. Longo, D.L. and Schwartz, R.H.: Inhibition of antigen-induced proliferation of T cells from radiation-induced bone marrow chimeras by a monoclonal antibody directed against an Ia determinant on the antigen-presenting cell. Proc. Natl. Acad. Sci. USA 78: 514-518, 1981.[Abs]

  25. Longo, D.L., Matis, L.A., and Schwartz, R.H.: Insights into immune response gene function from experiments with chimeric animals. CRC Crit. Rev. Immunol. 2: 83-132, 1981.

  26. Longo, D.L. and Young, R.C.: The natural history and treatment of ovarian cancer. Annu. Rev. Med. 32: 475-490, 1981.[Abs]

  27. Seigel, L.J. and Longo, D.L.: The control of chemotherapy-induced emesis. Ann. Intern. Med. 95: 352-359, 1981.[Abs]

  28. Rubinstein, D.B. and Longo, D.L.: Peripheral destruction of platelets in chronic lymphocytic leukemia: recognition, prognosis and therapeutic implications. Am. J. Med. 71: 729-732, 1981.[Abs]

  29. Glimcher, L.H., Longo, D.L., Green, I., and Schwartz, R.H.: Murine syngeneic mixed lymphocyte response. I. Target antigens are self Ia molecules. J. Exp. Med. 154: 1652-1670, 1981.

  30. Longo, D.L., Young, R.C., and DeVita, V.T.: What is so good about the `good prognosis' lymphomas? In Williams, C.J. and Whitehouse, J.M.A. (Eds.): Recent Advances in Clinical Oncology, No. 1. Edinburgh, Churchill-Livingstone, Ltd., 1982, pp. 223-231.

  31. Longo, D.L. and Paul, W.E.: Immune response genes and Ia antigens. The relationships between them and their role in lymphocyte interactions. In Parham, P. and Strominger, J.L. (Eds.): Histocompatibility Antigens Structure and Function. London, Chapman & Hall, Ltd., 1982, pp. 161-185.

  32. Tse, H.Y., Mond, J.J., and Longo, D.L.: B lymphocyte immune response gene phenotype is genetically determined. J. Exp. Med. 155: 1239-1244, 1982.[Abs]

  33. Longo, D.L., Young, R.C., and DeVita, V.T., Jr.: Chemotherapy for Hodgkin's disease: the remaining challenges. Cancer Treat. Rep. 66: 925-936, 1982.

  34. Schwartz, R.H., Glimcher, L.H., Hedrick, S.M., Singer, A., and Longo, D.L.: Restriction to thymic major histocompatibility complex (MHC) and immune response (Ir) phenotype of T cells from allogeneic chimeras. Behring Institute Research Communications. 70: 155-162, 1982 (meeting summarized in Science 214: 893-896, 1981).

  35. Blayney, D.W. and Longo, D.: Case 44-1981: radiation-induced pericarditis. N. Engl. J. Med. 306: 550, 1982.

  36. Glimcher, L.H., Schwartz, R.H., Longo, D.L., and Singer, A.: The specificity of the syngeneic mixed leukocyte response, a primary anti-I region T cell proliferative response, is determined intrathymically. J. Immunol. 129: 987-991, 1982.[Abs]

  37. Hedrick, S.M., Matis, L.A., Hecht, T.T., Samelson, L.E., Longo, D.L., Heber-Katz, E., and Schwartz, R.H.: The fine specificity of antigen and Ia determinant recognition by T cell hybridoma clones specific for pigeon cytochrome c. Cell 30: 141-152, 1982.[Abs]

  38. Longo, D.L. and DeVita, V.T., Jr.: Lymphomas. In Pinedo, H.M. (Ed.): Cancer Chemotherapy Annual 4. Amsterdam, Elsevier Science Publishers B.V., 1982, pp. 197-234.

  39. Longo, D.L., Wesley, M., Howser, D., Hubbard, S.M., Anderson, T., and Young, R.C.: Results of a randomized double-blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of cisplatin-induced emesis. Cancer Treat. Rep. 66: 1975-1976, 1982. [Abs]

  40. Thomas, J.L., Bernardino, M.E., Vermess, M., Barnes, P.A., Fuller, L.M., Hagemeister, F.B., Doppman, J., Fisher, R.I., and Longo, D.L.: EOE-l3 in the detection of hepatosplenic lymphoma. Radiology 145: 629-634, 1982.[Abs]

  41. Messerschmidt, G.L., Bowles, C., Parrillo, J., Parker, M., Shelhammer, J., Dowling, R., Osborne, L., Corbitt, R., McCormack, K., Longo, D., and Deisseroth, A.: The use of protein-A in the treatment of malignancy: rationale and the NCI experience. In Tindall, R.S.A. (Ed.): Therapeutic Apheresis and Plasma Perfusion. Proceedings of the Third National Conference on Therapeutic Apheresis, Dallas, Texas, May l3-l5, 1982. New York, Alan R. Liss, Inc., 1982, pp. 385-390.

  42. Blayney, D.W. and Longo, D.L.: Ovarian cancer: epidemiology, diagnosis, and management. Comprehensive Therapy 9: 50-58, 1983. [Abs]

  43. Matis, L.A., Longo, D.L., Hedrick, S.M., Hannum, C., Margoliash, E., and Schwartz, R.H.: Clonal analysis of the major histocompatibility complex restriction and the fine specificity of antigen recognition in the T cell proliferative response to cytochrome c. J. Immunol. 130: 1527-1535, 1983.

  44. Matis, L.A., Schwartz, R.H., Davis, M., and Longo, D.L.: The contributions of the developmental and priming environments to the expression of the T cell receptor repertoire. In Pierce, C.W., Cullen, S.E., Kapp, J.A., Schwartz, B.D., and Shreffler, D.C. (Eds.): Ir Genes: Past, Present, and Future. The Proceedings of the 5th Ir Gene Workshop. New Jersey, Humana Press, 1983, pp. 419-423.

  45. Matis, L.A., Glimcher, L., Lindgren, A., Longo, D.L., and Schwartz, R.H.: The effect of nominal antigen and Ia molecule concentrations on the magnitude of the proliferative response of T cell clones. In Pierce, C.W., Cullen, S.E., Kapp, J.A., Schwartz, B.D., and Shreffler, D.C. (Eds.): Ir Genes: Past, Present, and Future. The Proceedings of the 5th Ir Gene Workshop. New Jersey, Humana Press, 1983, pp. 439-443.

  46. Fisher, R.I., DeVita, V.T., Jr., Hubbard, S.M., Longo, D.L., Wesley, R., Chabner, B.A., and Young, R.C.: Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann. Intern. Med. 98: 304-309, 1983.[Abs]

  47. Longo, D.L. and Fisher, R.I.: Medical problems in long-term survivors of Hodgkin's disease. Internal Medicine for the Specialist 4: 165-l71, 1983.

  48. Longo, D.L. and Davis, M.L.: Early appearance of donor-type antigen-presenting cells in the thymuses of l200 R radiation-induced bone marrow chimeras correlates with self-recognition of donor I region gene products. J. Immunol. 130: 2525-2527, 1983.[Abs]

  49. Foss, F.M., Horneff, J., Longo, D.L., and Messerschmidt, G.L.: Cerebrospinal fluid rhinorrhea as a complication of malignant lymphoma. Am. J. Med. 74: 1077-1079, 1983.[Abs]

  50. Blayney, D.W., Jaffe, E.S., Blattner, W.A., Cossman, J., Robert-Guroff, M., Longo, D.L., Bunn, P.A., Jr., and Gallo, R.C.: The human T-cell leukemia/ lymphoma virus associated with American adult T-cell leukemia/lymphoma. Blood 62: 401-405, 1983.[Abs]

  51. Hecht, T.T., Longo, D.L., and Matis, L.A.: The relationship between immune interferon production and proliferation in antigen-specific, MHC-restricted T cell lines and clones. J. Immunol. 131: 1049-1055, 1983.[Abs]

  52. Macher, A.M., Reichert, C.M., Straus, S.E., Longo, D.L., Parrillo, J., Lane, H.C., Fauci, A.S., Rook, A.H., Manischewitz, J.F., and Quinnan, G.V.: Death in the AIDS patient: role of cytomegalovirus. N. Engl. J. Med. 309: 1454, 1983.

  53. Longo, D.L. and DeVita, V.T., Jr.: Lymphomas. In Pinedo, H.M. and Chabner, B.A. (Eds.): Cancer Chemotherapy Annual 5. New York, Elsevier, 1983, pp. 248-281.

  54. Straus, S.E., Armstrong, G., Seidlin, M., Horneff, J., Clark, J., Faggioni, A., Pearson, G., Ablashi, D.V., and Longo, D.: Acyclovir treatment of human herpesvirus infections: implications for the treatment of Epstein-Barr virus (EBV)-related disorders. In Prasad, et al. (Eds.): Nasopharyngeal Carcinoma: Current Concepts. Kuala Lumpur, University of Malaya, 1983, pp. 423-431.

  55. Fisher, R.I., Portlock, C.S., and Longo, D.L.: Hodgkin's disease. In Golomb, H. (Ed.): Hematology, 1983. San Francisco, American Society of Hematology, 1983, pp. 24-29.

  56. Hathcock, K.S., Singer, A., Davis, M., Longo, D., and Hodes, R.J.: The role of polymorphic MHC products in determining the T cell self-recognition repertoire. In Parker, J.W., and O'Brien, R.L. (Eds.): Intercellular Communication in Leucocyte Function. New York, John Wiley & Sons Ltd., 1983, pp. 377-380.

  57. Marti, G.E., Folks, T., Longo, D.L., and Klein, H.: Therapeutic cytapheresis in chronic lymphocytic leukemia. J. Clin. Apheresis 1: 243-248, 1983.[Abs]

  58. Armstrong, G., Longo, D., Faggioni, A., Ablashi, D., Pearson, G., and Slovin, S.: Detection and isolation of Epstein-Barr virus in lymphocytes from patients with chronic B-lymphocytic leukemia. In Magrath, I.T., O'Connor, G.T., and Ramot, B. (Eds.): Role of Environment in Pathogenesis of Leukemia and Lymphoma. New York, Raven Press, 1984, pp. 259-262.

  59. Averbuch, S.D., Austin, H.A., Sherwin, S.A., Antonovych, T., Bunn, P.A., Jr., and Longo, D.L.: Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides. N. Engl. J. Med. 310: 32-35, 1984.

  60. Longo, D.L.: Kaposi's sarcoma and other neoplasms. NIH Combined Clinical Staff Conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. A.S. Fauci, moderator. Ann. Intern. Med. 100: 96-98, 1984.

  61. Berkower, I., Matis, L.A., Buckenmeyer, G.K., Gurd, F.R.N., Longo, D.L., and Berzofsky, J.A.: Identification of distinct predominant epitopes recognized by myoglobin-specific T cells under the control of different Ir genes and characterization of representative T cell clones. J. Immunol. 132: 1370-1378, 1984.[Abs]

  62. Potter, D.A., Danforth, D.N., Jr., Macher, A.M., Longo, D.L., Stewart, L., and Masur, H.: Evaluation of abdominal pain in the AIDS patient. Ann. Surg. 199: 332-339, 1984.[Abs]

  63. Pizzo, P.A., Commers, J., Cotton, D., Gress, J., Hathorn, J., Hiemenz, J., Longo, D., Marshall, D., and Robichaud, K.J.: Approaching the controversies in antibacterial management of cancer patients. Am. J. Med. 76: 436-449, 1984. [Abs]

  64. Mongini, P.K.A., Longo, D.L., and Paul, W.E.: T cell regulation of immunoglobulin class expression in the B cell response to TNP-ficoll: characterization of the T cell responsible for preferential enhancement of the IgG2a response. J. Immunol. 132: 1647-1653, 1984.[Abs]

  65. Silver, M.A., Macher, A.M., Reichert, C.M., Levens, D.L., Parrillo, J.E., Longo, D.L., and Roberts, W.C.: Cardiac involvement by Kaposi's sarcoma in acquired immune deficiency syndrome (AIDS). Am. J. Cardiol. 53: 983-985, 1984.

  66. Longo, D.L., Young, R.C., Hubbard, S.M., Wesley, M., Fisher, R.I., Jaffe, E., Berard, C., and DeVita, V.T., Jr.: Prolonged initial remission in patients with nodular mixed lymphoma. Ann. Intern. Med. 100: 651-656, 1984.[Abs]

  67. Cossman, J., Neckers, L.M., Hsu, S.M., Longo, D., and Jaffe, E.S.: Low-grade lymphomas: expression of developmentally regulated B-cell antigens. Am. J. Pathol. 115: 117-124, 1984.[Abs]

  68. Young, R.C., Fisher, R.I., Longo, D.L., and DeVita, V.T., Jr.: Non-Hodgkin's lymphoma: evolution of the NCI approach to management. In Ogawa, M., Muggia, F.M., and Rozencweig, M. (Eds.): Adriamycin: Its Expanding Role in Cancer Treatment. Amsterdam, Excerpta Medica, 1984, pp. 31-42.

  69. Kovacs, J.A., Hiemenz, J.W., Macher, A.M., Stover, D., Murray, H.W., Shelhamer, J., Lane, H.C., Urmacher, C., Honig, C., Longo, D.L., Parker, M.M., Natanson, C., Parrillo, J.E., Fauci, A.S., Pizzo, P.A., and Masur, H.: Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann. Intern. Med. 100: 663-671, 1984. [Abs]

  70. Longo, D.L., Gelmann, E.P., Cossman, J., Young, R.A., Gallo, R.C., O'Brien, S.J., and Matis, L.A.: Isolation of HTLV-transformed B-lymphocyte clone from a patient with HTLV-associated adult T-cell leukaemia. Nature 310: 505-506, 1984.[Abs]

  71. Kruisbeek, A.M., Davis, M.L., Matis, L.A., and Longo, D.L.: Self-recognition specificity expressed by T cells from nude mice. Absence of detectable Ia-restricted T cells in nude mice that do exhibit self-K/D-restricted T cell responses. J. Exp. Med. 160: 839-857, 1984.[Abs]

  72. Helman, L.J., Ozols, R.F., and Longo, D.L.: Thrombocytopenia and extragonadal germ-cell neoplasm. Ann. Intern. Med. 101: 280, 1984.

  73. Young, R.C., Fisher, R.I., Longo, D.L., Bender, R.A., and DeVita, V.T., Jr.: Activity of the epipodophyllotoxin VP-l6 in diffuse large-cell lymphomas. In Issell, B.F., Muggia, F.M., and Carter, S.K. (Eds.): Etoposide (VP-l6): Current Status and New Developments. New York, Academic Press, 1984, pp. 301-311.

  74. Bunn, P.A., Jr., Foon, K.A., Ihde, D.C., Longo, D.L., Eddy, J., Winkler, C.F., Veach, S.R., Zeffren, J., Sherwin, S., and Oldham, R.: Recombinant leukocyte A interferon: An active agent in advanced cutaneous T-cell lymphomas. Ann. Intern. Med. 101: 484-487, 1984.[Abs]

  75. Lane, H.C., Masur, H., Longo, D.L., Klein, H.G., Rook, A.H., Quinnan, G.V., Jr., Steis, R.G., Macher, A., Whalen, G., Edgar, L.C., and Fauci, A.S.: Partial immune reconstitution in a patient with the acquired immunodeficiency syndrome. N. Engl. J. Med. 311: 1099-1103, 1984.

  76. Foon, K.A., Sherwin, S.A., Abrams, P.G., Longo, D.L., Fer, M.F., Stevenson, H.C., Ochs, J.J., Bottino, G.C., Schoenberger, C.S., Zeffren, J., Jaffe, E.S., and Oldham, R.K.: Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N. Engl. J. Med. 311: 1148-1152, 1984.[Abs]

  77. Lotze, M.T., Robb, R.J., Frana, L.W., Seipp, C.A., Sharrow, S.S., Longo, D.L., Gelmann, E.P., and Rosenberg, S.A.: Clinical studies with purified human IL-2 in patients with the acquired immunodeficiency syndrome and cancer. In Gottlieb, M.S. and Groopman, J.D. (Eds.): Acquired Immune Deficiency Syndrome. New York, Alan R. Liss, Inc., 1984, pp. 409-423.

  78. Palestine, A.G., Rodrigues, M.M., Macher, A.M., Chan, C-C., Lane, H.C., Fauci, A.S., Masur, H., Longo, D., Reichert, C.M., Steis, R., Rook, A.H., and Nussenblatt, R.B.: Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmol. 91: 1092-1099, 1984.[Abs]

  79. Boccia, R.V., Gelmann, E.P., Baker, C.C., Marti, G., and Longo, D.L.: A hemolytic-uremic syndrome with the acquired immunodeficiency syndrome. Ann. Intern. Med. 101: 716-717, 1984.

  80. Longo, D.L. and DeVita, V.T.: Lymphoma. In Pinedo, H.M. and Chabner, B.A. (Eds.): Cancer Chemotherapy Annual 6. Amsterdam, Elsevier Science Publishers B.V., 1984, pp. 232-271.

  81. Longo, D.L.: Hodgkin's disease. In Gams, R.A. (Ed.): Hematology. Miami, American Society of Hematology, 1984, pp. 14-19.

  82. Kruisbeek, A.M., Matis, L.A., and Longo, D.L.: Thymic dependence of the class II- restricted T cell repertoire: Role of bone marrow-derived IA-bearing thymic medullary antigen presenting cells. In Cantor, H., Chess, L., and Sercarz, E. (Eds.): Regulation of the Immune System, UCLA Symposium on Molecules and Cellular Biology, New Series, Vol. 18. New York, Alan R. Liss, 1984, pp. 243-251.

  83. Longo, D.L. and Broder, S.: Human T-cell leukemia/lymphoma virus (HTLV)- associated adult T-cell leukemia. Medical Grand Rounds 3: 239-249, 1984.

  84. Patow, C.A., Steis, R., Longo, D.L., Reichert, C.M., Findlay, P.A., Potter, D., Masur, H., Lane, H.C., Fauci, A.S., and Macher, A.M.: Kaposi's sarcoma of the head and neck in the acquired immune deficiency syndrome. Otolaryngol. Head Neck Surg. 92: 255-260, 1984.[Abs]

  85. Patow, C.A., Stark, T.W., Findlay, P.A., Steis, R., Longo, D.L., Masur, H., and Macher, A.M.: Pharyngeal obstruction by Kaposi's sarcoma in a homosexual male with the acquired immune deficiency syndrome. Otolaryngol. Head Neck Surg. 92: 713-716, 1984.[Abs]

  86. Shelhamer, J.H., Ognibene, F.P., Macher, A.M., Tuazon, C., Steis, R., Longo, D., Kovacs, J.A., Parker, M.M., Natanson, C., Lane, H.C., Fauci, A.S., Parrillo, J.E., and Masur, H.: Persistence of Pneumocystis carinii in lung tissue of acquired immunodeficiency syndrome patients treated for pneumocystis pneumonia. Am. Rev. Respir. Dis. 130: 1161-1165, 1984.[Abs]

  87. Preble, O.T., Rook, A.H., Steis, R., Silverman, R.H., Krause, D., Quinnan, G.V., Masur, H., Jacob, J., Longo, D., and Gelmann, E.P.: Interferon-induced 2'-5' oligoadenylate synthetase during interferon- therapy in homosexual men with Kaposi's sarcoma: Marked deficiency in biochemical response to interferon in patients with acquired immunodeficiency syndrome. J. Infect. Dis. 152: 457-465, 1985. [Abs]

  88. Muraguchi, A., Kehrl, J.H., Longo, D.L., Volkman, D.J., Smith, K.A., and Fauci, A.S.: Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function. J. Exp. Med. 161: 181-197, 1985.[Abs]

  89. Foon, K.A., Bottino, G.C., Abrams, P.G., Fer, M.F., Longo, D.L., Schoenberger, C.S., and Oldham, R.K.: Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. Am. J. Med. 78: 216-220, 1985.[Abs]

  90. Young, R.C., Fisher, R.I., and Longo, D.L.: NonHodgkin's disease: Unfavorable lymphomas. In Brain, M.C. and Carbone, P.P. (Eds.): Current Therapy in Hematology-Oncology. Toronto, B.C. Decker, Inc., 1985, pp. 280-284.

  91. Lane, H.C., Masur, H., Gelmann, E.P., Longo, D.L., Steis, R.G., Chused, T., Whalen, G., Edgar, L.C., and Fauci, A.S.: Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am. J. Med. 78: 417-422, 1985.[Abs]

  92. Longo, D.L., Steis, R.G., Lane, H.C., Lotze, M.T., Rosenberg, S.A., Preble, O., Masur, H., Rook, A.H., Fauci, A.S., Jacob, J., and Gelmann, E.P.: Malignancies in the AIDS patient: Natural history, treatment strategies, and preliminary results. Ann. N.Y. Acad. Sci. 437: 421-430, 1985.

  93. Kruisbeek, A.M., Mond, J.J., Fowlkes, B.J., Carmen, J.A., Bridges, S., and Longo, D.L.: Absence of the Lyt-2-, L3T4+ lineage of T cells in mice treated neonatally with anti-I-A correlates with absence of intrathymic I-A-bearing antigen-presenting cell function. J. Exp. Med. 161: 1029-1047, 1985.[Abs]

  94. Kruisbeek, A.M., Bridges, S., Carmen, J., Longo, D.L., and Mond, J.J.: In vivo treatment of neonatal mice with anti-I-A antibodies interferes with the development of the class I, class II, and M1s-reactive proliferating T cell subset. J. Immunol. 134: 3597-3604, 1985.[Abs]

  95. Kruisbeek, A.M., Titus, J.A., Stephany, D.A., Gause, B.L., and Longo, D.L.: In vivo treatment with monoclonal anti-I-A antibodies: disappearance of splenic antigen-presenting cell function concomitant with modulation of splenic cell surface I-A and I-E antigens. J. Immunol. 134: 3605-3614, 1985.[Abs]

  96. Hecht, T.T., Longo, D.L., Cossman, J., Bolen, J.B., Hsu, S., Israel, M., and Fisher, R.I.: Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells. J. Immunol. 134: 4231-4236, 1985. [Abs]

  97. Matis, L.A., Ruscetti, S.K., Longo, D.L., Jacobson, S., Brown, E.J., Zinn, S., and Kruisbeek, A.M.: Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen. J. Immunol. 135: 703-713, 1985.[Abs]

  98. Kruisbeek, A.M. and Longo, D.L.: Acquisition of MHC-restriction specificities: Role of thymic stromal cells. Surv. Immunol. Res. 4: 110-119, 1985.

  99. Geffen, D.B., Fisher, R.I., Longo, D.L., Young, R.C., and DeVita, V.T., Jr.: Renal involvement in diffuse aggressive lymphomas: results of treatment with combination chemotherapy. J. Clin. Oncol. 3: 646-653, 1985. [Abs]

  100. Urba, W.J. and Longo, D.L.: Cytologic, immunologic, and clinical diversity in non-Hodgkin's lymphoma: therapeutic implications. Semin. Oncol. 12: 250-267, 1985.

  101. Seifter, E.J., Parker, R.I., Gralnick, H.R., Wesley, M., DeVita, V.T., Jr., Young, R.C., and Longo, D.L.: Abnormal coagulation results in patients with Hodgkin's disease. Am. J. Med. 78: 942-950, 1985.[Abs]

  102. Waldmann, T.A., Longo, D.L., Leonard, W.J., Depper, J.M., Thompson, C.B., Kronke, M., Goldman, C.K., Sharrow, S., Bongiovanni, K., and Greene, W.C.: Interleukin-2 receptor (Tac antigen) expression in HTLV-I-associated adult T cell leukemia. Cancer Res. 45: 4559-4562, 1985.[Abs]

  103. Urba, W.J. and Longo, D.L.: Clinical spectrum of human retroviral-induced diseases. Cancer Res. 45: 4637-4643, 1985.

  104. Jaffe, E.S., Clark, J., Steis, R., Blattner, W., Macher, A.M., Longo, D.L., and Reichert, C.M.: Lymph node pathology of HTLV and HTLV associated neoplasms. Cancer Res. 45: 4662-4664, 1985.[Abs]

  105. Raffeld, M., Neckers, L., Longo, D.L., and Cossman, J.: Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by anti-idiotype. N. Engl. J. Med. 312: 1653-1658, 1985.[Abs]

  106. Longo, D.L., Kruisbeek, A.M., Davis, M.L., and Matis, L.A.: Bone marrow-derived thymic antigen-presenting cells determine self-recognition of Ia-restricted T lymphocytes. Proc. Natl. Acad. Sci. USA 82: 5900-5904, 1985. [Abs]

  107. Tomita, S., Ambrus, J.L., Volkman, D.J., Longo, D.L., Mitsuya, H., Reitz, M.S., and Fauci, A.S.: Human T cell leukemia/lymphoma virus I infection and subsequent cloning of normal human B cells. J. Exp. Med. 162: 393-398, 1985.[Abs]

  108. Longo, D.L. and DeVita, V.T., Jr.: Lymphomas. In Pinedo, H.M. and Chabner, B.A. (Eds.): Cancer Chemotherapy Annual 7. Amsterdam, Elsevier Science Publishers B.V., 1985, pp. 237-272.

  109. Bates, S.E. and Longo, D.L.: Tumor markers: Value and limitations in the management of cancer patients. Cancer Treat. Rev. 12: 163-207, 1985.[Abs]

  110. Gelmann, E.P., Preble, O.T., Steis, R., Lane, H.C., Rook, A.H., Wesley, M., Jacob, J., Fauci, A., Masur, H., and Longo, D.: Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome: clinical response and prognostic parameters. Am. J. Med. 78: 737-741, 1985.[Abs]

  111. Seifter, E.J., Young, R.C., and Longo, D.L.: Deep venous thrombosis during therapy for Hodgkin's disease. Cancer Treat. Rep. 69: 1011-1013, 1985.[Abs]

  112. Pizzo, P.A., Thaler, M., Hathorn, J., Hiemenz, J., Skelton, J., McKnight, J., Rubin, M., Browne, M., Longo, D., Cotton, D., Gress, J., and Marshall, D: New beta-lactam antibiotics in granulocytopenic patients: New options and new questions. Am. J. Med. 79 (suppl. 2A): 75-82, 1985. [Abs]

  113. Boccia, R.V., Longo, D.L., Lieber, M.L., Jaffe, E.S., and Fisher R.I.: Multiple recurrences of acute tumor lysis syndrome in an indolent non-Hodgkin's lymphoma. Cancer 56: 2295-2297, 1985.[Abs]

  114. Potter, D., Pass, H.I., Brower, S., Macher, A., Browne, M., Thaler, M., Cotton D., Hathorn J., Wesley, R., Longo, D., Pizzo, P., and Roth, J.A.: Prospective randomized study of open lung biopsy versus empirical antibiotic therapy for acute pneumonitis in nonneutropenic cancer patients. Ann. Thorac. Surg. 40: 422-428, 1985. [Abs]

  115. Fisher, R.I., Young, R.C., Longo, D., and DeVita, V.T.: ProMACE-MOPP combination chemotherapy for diffuse lymphomas. Semin. Oncol. 12: 29-32, 1985.[Abs]

  116. Fisher, R.I., Bates, S.E., Volkman, D.J., Diehl, V., Hecht, T.T., and Longo, D.L.: Origin and biologic function of Reed-Sternberg cells. In Cavalli, F., Bonadonna, G., and Rozencweig, M. (Eds.): Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. Boston, Martinus Nijhoff Publishers, 1985, pp. 17-24.

  117. Longo, D.L., Steis, R.G., Masur, H., Lane, H.C., Preble, O., Fauci, A.S., and Gelmann, E.P.: Acquired immune deficiency syndrome (AIDS): Basic findings. In Cavalli, F., Bonadonna, G., and Rozencweig, M. (Eds.): Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. Boston, Martinus Nijhoff Publishers, 1985, pp. 245-250.

  118. Young, R.C., Longo, D.L., Glatstein, E., Duffey, P.L., Winkler, C.F., Wiernik, P.H., and DeVita, V.T., Jr.: The current status of NCI trials in Hodgkin's disease. In Cavalli, F., Bonadonna, G., and Rozencweig, M. (Eds.): Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. Boston, Martinus Nijhoff Publishers, 1985, pp. 293-298.

  119. Fisher, R.I., DeVita, V.T., Jr., Longo, D.L., Ihde, D.C., and Young, R.C.: Treatment of diffuse large cell non-Hodgkin's lymphomas. In Cavalli, F., Bonadonna, G., and Rozencweig, M. (Eds.): Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. Boston, Martinus Nijhoff Publishers, 1985, pp. 465-470.

  120. Bunn, P.A., Foon, K.A., Ihde, D.C., Longo, D., Schroff, R., Minna, J.D., Carrasquillo, J., Kennan, A., Larson, S., and Glatstein, E.: Treatment of cutaneous T-cell lymphomas with biologic response modifiers: Recombinant leukocyte A interferon and T101 monoclonal antibody. In Cavalli, F., Bonadonna, G., and Rozencweig, M. (Eds.): Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. Boston, Martinus Nijhoff Publishers, 1985, pp. 579-590.

  121. Little, C. and Longo, D.L.: Non-Hodgkin's lymphomas: epidemiology, etiology, pathology, natural history, and disease evolution. In Moossa, A.R., Robson, M.C., and Schimpff, S.C. (Eds.): Comprehensive Textbook of Oncology. Baltimore, Williams and Wilkins, 1986, pp. 574-580.

  122. Little, C. and Longo, D.L.: Non-Hodgkin's lymphoma: diagnosis and management. In Moossa, A.R., Robson, M.C., and Schimpff, S.C. (Eds.): Comprehensive Textbook of Oncology. Baltimore, Williams and Wilkins, 1986, pp. 581-592.

  123. Little, C. and Longo, D.L.: Burkitt's lymphoma. In Moossa, A.R., Robson, M.C., and Schimpff, S.C. (Eds.): Comprehensive Textbook of Oncology. Baltimore, Williams and Wilkins, 1986, pp. 593-597.

  124. Browne, M.J., Hubbard, S.M., Longo, D.L., Fisher, R., Wesley, R., Ihde, D.C., Young, R.C., and Pizzo, P.A.: Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy. Ann. Intern. Med. 104: 338-344, 1986.[Abs]

  125. Clark, J.W., and Longo, D.L.: Biological response modifiers. In Wiernik, P.H. (Ed.): Mediguide to Oncology 6: 1-10, 1986.

  126. Dmitrovsky, E., Martin, S.E., Krudy, A.G., Chu, E.W., Jaffe, E.S., Longo, D.L., and Young, R.C.: Lymph node aspiration in the management of Hodgkin's disease. J. Clin. Oncol. 4: 306-310, 1986.[Abs]

  127. Pass, H.I., Potter, D., Shelhammer, J., Macher, A., Ognibene, F.P., Longo, D.L., Gelmann, E., Masur, H., and Roth, J.A.: Indications for and diagnostic efficacy of open-lung biopsy in the patient with acquired immunodeficiency syndrome (AIDS). Ann. Thorac. Surg. 41: 307-312, 1986. [Abs]

  128. Fisher, R.I., DeVita, V.T., Jr., Longo, D.L., and Young, R.C.: Treatment of diffuse aggressive lymphoma with ProMACE-based combination chemotherapy. In Skarin, A.T. (Ed.): Update on Treatment for Diffuse Large Cell Lymphoma. New York, Park Row Publishers, 1986, pp. 31-35.

  129. Urba, W.J. and Longo, D.L.: Primary solid tumors of the heart. In Kapoor, A.S. (Ed.): Cancer and the Heart. New York, Springer Verlag, 1986, pp. 62-75.

  130. Kant, J.A., Hubbard, S.M., Longo, D.L., Simon, R.M., DeVita, V.T., Jr., and Jaffe, E.S.: The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin's disease. J. Clin. Oncol. 4: 284-294, 1986.[Abs]

  131. Matis, L.A., Young R.C., and Longo, D.L.: Nodular lymphomas: current concepts. CRC Crit. Rev. Oncol./Hematol. 5: 171-192, 1986. [Abs]

  132. Foon, K.A., Nakano, G.M., Koller, C.A., Longo, D.L., and Steis, R.G.: Response to 2'-deoxycoformycin after failure of interferon- in nonsplenectomized patients with hairy cell leukemia. Blood 68: 297-300, 1986.[Abs]

  133. Pizzo, P.A., Hathorn, J.W., Hiemenz, J., Browne, M., Commers, J., Cotton, D., Gress, J., Longo, D., Marshall, D., McKnight, J., Rubin, M., Skelton, J., Thaler, M., and Wesley, R.: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N. Engl. J. Med. 315: 552-558, 1986.[Abs]

  134. Longo, D.L., Young, R.C., Wesley, M., Hubbard, S.M., Duffey, P.L., Jaffe, E.S., and DeVita, V.T., Jr.: Twenty years of MOPP therapy for Hodgkin's disease. J. Clin. Oncol. 4: 1295-1306, 1986.[Abs]

  135. Bookman, M.A. and Longo, D.L.: Concomitant illness in patients treated for Hodgkin's disease. Cancer Treat. Rev. 13: 77-111, 1986.

  136. Longo, D.L., DeVita, V.T., Jr., and Hubbard, S.M.: Non-Hodgkin's lymphomas. In Slevin, M.L., and Staquet, M.J. (Eds.): Randomized Trials in Cancer: A Critical Review by Sites. New York, Raven Press, 1986, pp. 91-130.

  137. Kruisbeek, A.M. and Longo, D.L.: Treatment of neonatal mice with anti-I-A antibodies: lessons on T cell development. In Brochier, J., Clot, J., and Sany, J. (Eds.): Immune Intervention: Anti-Ia Antibodies in the Treatment of Autoimmune Disease. London, Academic Press, 1986, pp. 51-57.

  138. Longo, D.L. and DeVita, V.T., Jr.: Malignant lymphomas. In Pinedo, H.M., and Chabner, B.A. (Eds.): Cancer Chemotherapy Annual 8. Amsterdam, Elsevier Science Publishers B.V., 1986, pp. 262-304.

  139. Longo, D.L. and Broder, S.: Plasma cell disorders. In Braunwald, E., Isselbacher, K.J., Petersdorf, R.G., Wilson, J.D., Martin, J.B., and Fauci, A.S. (Eds.): Harrison's Principles of Internal Medicine, 11th Edition. New York, McGraw-Hill, 1986, pp. 1396-1403.

  140. Perez, P., Titus, J.A., Lotze, M.T., Cuttitta, F., Longo, D.L., Groves, E.S., Rabin, H., Durda P.J., and Segal, D.M.: Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody. J. Immunol. 137: 2069-2072, 1986.[Abs]

  141. Longo, D., Klimo, P., and Korsmeyer, S.J.: Malignant lymphomas. ASCO Educational Booklet, 119-134, 1986.

  142. Urba, W.J. and Longo, D.L.: Alpha-interferon in the treatment of nodular lymphomas. Semin. Oncol. 13: 40-47, 1986.[Abs]

  143. Edington, H., Salwitz, J., Longo, D.L., Roth, J.A., and Pass, H.: Thymic hyperplasia masquerading as recurrent Hodgkin's disease: Case report and review of the literature. J. Surg. Oncol. 33: 120-123, 1986.[Abs]

  144. Simrell, C.R., Boccia, R.V., Longo, D.L., and Jaffe, E.S.: Coexisting Hodgkin's disease and mycosis fungoides: Immunohistochemical proof of its existence. Arch. Pathol. Lab. Med. 110: 1029-1034, 1986.[Abs]

  145. Young, R.C., Fisher, R.I., and Longo, D.L.: NonHodgkin's disease: Unfavorable lymphomas. In Bayless T.M., Brain M.C., and Cherniack R.M. (Eds.): Current Therapy in Internal Medicine - 2. B.C. Decker Inc., Toronto, Philadelphia, 1987, pp. 386-390.

  146. Beckner, S.K. and Longo, D.L.: Media for LAK cell generation. Cancer Treat. Rep. 71: 104, 1987.

  147. Blayney, D.W., Longo, D.L., Young, R.C., Greene, M.H., Hubbard, S.M., Postal, M.G., Duffey, P.L., and DeVita, V.T., Jr.: Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N. Engl. J. Med. 316: 710-714, 1987.[Abs]

  148. Gelmann, E.P., Longo, D., Lane, H.C., Fauci, A.S., Masur, H., Wesley, M., Preble, O.T., Jacob, J., and Steis, R.: Combination chemotherapy of disseminated Kaposi's sarcoma in patients with the acquired immune deficiency syndrome. Am. J. Med. 82: 456-462, 1987.[Abs]

  149. DeVita, V.T., Jr., Longo, D.L., Hubbard, S.M., Young, R.C., and Chabner, B.A.: The lymphomas: Biologic implications of therapy and therapeutic implications of the new biology. In Berard, C.W., Dorfman, R.F., Kaufman, N. (Eds.): Malignant Lymphomas. Baltimore, Williams & Wilkins, 1987, pp. 249-267.

  150. Steis, R.G., Foon, K.A., and Longo, D.L.: Current and future uses of recombinant interferon alpha in the treatment of low-grade non-Hodgkin's lymphoma. Cancer 59: 658-663, 1987.

  151. Fauci, A.S., Rosenberg, S.A., Sherwin, S.A., Dinarello, C.A., Longo, D.L., and Lane, H.C.: Immunomodulators in clinical medicine. Ann. Intern. Med. 106: 421-433, 1987.[Abs]

  152. Longo, D.L.: Biological therapy of cancer. In Fortner, J.G. and Rhoads, J.E. (Eds.): Accomplishments in Cancer Research. Philadelphia, J.B. Lippincott Company, 1987, pp. 233-257.

  153. Clark, J.W. and Longo, D.L.: Interferons in cancer therapy. In DeVita, V.T., Jr., Hellman, S., and Rosenberg, S.A. (Eds.): 2nd Edition Cancer Principles and Practices of Oncology Updates Vol. 1. Philadelphia, J.B. Lippincott Company, 1987, No. 4, pp. 1-16.

  154. Raffeld, M., Wright, J.J., Lipford, E., Cossman, J., Longo, D.L., Bakhshi, A., and Korsmeyer, S.J.: Clonal evolution of t(l4;l8) follicular lymphomas demonstrated by immunoglobulin genes and the 18q21 major breakpoint region. Cancer Res. 47: 2537-2542, 1987.[Abs]

  155. Longo, D.L.: Tumor markers: current status of the quest - introductory overview. Semin. Oncol. 14: 85-88, 1987.

  156. Bates, S.E. and Longo, D.L.: Use of serum tumor markers in cancer diagnosis and management. Semin. Oncol. 14: 102-138, 1987.

  157. Gregg, E.O., Bridges, S.H., Youle, R.J., Longo, D.L., Houston, L.L., Glennie, M.J., Stevenson, F.K., and Green, I.: Whole ricin and recombinant ricin a chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia. J. Immunol. 138: 4502-4508, 1987.[Abs]

  158. Ashwell, J.D., Longo, D.L., and Bridges, S.H.: T-cell tumor elimination as a result of T-cell receptor-mediated activation. Science 237: 61-64, 1987.[Abs]

  159. Giardina, S.L., Evans, S.W., Gandino, L., Robey, F.A., Bonvini, E., Longo, D.L., and Varesio, L.: Generation of a murine monoclonal antibody that detects the fos oncogene product. Anal. Biochem. 161: 109-116, 1987.[Abs]

  160. Beckner, S.K., Maluish, A.E., and Longo, D.L.: Lymphokine-activated killer cells: culture conditions for the generation of maximal in vitro cytotoxicity in cells from normal donors. Cancer Res. 47: 5504-5508, 1987. [Abs]

  161. Jaffe, E.S., Bookman, M.A., and Longo, D.L.: Lymphocytic lymphoma of intermediate differentiation-mantle zone lymphoma: A distinct subtype of B-cell lymphoma. Hum. Pathol. 18: 877-880, 1987.

  162. Hamilton, T.C., Ozols, R.F., and Longo, D.L.: Biologic therapy for the treatment of malignant common epithelial tumors of the ovary. Cancer 60: 2054-2063, 1987.[Abs]

  163. DeVita, V.T., Jr., Hubbard, S.M., and Longo, D.L.: The chemotherapy of lymphomas: Looking back, moving forward - The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 47: 5810-5824, 1987.

  164. Longo, D.L. and Broder, S.: Lymphoproliferative disorders. In Samter, M., Talmadge, D.W., Frank, M.M., Austen, K.F., and Claman, H.N. (Eds.): Immunological Diseases, Fourth Edition. Boston, Little, Brown and Company, 1987, pp. 553-595.

  165. Miser, J.S., Kinsella, T.J., Triche, T.J., Steis, R., Tsokos, M., Wesley, R., Horvath, K., Belasco, J., Longo, D.L., Glatstein, E., and Israel, M.A.: Treatment of peripheral neuroepithelioma in children and young adults. J. Clin. Oncol. 5: 1752-1758, 1987.[Abs]

  166. Bridges, S.H., Kruisbeek, A.M., and Longo, D.L.: Selective in vivo antitumor effects of monoclonal anti-I-A antibody on B cell lymphoma. J. Immunol. 139: 4242-4249, 1987.[Abs]

  167. Lipford, E., Wright, J.J., Urba, W., Whang-Peng, J., Kirsch, I.R., Raffeld, M., Cossman, J., Longo, D.L., Bakhshi, A., and Korsmeyer, S.J.: Refinement of lymphoma cytogenetics by the chromosome 18q21 major breakpoint region. Blood 70: 1816-1823, 1987.[Abs]

  168. Longo, D.L. and DeVita, V.T., Jr.: Lymphomas. In Pinedo, H.M., Longo, D.L., and Chabner, B.A. (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual 9. Amsterdam, Elsevier Science Publishers B.V., 1987, pp. 165-199.

  169. Urba, W.J. and Longo, D.L.: Adoptive cellular therapy. In Pinedo, H.M., Longo, D.L., and Chabner, B.A. (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual 9. Amsterdam, Elsevier Science Publishers B.V., 1987, pp. 473-483.

  170. Urba, W.J., Maluish, A.E., and Longo, D.L.: Strategies for immunological monitoring. In Pinedo, H.M., Longo, D.L., and Chabner, B.A. (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual 9. Amsterdam, Elsevier Science Publishers B.V., 1987, pp. 484-501.

  171. Bulloch, K., Cullen, M.R., Schwartz, R.H., and Longo, D.L.: Innervation of immune tissues. Development of innervation within syngeneic thymus tissue transplanted under the kidney capsule of the nude mouse: A light and ultrastructural microscope study. J. Neurosci. Res. 18: 16-27, 1987.[Abs]

  172. Bridges, S.H. and Longo, D.L.: In vivo antitumor effects of anti-I-A antibodies. In David, C.S. (Ed.): H-2 Antigens-Genes, Molecules, Function. Proceedings of a NATO Advanced Research Workshop on Major Histocompatibility Complex--Genes/ Molecules/Function, Bar Harbor, Maine, June 5-9, 1987. New York, Plenum Press, 1987, pp. 691-697.

  173. Smith, J.W. and Longo, D.L.: Clinical trials using monoclonal antibodies. In Cerutti, P.A., Nygaard, O.F., and Simic, M.G. (Eds.): Anticarcinogenesis and Radiation Protection. New York, Plenum Press, 1987, pp. 491-497.

  174. Clark, J. and Longo, D.: Monoclonal antibody therapy of leukemias and lymphomas. J. Exp. Pathol. 3: 319-327, 1987.

  175. Longo, D.L. and Hathorn, J.: Current therapy for diffuse large-cell lymphoma. Prog. Hematol. XV: 115-136, 1987.

  176. Maluish, A.E., Urba, W.J., Longo, D.L., Overton, W.R., Coggin D., Crisp, E.R., Williams, R., Sherwin, S.A., Gordon, K., and Steis, R.G.: The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J. Clin. Oncol. 6: 434-445, 1988. [Abs]

  177. Miser, J.S., Kinsella, T.J., Triche, T.J., Tsokos, M., Forquer, R., Wesley, R., Horvath, K., Belasco, J., Longo, D.L., Steis, R., Glatstein, E., and Pizzo, P.A.: Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality therapy without maintenance. J. Clin. Oncol. 6: 484-490, 1988.[Abs]

  178. Colamonici, O.R., Ang, S., Quinones, R., Henkart, P., Heikkila, R., Gress, R., Felix, C., Kirsch, I., Longo, D., Marti, G., Seidman, J.G., and Neckers, L.M.: IL-2-dependent expansion of CD3+ large granular lymphocytes expressing T cell receptor-: Evidence for a functional receptor by anti-CD3 activation of cytolysis. J. Immunol. 140: 2527-2533, 1988.[Abs]

  179. Whang-Peng, J., Young, R.C., Lee, E.C., Longo, D.L., Schechter, G.P., and DeVita, V.T., Jr.: Cytogenetic studies in patients with secondary leukemia/ dysmyelopoietic syndrome after different treatment modalities. Blood 71: 403-414, 1988.[Abs]

  180. Steis, R.G. and Longo, D.L.: Clinical, biologic, and therapeutic aspects of malignancies associated with the acquired immunodeficiency syndrome: Part I. Ann. Allergy 60: 310-314, 1988.[Abs]

  181. Steis, R.G. and Longo, D.L.: Clinical, biologic, and therapeutic aspects of malignancies associated with the acquired immunodeficiency syndrome: Part II. Ann. Allergy 60: 315-323, 1988.[Abs]

  182. Urba, W.J., Longo, D.L., Lombardo, F.A., and Weiss, R.B.: Enhancement of natural killer activity in human peripheral blood by flavone acetic acid. J. Natl. Cancer Inst. 80: 521-525, 1988.[Abs]

  183. Steis, R.G., Marcon, L., Clark, J., Urba, W., Longo, D.L., Nelson, D.L., and Maluish, A.E.: Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 71: 1304-1309, 1988.[Abs]

  184. Marusic-Galesic, S., Stephany, D.A., Longo, D.L., and Kruisbeek, A.M.: Development of CD4-CD8+ cytotoxic T cells requires interactions with class I MHC determinants. Nature 333: 180-183, 1988.[Abs]

  185. DeVita, V.T., Jr., Hubbard, S.M., Young, R.C., and Longo, D.L.: The role of chemotherapy in diffuse aggressive lymphomas. Semin. Hematol. 25: 2-10, 1988.[Abs]

  186. Young, R.C., Longo, D.L., Glatstein, E., Ihde, D.C., Jaffe, E.S., and DeVita, V.T., Jr.: The treatment of indolent lymphomas: watchful waiting vs. aggressive combined modality treatment. Semin. Hematol. 25: 11-16, 1988.[Abs]

  187. Steis, R.G., Smith, J.W., II, Urba, W.J., Clark, J.W., Itri, L.M., Evans, L.M., Schoenberger, C., and Longo, D.L.: Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med. 318: 1409-1413, 1988.[Abs]

  188. Steis, R.G., Urba, W.J., Clark, J.W., Smith, J.W., II, Itri, L.M., Evans, L.M., and Longo, D.L.: Immunogenicity of different types of interferons in the treatment of hairy-cell leukemia. N. Engl. J. Med. 319: 1226-1227, 1988.

  189. Giardina, S.L., Storm, S.M., Longo, D.L., Mathieson, B.J., Rapp, U., and Varesio, L.: Characterization of a murine monoclonal antibody that detects a c-terminal fragment of the raf oncogene product. J. Immunol. 140: 3528-3533, 1988.[Abs]

  190. Urba, W.J. and Longo, D.L.: T cell lymphoma. In Brain, M.C. and Carbone, P.P. (Eds.): Current Therapy in Hematology-Oncology-3. Toronto, B.C. Decker Inc., 1988, pp. 297-302.

  191. Steis, R.G. and Longo, D.L.: Update on the treatment of hairy cell leukemia. In DeVita, V.T., Jr., Hellman, S., and Rosenberg, S.A. (Eds.): 2nd Edition Cancer Principles and Practice of Oncology Updates, Vol. 2. Philadelphia, J.B. Lippincott Company, 1988, No. 6, pp. 1-12.

  192. Marcon, L., Rubin, L.A., Kurman, C.C., Fritz, M.E., Longo, D.L., Uchiyama, T., Edwards, B.K., and Nelson, D.L.: Elevated serum levels of soluble Tac peptide in adult T-cell leukemia: correlation with clinical status during chemotherapy. Ann. Intern. Med. 109: 274-279, 1988.[Abs]

  193. Ortaldo, J.R. and Longo, D.L.: Human natural lymphocyte effector cells: Definition, analysis of activity, and clinical effectiveness. J. Natl. Cancer Inst. 80: 999-1010, 1988.[Abs]

  194. VanderMolen, L.A., Swain, S., and Longo, D.L.: Lactic acidosis in lymphoma: Prompt resolution of acidosis with therapy directed at the lymphoma. J. Natl. Cancer Inst. 80: 1077-1078, 1988.

  195. Whang-Peng, J., Lee, E.C., Minna, J.D., Abeloff, M.D., Bradley, E.C., Young, R.C., and Longo, D.L.: Deletion of 3(p14p23) in secondary erythroleukemia arising in long-term survivors of small cell lung cancer. J. Natl. Cancer Inst. 80: 1253-1255, 1988.[Abs]

  196. Bookman, M.A., Longo, D.L., and Young, R.C.: Late complications of curative treatment in Hodgkin's disease. JAMA 260: 680-683, 1988.

  197. Vukelja, S.J., Weiss, R.B., Perry, D.J., and Longo, D.L.: Eosinophilia associated with adult T-cell leukemia/lymphoma. Cancer 62: 1527-1530, 1988.[Abs]

  198. Lipford, E.H., Jr., Margolick, J.B., Longo, D.L., Fauci, A.S., and Jaffe, E.S.: Angiocentric immunoproliferative lesions: A clinicopathologic spectrum of post-thymic T-cell proliferations. Blood 72: 1674-1681, 1988. [Abs]

  199. Giardina, S.L., Young, H.A., Faltynek, C.R., Jaffe, E.S., Clark, J.W., Steis, R.G., Urba, W.J., Mathieson, B.J., Gralnick, H., Lawrence, J., Overton, W.R., and Longo, D.L.: Rearrangement of both immunoglobulin and T-cell receptor genes in a prolymphocytic variant of hairy cell leukemia patient resistant to interferon-alpha. Blood 72: 1708-1716, 1988.[Abs]

  200. Waldmann, T.A., Goldman, C.K., Bongiovanni, K.F., Sharrow, S.O., Davey, M.P., Cease, K.B., Greenberg, S.J., and Longo, D.L.: Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood 72: 1805-1816, 1988.[Abs]

  201. Longo, D.L. and DeVita, Jr., V.T.: Lymphomas. In Pinedo, H.M., Longo, D.L., and Chabner, B.A. (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual 10. Amsterdam, Elsevier Science Publishers B.V., 1988, pp. 148-181.

  202. Urba, W.J. and Longo, D.L.: Adoptive cellular therapy. In Pinedo, H.M., Longo, D.L., and Chabner, B.A. (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual 10. Amsterdam, Elsevier Science Publishers B.V., 1988, pp. 460-472.

  203. Tentori, L., Longo, D.L., Zuniga-Pflucker, J.C., Wing, C., and Kruisbeek, A.M.: Essential role of the interleukin 2-interleukin 2 receptor pathway in thymocyte maturation in vivo. J. Exp. Med. 168: 1741-1747, 1988.[Abs]

  204. Catane, R. and Longo, D.L.: Monoclonal antibodies for cancer therapy. Isr. J. Med. Sci. 24: 471-476, 1988.[Abs]

  205. Surbone, A., Longo, D.L., DeVita, V.T., Jr., Ihde, D.C., Duffey, P.L., Jaffe, E.S., Solomon, D., Hubbard, S.M., and Young, R.C.: Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: Significance and management. J. Clin. Oncol. 6: 1832-1837, 1988.[Abs]

  206. Masuda, A., Longo, D.L., Kobayashi, Y., Appella, E., Oppenheim, J.J., and Matsushima, K.: Induction of mitochondrial manganese superoxide dismutase by interleukin 1. FASEB J. 2: 3087-3091, 1988.[Abs]

  207. Kruisbeek, A.M., Zuniga-Pflucker, J., Marusic-Galesic, S., Weston, M.A., Tentori, L., and Longo, D.L.: Thymic selection of the T-cell repertoire. Immunol. Res. 7: 318-328, 1988.

  208. Matis, L.A., Heckford, S.E., and Longo, D.L.: Influence of bone marrow-derived Ia-bearing cells on the selection of the T-cell repertoire. Immunol. Res. 7: 329-338, 1988.[Abs]

  209. Hornung, R.L., Back, T.C., Zaharko, D.S., Urba, W.J., Longo, D.L., and Wiltrout, R.H.: Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2. J. Immunol. 141: 3671-3679, 1988.[Abs]

  210. Wilding, G., Greene, H.L., Longo, D.L., and Urba, W.J.: Tumors of the heart and pericardium. Cancer Treat. Rev. 15: 165-181, 1988.

  211. Clark, J.W. and Longo, D.L.: Adoptive therapies: Quo vadis? Pathol. Immunopathol. Res. 7: 442-458, 1988.[Abs]

  212. Steis, R.G., Clark, J., Longo, D.L., Smith, J., Miller, R., Ruscetti, F., Hursey, J., and Urba, W.: A phase Ib evaluation of recombinant human granulocyte-macrophage colony-stimulating factor. In Beger, H.G., Buchler, M., Reisfeld, R.A., and Schulz, G. (Eds.): Cancer Therapy: Monoclonal Antibodies, Lymphokines. Berlin, Springer-Verlag Publishing Co., 1989, pp. 103-111.

  213. Urba, W.J., Baseler, M.W., Kopp, W.C., Steis, R.G., Clark, J.W., Smith, J.W., II, Coggin, D.L., and Longo, D.L.: Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 73: 38-46, 1989.[Abs]

  214. Longo, D.L. and Urba, W.J.: Hodgkin's disease. In Kelley, W.N. (Ed.): Textbook of Internal Medicine. Philadelphia, J.B. Lippincott Company, 1989, pp. 1191-1195.

  215. Urba, W.J. and Longo, D.L.: Lymphocytic lymphomas. In Kelley, W.N. (Ed.): Textbook of Internal Medicine. Philadelphia, J.B. Lippincott Company, 1989, pp. 1195-1202.

  216. Longo, D.L.: Principles of cancer treatment. In Kelley, W.N. (Ed.): Textbook of Internal Medicine. Philadelphia, J.B. Lippincott Company, 1989, pp. 1214-1228.

  217. Longo, D.L.: The spleen and its disorders. In Kelley, W.N. (Ed.): Textbook of Internal Medicine. Philadelphia, J.B. Lippincott Company, 1989, pp. 1306-1311.

  218. Longo, D.L. and Urba, W.J.: Differential diagnosis of lymphadenopathy and the management of patients with lymphoma. In Kelley, W.N. (Ed.): Textbook of Internal Medicine. Philadelphia, J.B. Lippincott Company, 1989, pp. 1311-1323.

  219. Kovacs, E.J., Beckner, S.K., Longo, D.L., Varesio, L., and Young, H.A.: Cytokine gene expression during the generation of human lymphokine-activated killer cells: Early induction of interleukin 1 by interleukin 2. Cancer Res. 49: 940-944, 1989.[Abs]

  220. Schiogolev, S.A., Goetzl, E.J., Urba, W.J., and Longo, D.L.: Appearance of neuropeptides in ascitic fluid after peritoneal therapy with interleukin-2 and lymphokine-activated killer cells for intraabdominal malignancy. J. Clin. Immunol. 9: 169-173, 1989.[Abs]

  221. Miller, R.L., Steis, R.G., Clark, J.W., Smith, J.W., II, Crum, E., McKnight, J.E., Hawkins, M.J., Jones, M.J., Longo, D.L., and Urba, W.J.: Randomized trial of recombinant 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res. 49: 1871-1876, 1989.[Abs]

  222. Zuniga-Pflucker, J.C., Longo, D.L., and Kruisbeek, A.M.: Positive selection of CD4-CD8+ T cells in the thymus of normal mice. Nature 338: 76-78, 1989.[Abs]

  223. Urba, W.J., Clark, J.W., Steis, R.G., Bookman, M.A., Smith, J.W., II, Beckner, S., Maluish, A.E., Rossio, J.L., Rager, H., Ortaldo, J.R., and Longo, D.L.: Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intra-abdominal cancer: Immunologic considerations. J. Natl. Cancer Inst. 81: 602-611, 1989.[Abs]

  224. Adachi, M., Cossman, J., Longo, D., Croce, C.M., and Tsujimoto, Y.: Variant translocation of the bcl-2 gene to immunoglobulin light chain gene in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 86: 2771-2774, 1989.[Abs]

  225. Marusic-Galesic, S., Longo, D.L., and Kruisbeek, A.M.: Preferential differentiation of T cell receptor specificities based on the MHC glycoproteins encountered during development: Evidence for positive selection. J. Exp. Med. 169: 1619-1630, 1989.[Abs]

  226. Rosenberg, S.A., Longo, D.L., and Lotze, M.T.: Principles and applications of biologic therapy. In DeVita, V.T., Jr., Hellman, S., and Rosenberg, S.A. (Eds.): Cancer: Principles and Practice of Oncology. Philadelphia, J.B. Lippincott Company, 1989, pp. 301-347.

  227. Linehan, W.M., Shipley, W.U., and Longo, D.L.: Cancer of the kidney and ureter. In DeVita, V.T., Jr., Hellman, S., and Rosenberg, S.A. (Eds.): Cancer: Principles and Practice of Oncology. Philadelphia, J.B. Lippincott Company, 1989, pp. 979-1007.

  228. DeVita, V.T., Jr., Jaffe, E.S., Mauch, P., and Longo, D.L.: Lymphocytic lymphomas. In DeVita, V.T., Jr., Hellman, S., and Rosenberg, S.A. (Eds.): Cancer: Principles and Practice of Oncology. Philadelphia, J.B. Lippincott Company, 1989, pp. 1741-1798.

  229. Hartmann, L.C., Urba, W.J., Steis, R.G., Smith, J.W., II, VanderMolen, L., Creekmore, S.P., and Longo, D.L.: Hypothyroidism after interleukin-2 therapy. J. Clin. Oncol. 7: 686-687, 1989.

  230. Jaffe, E.S., Lipford, E.H., Jr., Margolick, J.B., Longo, D.L., and Fauci, A.S.: Lymphomatoid granulomatosis and angiocentric lymphoma: A spectrum of post-thymic T-cell proliferations. Semin. Resp. Med. 10: 167-172, 1989.

  231. Talmadge, J.E., Schneider, M., Keller, J., Ruscetti, F., Longo, D., Pennington, R., Bowersox, O., and Tribble, H.: Myelostimulatory activity of recombinant human interleukin-2 in mice. Blood 73: 1458-1467, 1989.[Abs]

  232. Zuniga-Pflucker, J.C., McCarthy, S.A., Weston, M., Longo, D.L., Singer, A., and Kruisbeek, A.M.: Role of CD4 in thymocyte selection and maturation. J. Exp. Med. 169: 2085-2096, 1989.[Abs]

  233. Clark, J.W. and Longo, D.L.: Biologic response modifiers in cancer therapy. In Magrath, I. (Ed.): New Directions in Cancer Treatment. Geneva, Springer-Verlag Publishers, 1989, pp. 297-316.

  234. Longo, D.L.: Hodgkin's disease. In Magrath, I. (Ed.): New Directions in Cancer Treatment. Geneva, Springer-Verlag Publishers, 1989, 561-565.

  235. Urba, W.J. and Longo, D.L.: Diffuse aggressive lymphomas in adults. In Magrath, I. (Ed.): New Directions in Cancer Treatment. Geneva, Springer-Verlag Publishers, 1989, pp. 575-579.

  236. Kenny, J.J., Finkelman, F., Macchiarini, F., Kopp, W.C., Storb, U., and Longo, D.L.: Alteration of the B cell surface phenotype, immune response to phosphocholine and the B cell repertoire in M167 µ plus transgenic mice. J. Immunol. 142: 4466-4474, 1989.[Abs]

  237. Pearson, J.W., FitzGerald, D.J.P., Willingham, M.C., Wiltrout, R.H., Pastan, I., and Longo, D.L.: Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice. Cancer Res. 49: 3562-3567, 1989.[Abs]

  238. Wiltrout, R.H., Pilaro, A.M., Gruys, M.E., Talmadge, J.E., Longo, D.L., Ortaldo, J.R., and Reynolds, C.W.: Augmentation of mouse liver-associated natural killer activity by biologic response modifiers occurs largely via rapid recruitment of large granular lymphocytes from the bone marrow. J. Immunol. 143: 372-378, 1989.[Abs]

  239. Goey, H., Keller, J.R., Back, T., Longo, D.L., Ruscetti, F.W., and Wiltrout, R.H.: Inhibition of early murine hemopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factor-1. J. Immunol. 143, 877-880, 1989.[Abs]

  240. Hartmann, L.C., Urba, W.J., Steis, R.G., Smith, J.W., II, VanderMolen, L. A., Creekmore, S.P., Sznol, M., Casciano, M.A., Engler, N., and Longo, D.L.: Use of prophylactic antibiotics for prevention of intravascular catheter-related infections in interleukin-2-treated patients. J. Natl. Cancer Inst. 81: 1190-1193, 1989.

  241. VanderMolen, L.A., Smith, J.W., II, Longo, D.L., Steis, R.G., Kremers, P., and Sznol, M.: Adrenal insufficiency and interleukin-2 therapy. Ann. Intern. Med. 111: 185, 1989.

  242. Longo, D.L.: Combined modality therapy for localized aggressive lymphoma: enough or too much? J. Clin. Oncol. 7: 1179-1181, 1989.

  243. Longo, D.L., Glatstein, E., Duffey, P.L., Ihde, D.C., Hubbard, S.M., Fisher, R.I., Jaffe, E.S., Gilliom, M., Young, R.C., and DeVita, V.T., Jr.: Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J. Clin. Oncol. 7: 1295-1302, 1989.[Abs]

  244. VanderMolen, L.A., Urba, W.J., Longo, D.L., Lawrence, J., Gralnick, H., and Steis, R.G.: Diffuse osteosclerosis in hairy cell leukemia. Blood 74: 2066-2069, 1989.[Abs]

  245. Oppenheim, J.J., Neta, R., Tiberghien, P., Gress, R., Kenny, J.J., and Longo, D.L.: Interleukin-1 enhances survival of lethally irradiated mice treated with allogeneic bone marrow cells. Blood 74: 2257-2263, 1989.[Abs]

  246. Pearson, J.W., Sivam, G., Manger, R., Wiltrout, R.H., Morgan, A.C., Jr., and Longo, D.L.: Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an intraperitoneal human tumor xenograft in athymic mice. Cancer Res. 49: 4990-4995, 1989.[Abs]

  247. Bridges, S., Longo, D.L., and Youle, R.J.: Preparation and use of anti-idiotypic antibodies armed with holotoxins or hemitoxins in treatment of B-cell neoplasms. Methods Enzymol. 178: 356-368, 1989.

  248. Groves, E.S. and Longo, D.L.: Progression of lymphoproliferative disorders and hematologic malignancies. In Brunson, K.W. (Ed.): Local Invasion and Spread of Cancer. Dordrecht, Kluwer Academic Publishers, 1989, pp. 122-147.

  249. Zuniga-Pflucker, J.C., Jones, L.A., Longo, D.L., and Kruisbeek, A.M.: Both TCR/MHC and accessory molecule/MHC interactions are required for positive and negative selection of mature T cells in the thymus. Cold Spring Harbor Symp. Quant. Biol. LIV: 153-158, 1989.

  250. Jones, L.A., Zuniga-Pflucker, J.C., Fine, J.S., Longo, D.L., and Kruisbeek, A.M.: Development of the T cell repertoire: contribution of both TCR-MHC and accessory molecules-MHC interactions. Prog. Immunol. 7: 289-296, 1989.

  251. Morgan, A.C., Jr., Manger, R., Pearson, J.W., Longo, D., Abrams, P., Bjorn, M., and Sivam, G.: Holotoxin immunoconjugates of Pseudomonas exotoxin A: evaluation in mice, monkeys, and man. Antibody Immunoconjug. Radiopharmaceut. 2: 165-178, 1989.

  252. Kohn, E.C., Steis, R.G., Sausville, E.A., Veach, S.R., Stocker, J.L., Phelps, R., Franco, S., Longo, D.L., Bunn, P.A., and Ihde, D.C.: Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sezary syndrome. J. Clin. Oncol. 8: 155-160, 1990.[Abs]

  253. Urba, W.J., Steis, R.G., Longo, D.L., Kopp, W.C., Maluish, A.E., Marcon, L., Nelson, D.L., Stevenson, H.C., and Clark, J.W.: Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer. Cancer Res. 50: 185-192, 1990.[Abs]

  254. Longo, D.L. and Wilson, W.: Follicular lymphomas. In Magrath, I.T. (Ed.): Non-Hodgkin's Lymphoma. London, Edward Arnold Ltd., 1990, pp. 293-308.

  255. VanderMolen, L.A., Steis, R.G., Duffey, P.L., Foon, K.A., Smith, J.W., II, Clark, J.W., Conlon, K., Stevenson, H.C., Urba, W.J., Hartmann, L.C., Watson, T., Jaffe E.S., and Longo, D.L.: Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma. J. Natl. Cancer Inst. 82: 235-238, 1990.

  256. Steis, R.G., Carrasquillo, J.A., McCabe, R., Bookman, M.A., Reynolds, J.C., Larson, S.M., Smith, J.W., II, Clark, J.W., Dailey, V., Del Vecchio, S., Shuke, N., Pinsky, C.M., Urba, W.J., Haspel, M., Perentesis, P., Paris, B., Longo, D.L., and Hanna, M.G., Jr.: Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J. Clin. Oncol. 8: 476-490, 1990.[Abs]

  257. Bridges, S.H. and Longo, D.L.: T cell tumor cure by T cell receptor-mediated activation requires the development of CD8-dependent host immunity. J. Immunol. 144: 2010-2017, 1990.[Abs]

  258. Zuniga-Pflucker, J.C., Jones, L.A., Longo, D.L., and Kruisbeek, A.M.: CD8 is required during positive selection of CD4-/CD8+ T cells. J. Exp. Med. 171: 427-437, 1990.[Abs]

  259. Beckwith, M., Longo, D.L., O'Connell, C.D., Moratz, C.M., and Urba, W.J.: Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. J. Natl. Cancer Inst. 82: 501-509, 1990.[Abs]

  260. Martin, A., Nerenstone, S., Urba, W.J., Longo, D.L., Lawrence, J.B., Clark, J.W., Hawkins, M.J., Creekmore, S.P., Smith, J.W., II, and Steis, R.G.: Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study. J. Clin. Oncol. 8: 721-730, 1990.[Abs]

  261. DeVita, V.T., Jr., Hubbard, S.M., and Longo, D.L.: Treatment of Hodgkin's disease. J. Natl. Cancer Inst. Monogr. 10: 19-28, 1990.[Abs]

  262. Urba, W.J., Duffey, P.L., and Longo, D.L.: Treatment of patients with aggressive lymphomas: an overview. J. Natl. Cancer Inst. Monogr. 10: 29-37, 1990.[Abs]

  263. Young, R.C., Bookman, M.A., and Longo, D.L.: Late complications of Hodgkin's disease management. J. Natl. Cancer Inst. Monogr. 10: 55-60, 1990.[Abs]

  264. Steis, R.G., VanderMolen, L.A., Longo, D.L., Clark, J.W., Smith, J.W., II, Kopp, W.C., Ruscetti, F.W., Creekmore, S.P., Elwood, L.J., Hursey, J., and Urba, W.J.: Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: A phase Ib trial. J. Natl. Cancer Inst. 82: 697-703, 1990.[Abs]

  265. Espinoza-Delgado, I., Ortaldo, J.R., Winkler-Pickett, R., Sugamura, K., Varesio, L., and Longo, D.L.: Expression and role of p75 interleukin 2 receptor on human monocytes. J. Exp. Med. 171: 1821-1826, 1990.[Abs]

  266. VanderMolen, L.A., Duffey, P.L., Cossman, J., Jaffe, E.S., and Longo, D.L.: Surface light chain phenotype in indolent lymphomas: Lack of prognostic significance. Am. J. Hematol. 34: 15-20, 1990.[Abs]

  267. Urba, W.J., Hartmann, L.C., Longo, D.L., Steis, R.G., Smith, J.W., II, Kedar, I., Creekmore, S., Sznol, M., Conlon, K., Kopp, W.C., Huber, C., Herold, M., Alvord, W.G., Snow, S., and Clark, J.W.: Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. Cancer Res. 50: 2979-2986, 1990.[Abs]

  268. Bookman, M.A., Lardelli, P., Jaffe, E.S., Duffey, P.L., and Longo, D.L.: Lymphocytic lymphoma of intermediate differentiation: morphologic, immunophenotypic, and prognostic factors. J. Natl. Cancer Inst. 82: 742-748, 1990.[Abs]

  269. Aiello, F.B., Longo, D.L., Overton, R., Takacs, L., and Durum, S.K.: A role for cytokines in antigen presentation: IL-1 and IL-4 induce accessory functions of antigen-presenting cells. J. Immunol. 144: 2572-2581, 1990.[Abs]

  270. Conlon, K.C., Urba, W.J., Smith, J.W., II, Steis, R.G., Longo, D.L., and Clark, J.W.: Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 65: 2237-2242, 1990. [Abs]

  271. Steis, R.G., VanderMolen, L.A., Lawrence, J., Sing, G., Ruscetti, F., Smith, J.W., II, Urba, W.J., Clark, J., and Longo, D.L.: Erythrocytosis in hairy cell leukaemia following therapy with interferon alpha. Br. J. Haematol. 75: 133-135, 1990.[Abs]

  272. Longo, D.L.: Chemotherapy for advanced aggressive lymphoma: more is better...isn't it? J. Clin. Oncol. 8: 952-955, 1990.

  273. Blayney, D.W. and Longo, D.L.: Leukemia after treatment of ovarian cancer or Hodgkin's disease. N. Engl. J. Med. 322: 1818, 1990.

  274. Espinoza-Delgado, I., Longo, D.L., Gusella, G.L., and Varesio, L.: IL-2 enhances c-fms expression in human monocytes. J. Immunol. 145: 1137-1143, 1990.[Abs]

  275. Lardelli, P., Bookman, M.A., Sundeen, J., Longo, D.L., and Jaffe, E.S.: Lymphocytic lymphoma of intermediate differentiation: morphologic and immunophenotypic spectrum and clinical correlations. Am. J. Surg. Pathol. 14: 752-763, 1990.[Abs]

  276. Urba, W.J. and Longo, D.L.: Adoptive cellular therapy. In Pinedo, H.M., Chabner, B.A., and Longo, D.L., (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual 11. Amsterdam, Elsevier Science Publishers B.V., 1990, pp. 265-280.

  277. Longo, D.L. and DeVita, V.T., Jr.: Lymphomas. In Pinedo, H.M., Chabner, B.A., and Longo, D.L., (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual 11. Amsterdam, Elsevier Science Publishers B.V., 1990, pp. 343-378.

  278. Zuniga-Pflucker, J.C., Smith, K.A., Tentori, L., Pardoll, D.M., Longo, D.L., and Kruisbeek, A.M.: Are the IL-2 receptors expressed in the murine fetal thymus functional? Dev. Immunol. 1: 59-66, 1990.[Abs]

  279. Longo, D.L., and Hartmann, L.C.: Biological response modifiers in the management of patients with breast cancer. Breast Cancer Res. Treat. 16: 67-87, 1990.[Abs]

  280. Clark, J.W., Smith, J.W., II, Steis, R.G., Urba, W.J., Crum, E., Miller, R., McKnight, J., Beman, J., Stevenson, H.C., Creekmore, S., Stewart, M., Conlon, K., Sznol, M., Kremers, P., Cohen, P., and Longo, D.L.: Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen. Cancer Res. 50: 7343-7350, 1990.[Abs]

  281. Steis, R.G., Urba, W.J., VanderMolen, L.A., Bookman, M.A., Smith, J.W. II, Clark, J.W., Miller, R.L., Crum, E.D., Beckner, S.K., McKnight, J.E., Ozols, R.F., Stevenson, H.C., Young, R.C., and Longo, D.L.: Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity. J. Clin. Oncol. 8: 1618-1629, 1990.[Abs]

  282. Tiberghien, P., Longo, D.L., Wine, J.W., Alvord, W.G., and Reynolds, C.W.: Anti-asialo GM1 antiserum treatment of lethally irradiated recipients before bone marrow transplantation: evidence that recipient natural killer depletion enhances survival, engraftment, and hematopoietic recovery. Blood 76: 1419-1430, 1990.[Abs]

  283. Pearson, J.W., Hedrick, E., Fogler, W.E., Bull, R.L., Ferris, D.K., Riggs, C.W., Wiltrout, R.H., Sivam, G., Morgan, A.C., Groves, E., and Longo, D.L.: Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant -interferon. Cancer Res. 50: 6379-6388, 1990.[Abs]

  284. Lane, H.C., Zunich, K.M., Wilson, W., Cefali, F., Easter, M., Kovacs, J.A., Masur, H., Leitman, S.F., Klein, H.G., Steis, R.G., Longo, D.L., and Fauci, A.S.: Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection. Ann. Intern. Med. 113: 512-519, 1990.[Abs]

  285. Sing, G.K., Ruscetti, F.W., Beckwith, M., Keller, J.R., Ellingsworth, L., Urba, W.J., and Longo, D.L.: Growth inhibition of a human lymphoma cell line: induction of a transforming growth factor--mediated autocrine negative loop by phorbol myristate acetate. Cell Growth Differ. 1: 549-557, 1990.[Abs]

  286. Longo, D.L.: The use of chemotherapy in the treatment of Hodgkin's disease. Semin. Oncol. 17: 716-735, 1990.

  287. Musso, T., Espinoza-Delgado, I., Pulkki, K., Gusella, G.L., Longo, D.L., and Varesio, L.: Transforming growth factor- downregulates interleukin-1 (IL-1)-induced IL-6 production by human monocytes. Blood 76: 2466-2469, 1990.[Abs]

  288. Futami, H., Jansen, R., MacPhee, M.J., Keller, J., McCormick, K., Longo, D.L., Oppenheim, J.J., Ruscetti, F.W., and Wiltrout, R.H.: Chemoprotective effects of recombinant human IL-1 in cyclophosphamide-treated normal and tumor-bearing mice: protection from acute toxicity, hematologic effects, development of late mortality and enhanced therapeutic efficacy. J. Immunol. 145: 4121-4130, 1990.[Abs]

  289. Creekmore, S.P., Longo, D.L., and Urba, W.J.: The development of regimens for combination immunotherapy. In Rees, R.C. (Ed.): The Biology and Clinical Applications of Interleukin-2. Oxford, IRL Press, 1990, pp. 98-110.

  290. DeVita, V.T., Jr., Longo, D.L., Glatstein, E., Duffey, P.L., Hubbard, S.M., Wiernik, P.H., and Young, R.C.: A randomized comparison of radiotherapy versus primary treatment with MOPP chemotherapy in early stage Hodgkin's disease. In Salmon, S.E. (Ed.): Adjuvant Therapy of Cancer VI. Orlando, W.B. Saunders Company, 1990, pp. 601-609.

  291. Jones, L.A., Chin, L.T., Longo, D.L., and Kruisbeek, A.M.: Peripheral clonal elimination of functional T cells. Science 250: 1726-1729, 1990.[Abs]

  292. Longo, D.L.: Plasma cell disorders. In Wilson, J.D., Braunwald, E., Fauci, A.S., Isselbacher, K.J., Martin, J.B., Petersdorf, R.G., and Root, R.K. (Eds.): Harrison's Principles of Internal Medicine, 12th Edition. New York, McGraw-Hill Book Company, 1991, pp. 1410-1417.

  293. Smith, J.W., II and Longo, D.L.: The cancer patient. In Parrillo, J.E. (Ed.): Current Therapy in Critical Care Medicine, Second Edition. Ontario, B.C. Decker Inc., 1991, pp. 296-301.

  294. Longo, D.L., DeVita, V.T., Jr., Duffey, P.L., Wesley, M.N., Ihde, D.C., Hubbard, S.M., Gilliom, M., Jaffe, E.S., Cossman, J., Fisher, R.I., and Young, R.C.: Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J. Clin. Oncol. 9: 25-38, 1991.[Abs]

  295. Longo, D.L., Russo, A., Duffey, P.L., Hubbard, S.M., Glatstein, E., Hill, J.B., Jaffe, E.S., Young, R.C., and DeVita, V.T., Jr.: Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. J. Clin. Oncol. 9: 227-235, 1991.[Abs]

  296. Rudnick, S., Stevenson, G.W., Hall, S.C., Espinoza-Delgado, I., Stevenson, H.C., and Longo, D.L.: Halothane potentiates the antitumor activity of gamma-interferon and mimics calmodulin-blocking agents. Anesthesiol. 74: 115-119, 1991.[Abs]

  297. Urba, W.J. and Longo, D.L.: Lymphocytic lymphomas: epidemiology, etiology, pathology and staging. In Moossa, A.R., Schimpff, S.C., and Robson, M.C. (Eds.): Comprehensive Textbook of Oncology, Second Edition. Baltimore, Williams & Wilkins, 1991, pp. 1268-1276.

  298. Urba, W.J. and Longo, D.L.: Lymphocytic lymphomas: clinical course and management. In Moossa, A.R., Schimpff, S.C., and Robson, M.C. (Eds.): Comprehensive Textbook of Oncology, Second Edition. Baltimore, Williams & Wilkins, 1991, pp. 1277-1295.

  299. Urba, W.J. and Longo, D.L.: Burkitt's lymphoma. In Moossa, A.R., Schimpff, S.C., and Robson, M.C. (Eds.): Comprehensive Textbook of Oncology, Second Edition. Baltimore, Williams & Wilkins, 1991, pp. 1296-1301.

  300. Fisher, R.I., Longo, D.L., DeVita, V.T., Jr., Hubbard, S.M., Miller, T.P., and Young, R.C.: Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. Ann. Oncol. 2: 33-35, 1991.[Abs]

  301. Kantor, R.R.S., Giardina, S.L., Bartolazzi, A., Townsend, A.J., Myers, C.E., Cowan, K.H., Longo, D.L., and Natali, P.G.: Monoclonal antibodies to glutathione S-transferase -immunohistochemical analysis of human tissues and cancers. Int. J. Cancer 47: 193-201, 1991.[Abs]

  302. Steis, R.G., Smith, J.W., II, Urba, W.J., Venzon, D.J., Longo, D.L., Barney, R., Evans, L.M., Itri, L.M., and Ewel, C.H.: Loss of interferon antibodies during prolonged continuous interferon-2a therapy in hairy cell leukemia. Blood 77: 792-798, 1991.[Abs]

  303. Jin, F-S., Youle, R.J., Johnson, V.G., Shiloach, J., Fass, R., Longo, D.L., and Bridges, S.H.: Suppression of the immune response to immunotoxins with anti-CD4 monoclonal antibodies. J. Immunol. 146: 1806-1811, 1991.[Abs]

  304. Kenny, J.J., Stall, A.M., Sieckmann, D.G., Lamers, M.C., Finkelman, F.D., Finch, L., and Longo, D.L.: Receptor-mediated elimination of phosphocholine-specific B cells in x-linked immune deficient mice. J. Immunol. 146: 2568-2577, 1991.[Abs]

  305. Loeffler, C.M., Platt, J.L., Anderson, P.M., Katsanis, E., Ochoa, J.B., Urba, W.J., Longo, D.L., Leonard, A.S., and Ochoa, A.C.: Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis. Cancer Res. 51: 2127-2132, 1991.[Abs]

  306. Urba, W.J. and Longo, D.L.: T-cell lymphoma. In Kassirer, J.P. (Ed.): Current Therapy of Internal Medicine, Third Edition. Philadelphia, B.C. Decker, 1991, pp. 913-919.

  307. Geller, R.L., Smyth, M.J., Strobl, S.L., Bach, F.H., Ruscetti, F.W., Longo, D.L., and Ochoa, A.C.: Generation of lymphokine-activated killer activity in T cells: possible regulatory circuits. J. Immunol. 146: 3280-3288, 1991.[Abs]

  308. Ortaldo, J.R., Mason, A.T., O'Shea, J.J., Smyth, M.J., Falk, L.A., Kennedy, I.C.S., Longo, D.L., and Ruscetti, F.W.: Mechanistic studies of transforming growth factor- inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions: regulation of IL-2R (p75) signal transduction. J. Immunol. 146: 3791-3798, 1991.[Abs]

  309. Walsh, T.J., Rubin, M., Hathorn, J., Gress, J., Thaler, M., Skelton, J., McKnight, J., Browne, M., Marshall, D., Cotton, D., Hiemenz, J., Longo, D., Wesley, R., and Pizzo, P.A.: Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. Arch. Intern. Med. 151: 765-770, 1991.[Abs]

  310. Ruscetti, F.W., Dubois, C., Falk, L.A., Jacobsen, S.E., Sing, G., Longo, D.L., Wiltrout, R.H., and Keller, J.R.: In vivo and in vitro effects of TGF-1 on normal and neoplastic haemopoiesis. In Sporn, M.B. (Ed.): Clinical Applications of TGF-. Chichester, John Wiley & Sons, 1991, pp. 212-231.

  311. Longo, D.L., Glatstein, E., Duffey, P.L., Young, R.C., Hubbard, S.M., Urba, W.J., Wesley, M.N., Raubitschek, A., Jaffe, E.S., Wiernik, P.H., and DeVita, Jr., V.T.: Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial. J. Clin. Oncol. 9: 906-917, 1991.[Abs]

  312. Creekmore, S.P., Urba, W.J., and Longo, D.L.: Principles of the clinical evaluation of biologic agents. In DeVita, V.T., Jr., Hellman, S., and Rosenberg, S.A. (Eds.): Biologic Therapy of Cancer. Philadelphia, J.B. Lippincott, 1991, pp. 67-86.

  313. Longo, D.L. and DeVita, Jr., V.T.: Lymphomas. In Pinedo, H.M., Longo, D.L., and Chabner, B.A. (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual 12. Amsterdam, Elsevier Science Publishers B.V., 1991, pp. 347-393.

  314. Hestdal, K., Ruscetti, F.W., Ihle, J.N., Jacobsen, S.E.W., Dubois, C.M., Kopp, W.C., Longo, D.L., and Keller, J.R.: Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J. Immunol. 147: 22-28, 1991.[Abs]

  315. Smith, J.W., II, Urba, W.J., Steis, R.G., Sznol, M., Creekmore, S.P., and Longo, D.L.: Clinical trials of selected interleukins: the Biological Response Modifiers Program experience. In Baxter, A. and Ross, R. (Eds.): Cytokine Interactions and Their Control. Sussex, John Wiley & Sons Ltd., 1991, pp. 177-194.

  316. Ferris, D.K., White, G.A., Kelvin, D.J., Copeland, T.D., Li, C-C.H., and Longo, D.L.: p34cdc2 is physically associated with and phosphorylated by a cdc2-specific tyrosine kinase. Cell Growth Differ. 2: 343-349, 1991.[Abs]

  317. Medeiros, L.J., Lardelli, P., Stetler-Stevenson, M., Longo, D.L., and Jaffe, E.S.: Genotypic analysis of diffuse, mixed cell lymphomas. Comparison with morphologic and immunophenotypic findings. Am. J. Clin. Pathol. 95: 547-555, 1991.[Abs]

  318. Longo, D.L., Duffey, P.L., DeVita, V.T., Jr., Wiernik, P.H., Hubbard, S.M., Phares, J.C., Bastian, A.W., Jaffe, E.S., and Young, R.C.: Treatment of advanced-stage Hodgkin's disease: alternating non-crossresistant MOPP/CABS is not superior to MOPP. J. Clin. Oncol. 9: 1409-1420, 1991.[Abs]

  319. Longo, D.L. and Urba, W.J.: Hodgkin's disease. In Kelley, W.N. (Ed.): Textbook of Internal Medicine, Second Edition. Philadelphia, J.B. Lippincott Company, 1991, pp. 1092-1096.

  320. Urba, W.J. and Longo, D.L.: Lymphocytic lymphomas. In Kelley, W.N. (Ed.): Textbook of Internal Medicine, Second Edition. Philadelphia, J.B. Lippincott Company, 1991, pp. 1096-1102.

  321. Longo, D.L. and Urba, W.J.: Principles of cancer treatment. In Kelley, W.N. (Ed.): Textbook of Internal Medicine, Second Edition. Philadelphia, J.B. Lippincott Company, 1991, pp. 1113-1126.

  322. Longo, D.L. and Urba, W.J.: Approach to the management of disorders of the spleen. In Kelley, W.N. (Ed.): Textbook of Internal Medicine, Second Edition. Philadelphia, J.B. Lippincott Company, 1991, pp. 1185-1189.

  323. Longo, D.L. and Urba, W.J.: Differential diagnosis of lymphadenopathy and approach to the management of lymphomas. In Kelley, W.N. (Ed.): Textbook of Internal Medicine, Second Edition. Philadelphia, J.B. Lippincott Company, 1991, pp. 1189-1200.

  324. Longo, D.L., Duffey, P.L., DeVita, V.T., Jr., Wesley, M.N., Hubbard, S.M., and Young, R.C.: The calculation of actual or received dose intensity: a comparison of published methods. J. Clin. Oncol. 9: 2042-2051, 1991.

  325. Longo, D.L.: Biologic agents and approaches in the management of patients with lymphoma: a critical appraisal. Hematol./Oncol. Clin. North Am. 5: 1067-1087, 1991.[Abs]

  326. Pearson, J.W., Fogler, W.E., Volker, K., Usui, N., Goldenberg, S.K., Gruys, E., Riggs, C.W., Komschlies, K., Wiltrout, R.H., Tsuruo, T., Pastan, I., Gottesman, M.M., and Longo, D.L.: Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J. Natl. Cancer Inst. 83: 1386-1391, 1991.[Abs]

  327. Hubbard, S.M. and Longo, D.L.: Treatment-related morbidity in patients with lymphoma. Curr. Opin. Oncol. 3: 852-862, 1991.[Abs]

  328. Smith, J.W., II, Urba, W.J., Clark, J.W., Longo, D.L., Farrell, M., Creekmore, S.P., Conlon, K.C., Jaffe, H., and Steis, R.G.: Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma. J. Immunother. 10: 355-362, 1991.[Abs]

  329. Beckwith, M., Urba, W.J., Ferris, D.K., Freter, C.E., Kuhns, D.B., Moratz, C.M., and Longo, D.L.: Anti-IgM-mediated growth inhibition of a human B lymphoma cell line is independent of phosphatidylinositol turnover and protein kinase C activation and involves tyrosine phosphorylation. J. Immunol. 147: 2411-2418, 1991.[Abs]

  330. Smith, J.W., II, Longo, D.L., Urba, W.J., Clark, J.W., Watson, T., Beveridge, J., Conlon, K.C., Sznol, M., Creekmore, S.P., Alvord, W.G., Lawrence, J.B., and Steis, R.G.: Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-2a. Blood 78: 1664-1671, 1991.[Abs]

  331. Johnston, P.G., Ruscetti, F.W., Connaghan, D.G., Sullivan, F.J., and Longo, D.L.: Transient reversal of bone marrow aplasia associated with lymphocyte depleted Hodgkin's disease after combination chemotherapy. Am. J. Hematol. 38: 54-60, 1991.[Abs]

  332. Urba, W.J., Kopp, W.C., Clark, J.W., Smith, J.W., II, Steis, R.G., Huber, C., Coggin, D., and Longo, D.L.: The in vivo immunomodulatory effects of recombinant interferon gamma plus recombinant tumor necrosis factor-alfa. J. Clin. Oncol. 9: 1831-1839, 1991.[Abs]

  333. Richardson, G.E. and Longo, D.L.: Multiple cavitating pulmonary nodules in Hodgkin's disease. Cancer 68: 930-933, 1991.[Abs]

  334. Tura, S., Canellos, G., Goldstone, A., Longo, D., McMillan, A., Urba, W., and Zinzani, P.L.: Hodgkin's disease: controversies and challenges for the future. Haematologica 76: 263-279, 1991.

  335. Longo, D.L.: Editorial: Series on growth factors. Cancer Invest. 9: 321-323, 1991.

  336. Kenny, J.J., O'Connell, C., Sieckmann, D.G., Fischer, R.T., and Longo, D.L.: Selection of antigen-specific, idiotype-positive B cells in transgenic mice expressing a rearranged M167-µ heavy chain gene. J. Exp. Med. 174: 1189-1201, 1991.[Abs]

  337. Jacobsen, S.E.W., Ruscetti, F.W., Longo, D.L., and Keller, J.R.: Antineoplastic dolastatins: potent inhibitors of hematopoietic progenitor cells. J. Natl. Cancer Inst. 83: 1672-1677, 1991.[Abs]

  338. Steis, R.G., Urba, W.J., Kopp, W.C., Alvord, W.G., Smith, J.W., II, and Longo, D.L.: Kinetics of recovery of CD4+ T cells in the peripheral blood of deoxycoformycin-treated patients. J. Natl. Cancer Inst. 83: 1678-1679, 1991.[Abs]

  339. Jansen, R., Damia, G., Usui, N., Keller, J., Futami, H., Goey, H., Back, T.T., Longo, D.L., Ruscetti, F.W., and Wiltrout, R.H.: Effects of recombinant transforming growth factor-1 on hematologic recovery after treatment of mice with 5-fluorouracil. J. Immunol. 147: 3342-3347, 1991.[Abs]

  340. Armitage, J.O. and Longo, D.L.: Hodgkin's and non-Hodgkin's malignant lymphomas: management options. In Schafer, A.I. and McArthur, J.R. (Eds.): Hematology, 1991. Denver, American Society of Hematology, 1991, pp. 22-30.

  341. Pai, L.H., Bookman, M.A., Ozols, R.F., Young, R.C., Smith, J.W., II, Longo, D.L., Gould, B., Frankel, A., McClay, E.F., Howell, S., Reed, E., Willingham, M.C., FitzGerald, D.J., and Pastan, I.: Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J. Clin. Oncol. 9: 2095-2103, 1991.[Abs]

  342. Janik, J.E. and Longo, D.L.: Biological response modifiers in breast cancer. Comprehensive Therapy 17: 28-31, 1991.

  343. Morgan, A.C., Jr., Manger, R., Pearson, J.W., Longo, D., Abrams, P., Sivam, G., and Bjorn, M.: Immunoconjugates of Pseudomonas exotoxin A: evaluation in mice, monkeys, and man. Cancer Detect. Prev. 15: 137-143, 1991.[Abs]

  344. Hornung, R.L., Pearson, J.W., Beckwith, M., and Longo, D.L.: Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res. 52: 101-107, 1992.[Abs]

  345. O'Connor, P.M., Ferris, D.K., White, G.A., Pines, J., Hunter, T., Longo, D.L., and Kohn, K.W.: Relationships between cdc2 kinase, DNA cross-linking and cell cycle perturbations induced by nitrogen mustard. Cell Growth Differ. 3: 43-52, 1992.[Abs]

  346. Musso, T., Espinoza-Delgado, I., Pulkki, K., Gusella, G.L., Longo, D.L., and Varesio, L.: IL-2 induces IL-6 production in human monocytes. J. Immunol. 148: 795-800, 1992.[Abs]

  347. Longo, D.L., Duffey, P.L., Young, R.C., Hubbard, S.M., Ihde, D.C., Glatstein, E., Phares, J.C., Jaffe, E.S., Urba, W.J., and DeVita, V.T., Jr.: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J. Clin. Oncol. 10: 210-218, 1992.[Abs]

  348. Sundeen, J.T., Longo, D.L., and Jaffe, E.S.: CD5 expression in B-cell small lymphocytic malignancies: correlations with clinical presentation and sites of disease. Am. J. Surg. Pathol. 16: 130-137, 1992.[Abs]

  349. Longo, D.L. and DeVita, V.T., Jr.: The use of combination chemotherapy in the treatment of early stage Hodgkin's disease. In DeVita, V.T., Jr., Hellman, S., and Rosenberg, S.A. (Eds.): Important Advances in Oncology 1992. Philadelphia, J.B. Lippincott, 1992, pp. 155-165.

  350. Urba, W.J. and Longo, D.L.: Hodgkin's disease. N. Engl. J. Med. 326: 678-687, 1992.

  351. Yano, T., Van Krieken, J.H.J.M., Magrath, I.T., Longo, D.L., Jaffe, E.S., Raffeld, M.: Histogenetic correlation between subcategories of small noncleaved cell lymphomas. Blood 79: 1282-1290, 1992.[Abs]

  352. Longo, D.L. and DeVita, Jr., V.T.: Lymphomas. In Pinedo, H.M., Longo, D.L., and Chabner, B.A. (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual 13. Amsterdam, Elsevier Science Publishers B.V., 1992, pp. 349-403.

  353. Murphy, W.J., Bennett, M., Kumar, V., and Longo, D.L.: Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation. J. Immunol. 148: 2953-2960, 1992.[Abs]

  354. Wiltrout, R.H., Damia, G., MacPhee, M., Futami, H., Faltynek, C.R., Longo, D.L., Ruscetti, F.W., and Komschlies, K.L.: Cytokine-based combined modality approaches to the treatment of murine renal cancer. In Goldstein, A.L. and Garaci, E. (Eds.): Biological Response Modifiers in the Treatment of Cancer and Infectious Diseases. New York, Plenum Publishing Corporation, 1992, pp. 269-274.

  355. Fenton, R.G., Kung, H-F., Longo, D.L., and Smith, M.R.: Regulation of intracellular actin polymerization by prenylated cellular proteins. J. Cell Biol. 117: 347-356, 1992.[Abs]

  356. Urba, W.J., Ewel, C., Kopp, W., Smith, J.W., II, Steis, R.G., Ashwell, J.D., Creekmore, S.P., Rossio, J., Sznol, M., Sharfman, W., Fenton, R., Janik, J., Conlon, K., Watson, T., Beveridge, J., and Longo, D.L.: Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase Ia/b study. Cancer Res. 52: 2394-2401, 1992.[Abs]

  357. Longo, D.L.: Introduction: section on monitoring immunological therapies. In Rose, N.R., de Macario, E.C., Fahey, J.L., Friedman, H., and Penn, G.M. (Eds.): Manual of Clinical Laboratory Immunology, Fourth Edition. Washington, American Society for Microbiology, 1992, pp. 913-914.

  358. Creekmore, S.P., Urba, W.J., and Longo, D.L.: Strategies for clinical monitoring of therapeutic trials. In Rose, N.R., de Macario, E.C., Fahey, J.L., Friedman, H., and Penn, G.M. (Eds.): Manual of Clinical Laboratory Immunology, Fourth Edition. Washington, American Society for Microbiology, 1992, pp. 915-922.

  359. Murphy, W.J., Durum, S.K., and Longo, D.L.: Human growth hormone promotes engraftment of murine or human T cells in severe combined immunodeficient mice. Proc. Natl. Acad. Sci. USA 89: 4481-4485, 1992.[Abs]

  360. Ochoa, J.B., Curti, B., Peitzman, A.B., Simmons, R.L., Billiar, T.R., Hoffman, R., Rault, R., Longo, D.L., Urba, W.J., and Ochoa, A.C.: Increased circulating nitrogen oxides after human tumor immunotherapy: correlation with toxic hemodynamic changes. J. Natl. Cancer Inst. 84: 864-867, 1992.[Abs]

  361. Ewel, C.H., Urba, W.J., Kopp, W.C., Smith, J.W., II, Steis, R.G., Rossio, J.L., Longo, D.L., Jones, M.J., Alvord, W.G., Pinsky, C.M., Beveridge, J.M., McNitt, K.L., and Creekmore, S.P.: Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. Cancer Res. 52: 3005-3010, 1992.[Abs]

  362. Sznol, M., Clark, J.W., Smith, J.W., II, Steis, R.G., Urba, W.J., Rubinstein, L.V., VanderMolen, L.A., Janik, J., Sharfman, W.H., Fenton, R.G., Creekmore, S.P., Kremers, P., Conlon, K., Hursey, J., Beveridge, J., and Longo, D.L.: A pilot study of interleukin-2 and lymphokine- activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa2a in patients with metastatic melanoma and renal cell carcinoma. J. Natl. Cancer Inst. 84: 929-937, 1992.[Abs]

  363. Murphy, W.J., Durum, S.K., Anver, M.R., and Longo, D.L.: Immunologic and hematologic effects of neuroendocrine hormones: studies on DW/J dwarf mice. J. Immunol. 148: 3799-3805, 1992.[Abs]

  364. Murphy, W.J., Bennett, M., Anver, M.R., Baseler, M., and Longo, D.L.: Human-mouse lymphoid chimeras: host-vs.-graft and graft-vs.-host reactions. Eur. J. Immunol. 22: 1421-1427, 1992.[Abs]

  365. Sznol, M., Steis, R.G., Smith, J.W., II, Janik, J.E., Sharfman, W.H., Urba, W.J., Fenton, R.G., Creekmore, S.P., Beveridge, J., and Longo, D.L.: Intensive therapy with cisplatin, interleukin-2 and interferon-alpha2a in patients with metastatic melanoma: a phase II study. Online J. Curr. Clin. Trials July 1 (Doc No. 9): 3841 words;32 paragraphs, 1992.[Abs]

  366. Hornung, R.L. and Longo, D.L.: Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood 80: 77-83, 1992.[Abs]

  367. Smith, J.W., II, Urba, W.J., Curti, B.D., Elwood, L.J., Steis, R.G., Janik, J.E., Sharfman, W.H., Miller, L.L., Fenton, R.G., Conlon, K.C., Sznol, M., Creekmore, S.P., Wells, N.F., Ruscetti, F.W., Keller, J.R., Hestdal, K., Shimizu, M., Rossio, J., Alvord, W.G., Oppenheim, J.J., and Longo, D.L.: The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J. Clin. Oncol. 10: 1141-1152, 1992.[Abs]

  368. Loeffler, C.M., Smyth, M.J., Longo, D.L., Kopp, W.C., Harvey, L.K., Tribble, H.R., Tase, J.E., Urba, W.J., Leonard, A.S., Young, H.A., and Ochoa, A.C.: Immunoregulation in cancer-bearing hosts: down-regulation of gene expression and cytotoxic function in CD8+ T cells. J. Immunol. 149: 949-956, 1992.[Abs]

  369. Damia, G., Komschlies, K.L., Futami, H., Back, T., Gruys, M.E., Longo, D.L., Keller, J.R., Ruscetti, F.W., and Wiltrout, R.H.: Prevention of acute chemotherapy-induced death in mice by recombinant human interleukin 1: protection from hematological and nonhematological toxicities. Cancer Res. 52: 4082-4089, 1992.[Abs]

  370. Murphy, W.J. and Longo, D.L.: Hematopoietic growth-promoting effects of natural killer cells in mice in response to in vivo administration of human interleukin-2. J. Natl. Cancer Inst. 84: 1195-1200, 1992.[Abs]

  371. Longo, D.L., Duffey, P.L., Hubbard, S.M., Young, R.C., and DeVita, V.T., Jr.: Radiation therapy is better than chemotherapy in early-stage Hodgkin's disease? Not so fast. J. Clin. Oncol. 10: 1367-1368, 1992.

  372. Murphy, W.J., Keller, J.R., Harrison, C.L., Young, H.A., and Longo, D.L.: Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood 80: 670-677, 1992.[Abs]

  373. Yano, T., Jaffe, E.S., Longo, D.L., and Raffeld, M.: MYC rearrangements in histologically progressed follicular lymphomas. Blood 80: 758-767, 1992.[Abs]

  374. Tan, T-H., Huang, G.P., Sica, A., Ghosh, P., Young, H.A., Longo, D.L., and Rice, N.A.: Kappa B site-dependent activation of the interleukin-2 receptor -chain gene promoter by human c-Rel. Mol. Cell. Biol. 12: 4067-4075, 1992.[Abs]

  375. Zarate-Osorno, A., Medeiros, L.J., Longo, D.L., and Jaffe, E.S.: Non-Hodgkin's lymphomas arising in patients successfully treated for Hodgkin's disease. A clinical, histologic, and immunophenotypic study of 14 cases. Am. J. Surg. Pathol. 16: 885-895, 1992.[Abs]

  376. Murphy, W.J., Tsarfaty, G., and Longo, D.L.: Growth hormone exerts hematopoietic growth-promoting effects in vivo and partially counteracts the myelosuppressive effects of azidothymidine. Blood 80: 1443-1447, 1992. [Abs]

  377. Kaufman, D. and Longo, D.L.: Hodgkin's disease. Crit. Rev. Oncol. Hematol. 13: 135-187, 1992.

  378. Kennedy, I.C.S. and Longo, D.L.: Salvage therapy for Hodgkin's disease. Contemp. Oncol. 2(8): 16-25, 1992.

  379. Espinoza-Delgado, I., Longo, D.L., Gusella, G.L., and Varesio, L.: Regulation of IL-2 receptor subunit genes in human monocytes. Differential effects of IL-2 and IFN-. J. Immunol. 149: 2961-2968, 1992.[Abs]

  380. Wilson, W.H., Jain, V., Bryant, G., Cowan, K.H., Carter, C., Cottler-Fox, M., Goldspiel, B., Steinberg, S.M., Longo, D.L., and Wittes, R.E.: A phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J. Clin. Oncol. 10: 1712-1722, 1992.[Abs]

  381. Urba, W.J., Wilson, W.H., Duffey, P.L., Wittes, R., Chabner, B.A., and Longo, D.L.: Recent National Cancer Institute lymphoma trials of etoposide-containing combination chemotherapy. Semin. Oncol. 19 (suppl 13): 26-32, 1992.[Abs]

  382. Hestdal, K., Jacobsen, S.E.W., Ruscetti, F.W., Dubois, C.M., Longo, D.L., Chizzonite, R., Oppenheim, J.J., and Keller, J.R.: In vivo effect of interleukin-1 on hematopoiesis: role of colony-stimulating factor receptor modulation. Blood 80: 2486-2494, 1992.[Abs]

  383. Conlon, K.C., Ochoa, A.C., Kopp, W.C., Ortaldo, J.R., Longo, D.L., and Young, H.A.: Enhanced lymphokine production and lymphokine receptor expression in multiple antibody-stimulated human CD4+ peripheral blood lymphocytes. J. Immunol. 149: 3278-3289, 1992.[Abs]

  384. Murphy, W.J., Durum, S.K., and Longo, D.L.: Role of neuroendocrine hormones in murine T cell development: growth hormone exerts thymopoietic effects in vivo. J. Immunol. 149: 3851-3857, 1992.[Abs]

  385. Sotos, G.A., Liebmann, J.E., Kohler, D.R., and Longo, D.L.: Reactivation of thermal burn by methotrexate. J. Natl. Cancer Inst. 84: 1936-1938, 1992.

  386. Mizoguchi, H., O'Shea, J.J., Longo, D.L., Loeffler, C.M., McVicar, D.W., and Ochoa, A.C.: Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258: 1795-1798, 1992.[Abs]

  387. Kenny, J.J., Moratz, C.M., Guelde, G., O'Connell, C.D., George, J., Dell, C., Penner, S.J., Weber, J.S., Berry, J., Claflin, J.L., and Longo, D.L.: Antigen binding and idiotype analysis of antibodies obtained following electroporation of heavy and light chain genes encoding phosphocholine-specific antibodies: a model for T15-idiotype dominance. J. Exp. Med. 176: 1637-1643, 1992.[Abs]

  388. Mueller, B.U., Skelton, J., Callender, D.P.E., Marshall, D., Gress, J., Longo, D., Norton, J., Rubin, M., Venzon, D., and Pizzo, P.A.: A prospective randomized trial comparing the infectious and noninfectious complications of an externalized catheter versus a subcutaneously implanted device in cancer patients. J. Clin. Oncol. 10: 1943-1948, 1992.[Abs]

  389. Kenny, J.J., Sieckmann, D.G., Freter, C., Hodes, R., Hathcock, K., and Longo, D.L.: Modulation of signal transduction in phosphocholine-specific B cells from µ transgenic mice. Curr. Top. Microbiol. Immunol. 182: 95-103, 1992.

  390. Murphy, W.J., Durum, S.K., Anver, M., Frazier, M., and Longo, D.L.: Recombinant human growth hormone promotes human lymphocyte engraftment in immunodeficient mice and results in an increased incidence of human Epstein Barr Virus-induced B-cell lymphoma. Brain Behav. Immun. 6: 355-364, 1992.[Abs]

  391. Oppenheim, J.J., Neta, R., Smith, J.W., II, and Longo, D.L.: Neuroendocrine and other in vivo effects of interleukin-1 in mouse and man. In Bartfai, T. and Ottoson, D. (Eds.): Neuroimmunology of Fever. Oxford, Pergamon Press, 1992, pp. 79-86.

  392. Longo, D.L.: Oncology. In Joyce, M. (Ed.): Encyclopedia of Science & Technology, 7th edition, vol. 12. New York, McGraw-Hill Publishing Company, pp. 359-365, 1992.

  393. Creekmore, S.P. and Longo, D.L.: Cytokines in oncology. In Niederhuber, J.E. (Ed.): Current Therapy in Oncology. St. Louis, Mosby-Year Book, Inc., pp. 36-41, 1993.

  394. Janik, J., Kopp, W.C., Smith, J.W., II, Longo, D.L., Alvord, W.G., Sharfman, W.H., Fenton, R.G., Sznol, M., Steis, R.G., Creekmore, S.P., Ewel, C.H., Hursey, J., and Urba, W.J.: Dose-related immunologic effects of levamisole in patients with cancer. J. Clin. Oncol. 11: 125-135, 1993.[Abs]

  395. Longo, D.L.: Editorial: What's the deal with follicular lymphomas? J. Clin. Oncol. 11: 202-208, 1993.

  396. Longo, D.L., DeVita, V.T., Jr., Jaffe, E.S., Mauch, P., and Urba, W.J.: Lymphocytic lymphoma. In DeVita, V.T., Jr., Hellman, S., and Rosenberg, S.A. (Eds.): Cancer: Principles and Practice of Oncology, Fourth Edition. Philadelphia, J.B. Lippincott Company, 1993, pp. 1859-1921.

  397. Zarate-Osorno, A., Medeiros, L.J., Kingma, D.W., Longo, D.L., and Jaffe, E.S.: Hodgkin's disease following non-Hodgkin's lymphoma: a clinicopathologic and immunophenotypic study of nine cases. Am. J. Surg. Pathol. 17: 123-132, 1993.[Abs]

  398. Sznol, M. and Longo, D.L.: Chemotherapy drug interactions with biological agents. Semin. Oncol. 20: 80-93, 1993.

  399. Hirose, K., Longo, D.L., Oppenheim, J.J., and Matsushima, K.: Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin-1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation. FASEB J. 7: 361-368, 1993.[Abs]

  400. Smith, J.W., II, Longo, D.L., Alvord, W.G., Janik, J.E., Sharfman, W.H., Gause, B.L., Curti, B.D., Creekmore, S.P., Holmlund, J.T., Fenton, R.G., Sznol, M., Miller, L.L., Shimizu, M., Oppenheim, J.J., Fiem, S.J., Hursey, J.C., Powers, G.C., and Urba, W.J.: The effects of treatment with interleukin-1 on platelet recovery after high-dose carboplatin. N. Engl. J. Med. 328: 756-761, 1993.[Abs]

  401. Beckwith, M., Urba, W.J., and Longo, D.L.: Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J. Natl. Cancer Inst. 85: 483-488, 1993.[Abs]

  402. Kopp, W.C., Smith, J.W., II, Ewel, C.H., Alvord, W.G., Main, C., Guyre, P.M., Steis, R.G., Longo, D.L., and Urba, W.J.: Immunomodulatory effects of interferon- in patients with metastatic malignant melanoma. J. Immunother. 13: 181-190, 1993.[Abs]

  403. Curti, B.D., Longo, D.L., Ochoa, A.C., Conlon, K.C., Smith, J.W., II, Alvord, W.G., Creekmore, S.P., Fenton, R.G., Gause, B.L., Holmlund, J., Janik, J.E., Ochoa, J., Rice, P.A., Sharfman, W.H., Sznol, M., and Urba, W.J.: Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. J. Clin. Oncol. 11: 652-660, 1993.[Abs]

  404. Murphy, W.J., Conlon, K.C., Sayers, T.J., Wiltrout, R.H., Back, T.C., Ortaldo, J.R., and Longo, D.L.: Engraftment and activity of anti-CD3-activated human peripheral blood lymphocytes transferred into mice with severe combined immune deficiency. J. Immunol. 150: 3634-3642, 1993.[Abs]

  405. Longo, D.L. and Duffey, P.L.: Management of aggressive histology lymphoma: an approach based on data from the National Cancer Institute. Hem/Onc. Annals 1: 19-28, 1993.

  406. Curti, B.D., Urba, W.J., Alvord, W.G., Janik, J.E., Smith, J.W., II, Madara, K., and Longo, D.L.: Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res. 53: 2204-2207, 1993.[Abs]

  407. O'Connor, P.M., Ferris, D.K., Pagano, M., Draetta, G., Pines, J., Hunter, T., Longo, D.L., and Kohn, K.W.: G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J. Biol. Chem. 268: 8298-8308, 1993.[Abs]

  408. Pearson, J.W., Fogler, W.E., Volker, K., Riggs, C.W., Gruys, E., Groves, E.S., Wiltrout, R.H., and Longo, D.L.: Restoration of interferon potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors. J. Natl. Cancer Inst. 85: 907-912, 1993.[Abs]

  409. Li, C-C.H., Chen, E., O'Connell, C.D., and Longo, D.L.: Detection of c-mos proto-oncogene expression in human cells. Oncogene 8: 1685-1691, 1993.[Abs]

  410. Li, C-C.H., Ruscetti, F.W., Rice, N.R., Chen, E., Yang, N-S., Mikovits, J., and Longo, D.L.: Differential expression of Rel family members in human T-cell leukemia virus type I-infected cells: transcriptional activation of c-rel by Tax protein. J. Virol. 67: 4205-4213, 1993.[Abs]

  411. Hestdal, K., Jacobsen, S.E.W., Ruscetti, F.W., Longo, D.L., Boone, T.C., and Keller, J.R.: Increased granulopoiesis after sequential administration of transforming growth factor-1 and granulocyte-macrophage colony-stimulating factor. Exp. Hematol. 21: 799-805, 1993.[Abs]

  412. Hollingsworth, H.C., Longo, D.L., and Jaffe, E.S.: Small noncleaved cell lymphoma associated with florid epithelioid granulomatous response: a clinicopathologic study of seven patients. Am. J. Surg. Pathol. 17: 51-59, 1993.[Abs]

  413. Murphy, W.J., Durum, S.K., and Longo, D.L.: Differential effects of growth hormone and prolactin on murine T cell development and function. J. Exp. Med. 178: 231-236, 1993.[Abs]

  414. Fenton, R.G., Taub, D.D., Kwak, L.W., Smith, M.R., and Longo, D.L.: Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J. Natl. Cancer Inst. 85: 1294-1302, 1993.[Abs]

  415. Janik, J., Kopp, W.C., Smith, J.W., II, Longo, D.L., Alvord, W.G., and Urba, W.J.: Levamisole-induced neopterin synthesis. Ann. NY Acad. Sci. 685: 252-258, 1993.

  416. Murphy, W.J., Reynolds, C.W., Tiberghien, P., and Longo, D.L.: Natural killer cells and bone marrow transplantation. J. Natl. Cancer Inst. 85: 1475-1482, 1993.[Abs]

  417. Phillips, G.L. and Longo, D.L.: Indications for high-dose therapy with hematopoietic support in patients with Hodgkin's disease. Leukemia 7: 1087-1090, 1993.

  418. Yano, T., Sander, C.A., Andrade, R.E., Gauwerky, C.E., Croce, C.M., Longo, D.L., Jaffe, E.S., and Raffeld, M.: Molecular analysis of the BCL-3 locus at chromosome 17q22 in B-cell neoplasms. Blood 82: 1813-1819, 1993.[Abs]

  419. Longo, D.L., DeVita, V.T., Jr., and Young, R.C.: Letter to the Editor: CHOP versus intensive regimens in non-Hodgkin's lymphoma. N. Engl. J. Med. 329: 580-581, 1993.

  420. Horowitz, M.E., Kinsella, T.J., Wexler, L.H., Belasco, J., Triche, T., Tsokos, M., Steinberg, S.M., McClure, L., Longo, D.L., Steis, R.G., Glatstein, E., Pizzo, P.A., and Miser, J.S.: Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J. Clin. Oncol. 11: 1911-1918, 1993.[Abs]

  421. Sander, C.A., Yano, T., Clark, H.M., Harris, C., Longo, D.L., Jaffe, E.S., and Raffeld, M.: p53 mutation is associated with progression in follicular lymphomas. Blood 82: 1994-2004, 1993.[Abs]

  422. Urba, W.J. and Longo, D.L.: Hodgkin's disease in adults. Part I. Invest. Radiol. 28: 737-752, 1993.[Abs]

  423. Urba, W.J. and Longo, D.L.: Hodgkin's disease in adults. Part II. Invest. Radiol. 28: 848-859, 1993. [Abs]

  424. Longo, D.L.: Editorial: Is anything better than MOPP? Hematologic. Oncol. 11: 65-71, 1993.

  425. Murphy, W.J., Back, T.C., Conlon, K.C., Komschlies, K.L., Ortaldo, J.R., Sayers, T.J., Wiltrout, R.H., and Longo, D.L.: Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. J. Clin. Invest. 92: 1918-1924, 1993.[Abs]

  426. Siefer, A.K., Longo, D.L., Harrison, C.L., Reynolds, C.W., and Murphy, W.J.: Activated natural killer cells and interleukin-2 promote granulocytic and megakaryocytic reconstitution after syngeneic bone marrow transplantation in mice. Blood 82: 2577-2584, 1993.[Abs]

  427. Creekmore, S.P., Reynolds, C.W., Hecht, T.T., Urba, W.J., and Longo, D.L.: Interleukin-2 therapy for human cancer. In Oppenheim, J.J., Rossio, J.L., and Gearing, A.J.H. (Eds.): Clinical Applications of Cytokines: Role in Pathogenesis, Diagnosis and Therapy. Oxford, Oxford University Press, 1993, pp. 147-154.

  428. Longo, D.L.: Treatment of aggressive lymphomas: recent progress and future prospects. In Kimura, K., Yamada, K., Carter, S.K., and Longo, D.L. (Eds.): Cancer Chemotherapy: Challenges for the Future, Vol. 8. Tokyo, Excerpta Medica, Ltd., 1993, pp. 3-14.

  429. Kwak, L.W., DeVita, Jr., V.T., and Longo, D.L.: Lymphomas. In Pinedo, H.M., Longo, D.L., and Chabner, B.A. (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual 14. Amsterdam, Elsevier Science Publishers B.V., 1993, pp. 383-426.

  430. Wang, J., Raffeld, M., Medeiros, L.J., Longo, D.L., Jaffe, E.S., Duffey, P., and Stetler-Stevenson, M.: Follicular center cell lymphoma with the t(14;18) translocation in which the rearranged BCL-2 gene is silent. Leukemia 7: 1834-1839, 1993.[Abs]

  431. Janik, J.E., Sznol, M., Urba, W.J., Figlin, R., Bukowski, R.M., Fyfe, G., Pierce, W.C., Belldegrun, A., Sharfman, W.H., Smith, J.W., II, and Longo, D.L.: Erythropoietin production: a potential marker for interleukin-2/interferon-responsive tumors. Cancer 72: 2656-2659, 1993.[Abs]

  432. Williams, M.E., Lister, T.A., and Longo, D.L.: Hodgkin's disease and non-Hodgkin's lymphoma. ASH Educational Booklet 49-61, 1993.

  433. Finke, J.H., Zea, A.H., Stanley, J., Longo, D.L., Mizoguchi, H., Tubbs, R.R., Wiltrout, R.H., O'Shea, J.J., Kudoh, S., Klein, E., Bukowski, R.M., and Ochoa, A.C.: Loss of T-cell receptor chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 53: 5613-5616, 1993. [Abs]

  434. Aiello, F.B., Gusella, L., Longo, D.L., Birchenall-Roberts, M., Takacs, L., Takei, F., Ruscetti, F., Musiani, P., and Durum, S.K.: Inducible accessory function of a macrophage cell line. Immunopharmacol. Immunotoxicol. 15: 327-353, 1993.[Abs]

  435. Longo, D.L., Banks, P.M., and Hoppe, R.T.: Hodgkin's disease. La Rev. De Invest. Clin. 45 (suppl): 73-83, 1993.

  436. Bosco, M.C., Gusella, G.L., Espinoza-Delgado, I., Longo, D.L., and Varesio, L.: Interferon- upregulates interleukin-8 gene expression in human monocytic cells by a posttranscriptional mechanism. Blood 83: 537-542, 1994.[Abs]

  437. Hamanaka, R., Maloid, S., Smith, M.R., O'Connell, C.D., Longo, D.L., and Ferris, D.K.: Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ. 5: 249-257, 1994.[Abs]

  438. Musso, T., Gusella, G.L., Brooks, A., Longo, D.L., and Varesio, L.: Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. Blood 83: 1408-1411, 1994.[Abs]

  439. Longo, D.L.: Follicular lymphoma. In Foley, J.F., Vose, J.M., and Armitage, J.O. (Eds.): Current Therapy in Oncology. Philadelphia, W.B. Saunders, 1994, pp. 255-261.

  440. Longo, D.L.: Plasma cell disorders. In Isselbacher, K.J., Braunwald, E., Wilson, J.D., Martin, J.B., Fauci, A.S., and Kasper, D.L. (Eds.): Harrison's Principles of Internal Medicine, 13th Edition. New York, McGraw-Hill Book Company, 1994, pp. 1618-1625.

  441. Norihisa, Y., McVicar, D.W., Ghosh, P., Houghton, A.N., Longo, D.L., Creekmore, S.P., Blake, T., Ortaldo, J.R., and Young, H.A.: Increased proliferation, cytotoxicity, and gene expression after stimulation of human peripheral blood T lymphocytes through a surface ganglioside (GD3). J. Immunol. 152: 485-495, 1994.[Abs]

  442. Kenny, J.J., Guelde, G., Fischer, R.T., and Longo, D.L.: Induction of phosphocholine-specific antibodies in X-linked immune deficient mice: in vivo protection against a Streptococcus pneumoniae challenge. Int. Immunol. 6: 561-568, 1994.[Abs]

  443. Sarkar, F.H., Smith, M.R., Hoover, T., Princler, G., Crissman, J.D., Visscher, D.W., Longo, D.L., Kung, H-F., and Raziuddin: c-erbB-2 promoter-specific DNA-binding protein isolated from human breast cancer tissues displays mitogenic activity. J. Biol. Chem. 269: 12285-12289, 1994.[Abs]

  444. Sieckmann, D.G., Holmes, K., Hornbeck, P., Martin, E., Guelde, G., Bondada, S., Longo, D.L., and Kenny, J.J.: B cells from M167 µ transgenic mice fail to proliferate after stimulation with soluble anti-Ig antibodies. A model for antigen-induced B cell anergy. J. Immunol. 152: 4873-4883, 1994.[Abs]

  445. Janik, J.E. and Longo, D.L.: Laboratory characterization of malignancies of the immune system. Immunol. Allergy Clin. North Am. 14: 301-322, 1994.

  446. Funakoshi, S., Longo, D.L., Beckwith, M., Conley, D.K., Tsarfaty, G., Tsarfaty, I., Armitage, R.J., Fanslow, W.C., Spriggs, M.K., and Murphy, W.J.: Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83: 2787-2794, 1994.[Abs]

  447. Bosco, M.C., Espinoza-Delgado, I., Schwabe, M., Gusella, G.L., Longo, D.L., Sugamura, K., and Varesio, L.: Regulation by interleukin-2 (IL-2) and interferon of IL-2 receptor chain gene expression in human monocytes. Blood 83: 2995-3002, 1994.[Abs]

  448. Espinoza-Delgado, I., Bosco, M.C., Musso, T., Mood, K., Ruscetti, F.W., Longo, D.L., and Varesio, L.: Inhibitory cytokine circuits involving transforming growth factor-, interferon-, and interleukin-2 in human monocyte activation. Blood 83: 3332-3338, 1994.[Abs]

  449. Bosco, M.C., Espinoza-Delgado, I., Schwabe, M., Russell, S.M., Leonard, W.J., Longo, D.L., and Varesio, L.: The subunit of the interleukin-2 receptor is expressed in human monocytes and modulated by interleukin-2, interferon , and transforming growth factor 1. Blood 83: 3462-3467, 1994.[Abs]

  450. Ghosh, P., Sica, A., Young, H.A., Ye, J., Franco, J.L., Wiltrout, R.H., Longo, D.L., Rice, N.R., and Komschlies, K.L.: Alterations in NFB/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res. 54: 2969-2972, 1994.[Abs]

  451. Linnekin, D., Howard, O.M.Z., Park, L., Farrar, W., Ferris, D., and Longo, D.L.: Hck expression correlates with granulocyte-macrophage colony-stimulating factor-induced proliferation in HL-60 cells. Blood 84: 94-103, 1994.[Abs]

  452. Hestdal, K., Ruscetti, F.W., Chizzonite, R., Ortiz, M., Gooya, J.M., Longo, D.L., and Keller, J.R.: Interleukin-1 (IL-1) directly and indirectly promotes hematopoietic cell growth through type I IL-1 receptor. Blood 84: 125-132, 1994.[Abs]

  453. Musso, T., Bosco, M.C., Longo, D.L., Espinoza-Delgado, I., Sica, A., Cox, G.W., Gusella, G.L., Forni, G., and Varesio, L.: LPS-inducible nuclear factor in human monocytes that binds the negative regulatory element of the HIV LTR. J. Leukoc. Biol. 56: 21-26, 1994.[Abs]

  454. Longo, D.L.: Non-Hodgkin's lymphoma. Curr. Opin. Hematol. 1: 295-302, 1994.

  455. Taub, D.D., Tsarfaty, G., Lloyd, A.R., Durum, S.K., Longo, D.L., and Murphy, W.J.: Growth hormone promotes human T cell adhesion and migration to both human and murine matrix proteins in vitro and directly promotes xenogeneic engraftment. J. Clin. Invest. 94: 293-300, 1994.[Abs]

  456. Murphy, W.J., Durum, S.K., Anver, M.R., Ferris, D.K., McVicar, D.W., O'Shea, J.J., Ruscetti, S.K., Smith, M.R., Young, H.A., and Longo, D.L.: Induction of T cell differentiation and lymphomagenesis in the thymus of mice with severe combined immune deficiency (SCID). J. Immunol. 153: 1004-1014, 1994.[Abs]

  457. Tiberghien, P., Reynolds, C.W., Keller, J., Spence, S., Deschaseaux, M., Certoux, J-M., Contassot, E., Murphy, W.J., Lyons, R., Chiang, Y., Herve, P., Longo, D.L., and Ruscetti, F.W.: Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T-lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 84: 1333-1341, 1994.[Abs]

  458. Longo, D.L.: Prefatory chapter: Cytokines, genes, and cancer therapy. In Forni, G., Foa, R., Santoni, A., and Frati, L. (Eds.): Cytokine-Induced Tumor Immunogenicity. From Exogenous Molecules to Gene Therapy. London, Academic Press, 1994, pp. xxi-xxv.

  459. Longo, D.L.: New clinical prospects. In Forni, G., Foa, R., Santoni, A., and Frati, L. (Eds.): Cytokine-Induced Tumor Immunogenicity. From Exogenous Molecules to Gene Therapy. London, Academic Press, 1994, pp. 469-480.

  460. Longo, D.L.: Commentary: The Palackdharry article reviewed. Oncology 8: 73-77, 1994.

  461. Murphy, W.J., Taub, D.D., Anver, M., Conlon, K., Oppenheim, J.J., Kelvin, D.J., and Longo, D.L.: Human RANTES induces the migration of human T lymphocytes into the peripheral tissues of mice with severe combined immune deficiency. Eur. J. Immunol. 24: 1823-1827, 1994.[Abs]

  462. Grzegorzewski, K., Ruscetti, F.W., Usui, N., Damia, G., Longo, D.L., Carlino, J.A., Keller, J.R., and Wiltrout, R.H.: Recombinant transforming growth factor 1 and 2 protect mice from acutely lethal doses of 5-fluorouracil and doxorubicin. J. Exp. Med. 180: 1047-1057, 1994.[Abs]

  463. Kwak, L.W. and Longo, D.L.: Lymphoproliferative disorders. In Frank, M.M., Austen, K.F., Claman, H.N., and Unanue, E.R. (Eds.): Samter's Immunologic Diseases, Fifth Edition. Boston, Little, Brown and Company, 1994, pp. 551-597.

  464. Johnston, J.A., Ferris, D.K., Wang, J.M., Longo, D.L., Oppenheim, J.J., and Kelvin, D.J.: Staurosporine restores signaling and inhibits interleukin-8-induced chemotactic desensitization. Eur. J. Immunol. 24: 2556-2562, 1994.[Abs]

  465. Li, C-C.H., Korner, M., Ferris, D.K., Chen, E., Dai, R.M., and Longo, D.L.: NF-B/Rel family members are physically associated phosphoproteins. Biochem. J. 303: 499-506, 1994.[Abs]

  466. Whang-Peng, J., Knutsen, T., Jaffe, E., Raffeld, M., Zhao, W.P., Duffey, P., and Longo, D.L.: Cytogenetic study of two cases with lymphoma of mucosa-associated lymphoid tissue. Cancer Genet. Cytogenet. 77: 74-80, 1994.[Abs]

  467. Tsarfaty, G., Longo, D.L., and Murphy, W.J.: Human insulin-like growth factor I exerts hematopoietic growth-promoting effects after in vivo administration. Exp. Hematol. 22: 1273-1277, 1994.[Abs]

  468. Longo, D.L., Duffey, P.L., Jaffe, E.S., Raffeld, M., Hubbard, S.M., Fisher, R.I., Wittes, R.E., DeVita, Jr., V.T., and Young, R.C.: Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. J. Clin. Oncol. 12: 2153-2159, 1994.[Abs]

  469. Kim, W.K., Tang, Y., Kenny, J.J., Longo, D.L., and Morse III, H.C.: In murine AIDS, B cells are early targets of defective virus and are required for efficient infection and expression of defective virus in T cells and macrophages. J. Virol. 68: 6767-6769, 1994.[Abs]

  470. Li, C-C.H., Dai, R-M., Chen, E., and Longo, D.L.: Phosphorylation of NF-KB1-p50 is involved in NF-B activation and stable DNA binding. J. Biol. Chem. 269: 30089-30092, 1994.[Abs]

  471. Kwak, L.W., DeVita, V.T., Jr., and Longo, D.L.: Lymphomas. In Pinedo, H.M., Longo, D.L., and Chabner, B.A. (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual 15. Amsterdam, Elsevier Science Publishers B.V., 1994, pp. 413-470.

  472. Steis, R.G. and Longo, D.L.: Clinical relevance of recombinant interferon-2a antibodies in patients with hairy cell leukemia. J. Interferon Res. 14: 207-209, 1994.

  473. Ochoa, A.C., Curti, B.D., Zea, A.H., Anderson, P.M., Saxton, M., Strobl, S.S., Kopp, W.C., Urba, W.J., and Longo, D.L.: Anti-CD3-stimulated T cells and IL2 liposomes in adoptive immunotherapy: advantages and limitations. In Chang, A.E., and Shu, S. (Eds.): Immunotherapy of Cancer with Sensitized T Lymphocytes. Austin, R.G. Landes, Co., 1994, pp. 69-78.

  474. Curti, B.D. and Longo, D.L.: Specific oncologic issues in the critically ill. In Parrillo, J.E., and Bone, R.C. (Eds.): Critical Care Medicine: Principles of Diagnosis and Management. St. Louis, Mosby-Year Book, Inc., 1995, pp. 1345-1362.

  475. Whang-Peng, J., Knutsen, T., Jaffe, E.S., Steinberg, S.M., Raffeld, M., Zhao, W.P., Duffey, P., Condron, K., Yano, T., and Longo, D.L.: Sequential analysis of 43 patients with non-Hodgkin's lymphoma: clinical correlations with cytogenetic, histologic, immunophenotyping and molecular studies. Blood 85: 203-216, 1995.[Abs]

  476. Fogler, W.E., Pearson, J.W., Volker, K., Ariyoshi, K., Watabe, H., Riggs, C.W., Wiltrout, R.H., and Longo, D.L.: Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody. J. Natl. Cancer Inst. 87: 94-104, 1995.[Abs]

  477. Sela, S., Husain, S.R., Pearson, J.W., Longo, D.L., and Rahman, A.: Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil. J. Natl. Cancer Inst. 87: 123-128, 1995.[Abs]

  478. Holmlund, J.T., Kopp, W.C., Wiltrout, R.H., Longo, D.L., Urba, W.J., Janik, J.E., Sznol, M., Conlon, K.C., Fenton, R.G., Hornung, R., Madara, K., Shields, M.A., Smith II, J.W., Sharfman, W., Steis, R.G., Ewel, C., Malspeis, L., and Creekmore, S.P.: A phase I clinical trial of flavone-8-acetic acid in combination with interleukin-2. J. Natl. Cancer Inst. 87: 134-136, 1995.[Abs]

  479. Espinoza-Delgado, I., Bosco, M.C., Musso, T., Gusella, G.L., Longo, D.L., and Varesio, L.: Interleukin-2 and human monocyte activation. J. Leukoc. Biol. 57: 13-19, 1995.[Abs]

  480. Fenton, R.G. and Longo, D.L.: Editorial: Genetic instability and tumor cell variation: implications for immunotherapy. J. Natl. Cancer Inst. 87: 241-243, 1995.

  481. Sharfman, W.H., Urba, W.J., Smith, J.W., II, Janik, J.E., Curti, B.D., Gause, B.L., Holmlund, J.T., Steis, R.G., Beauchamp, A.E., and Longo, D.L.: Phase I/II trial of 5-fluorouracil, leucovorin, zidovudine and dipyridamole for patients with metastatic colorectal cancer, renal cell carcinoma and malignant melanoma. Int. J. Oncol. 6: 579-583, 1995.

  482. Wiltrout, R.H., Gregorio, T.A., Fenton, R.G., Longo, D.L., Ghosh, P., Murphy, W.J., and Komschlies, K.L.: Cellular and molecular studies in the treatment of murine renal cancer. Semin. Oncol. 22: 9-16, 1995. [Abs]

  483. Fischer, R.T., Longo, D.L., and Kenny, J.J.: A novel phosphocholine antigen protects both normal and X-linked immune deficient mice against Streptococcus pneumoniae: comparison of the 6-0-phosphocholine hydroxyhexanoate-conjugate with other phosphocholine-containing vaccines. J. Immunol. 154: 3373-3382, 1995.[Abs]

  484. Taub, D.D., Proost, P., Murphy, W.J., Anver, M., Longo, D.L., Van Damme, J., and Oppenheim, J.J.: Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J. Clin. Invest. 95: 1370-1376, 1995.[Abs]

  485. Kwak, L.W., Taub, D.D., Duffey, P.L., Bensinger, W.I., Bryant, E.M., Reynolds, C.W., and Longo, D.L.: Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345: 1016-1020, 1995.[Abs]

  486. Beckwith, M., Ruscetti, F.W., Sing, G.K., Urba, W.J., and Longo, D.L.: Anti-IgM induces transforming growth factor- sensitivity in a human B-lymphoma cell line: inhibition of growth is associated with a downregulation of mutant p53. Blood 85: 2461-2470, 1995.[Abs]

  487. Murphy, W.J., Rui, H., and Longo, D.L.: Effects of growth hormone and prolactin on immune development and function. Life Sci. 57: 1-14, 1995.[Abs]

  488. Fenton, R.G., Sznol, M., Luster, D.G., Taub, D.D., and Longo, D.L.: A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401. Hum. Gene Ther. 6: 87-106, 1995.[Abs]

  489. Li, C-C.H., O'Connell, C.D., Beckwith, M., and Longo, D.L.: Detection of p53 mutations in B cell non-Hodgkin's lymphoma cell lines. Leukemia 9: 650-655, 1995.[Abs]

  490. Kaufman, D. and Longo, D.L.: Hodgkin's disease. In Abeloff, M.D., Armitage, J.O., Lichter, A.S., and Niederhuber, J.E. (Eds.): Clinical Oncology. New York, Churchill Livingstone, 1995, pp. 2075-2107.

  491. Kenny, J.J., Tucker, P.W., Claflin, L., Katsumata, M., Green, M., Reed, J., and Longo, D.L.: Analysis of antigen-driven positive and negative selection of phosphocholine-specific bone marrow B-cells. Curr. Top. Microbiol. Immunol. 194: 235-244, 1995.

  492. Tortolani, P.J., Johnston, J.A., Bacon, C.M., McVicar, D.W., Shimosaka, A., Linnekin, D., Longo, D.L., and O'Shea, J.J.: Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2. Blood 85: 3444-3451, 1995.[Abs]

  493. Kenny, J.J., Stall, A.M., Fischer, R.T., Derby, E., Yang, M.C.W., Tucker, P.W., and Longo, D.L.: Ig2b transgenes promote B cell development but alternate developmental pathways appear to function in different transgenic lines. J. Immunol. 154: 5694-5705, 1995.[Abs]

  494. Turley, J.M., Funakoshi, S., Ruscetti, F.W., Kasper, J., Murphy, W.J., Longo, D.L., and Birchenall-Roberts, M.C.: Growth inhibition and apoptosis of RL human B lymphoma cells by vitamin E succinate and retinoic acid: role for transforming growth factor . Cell Growth Differ. 6: 655-663, 1995.[Abs]

  495. Linnekin, D., Mou, S.M., Greer, P., Longo, D.L., and Ferris, D.K.: Phosphorylation of a Fes-related protein in response to granulocyte-macrophage colony stimulating factor. J. Biol. Chem. 270: 4950-4954, 1995.[Abs]

  496. Xu, L., Badolato, R., Murphy, W.J., Longo, D.L., Anver, M., Hale, S., Oppenheim, J.J., and Wang, J.M.: A novel biologic function of serum amyloid A. Induction of T lymphocyte migration and adhesion. J. Immunol. 155: 1184-1190, 1995.[Abs]

  497. Bosco, M.C., Pulkki, K., Rowe, T.K., Zea, A.H., Musso, T., Longo, D.L., Varesio, L., and Espinoza-Delgado, I.: IL-4 inhibits IL-2-induced tumoricidal activity and secretory functions of human monocytes. Modulation of IL-2 binding and IL-2 receptor chain expression. J. Immunol. 155: 1411-1419, 1995.[Abs]

  498. Ochoa, A.C. and Longo, D.L.: Alterations of signal transduction in T cells from cancer patients. In DeVita, V.T., Jr., Hellman, S., and Rosenberg, S.A. (Eds.): . Important Advances in Oncology 1995. Philadelphia, J.B. Lippincott, 1995, pp. 43-54.

  499. Gause, B.L. and Longo, D.L.: Lymphoma and Hodgkin's disease. In Rich, R.R., Shearer, W.T., Strober, W., Fleisher, T.A., and Schwartz, B.D., (Eds.): Clinical Immunology: Principles and Practice, First Edition. St. Louis, Mosby-Year Book, 1995, pp. 1745-1767.

  500. Zea, A.H., Longo, D.L., Finke, J.H., Bukowski, R.M.., and Ochoa, A.C.: Alterations in signal transduction in T cells from cancer patients. In Bukowski, R.M., Finke, J.H., and Klein, E.A. (Eds): Biology of Renal Cell Carcinoma. New York, Springer-Verlag, 1995, pp. 65-71.

  501. Wiltrout, R.H., Ghosh, P., Franco, J.L., Mori, M., Fenton, R.G., Longo, D.L., Murphy, W.J., Grzegorzewski, K., Kelvin, D.J., and Komschlies, K.L.: Cellular and molecular considerations for the treatment of murine renal cancer. In Bukowski, R.M., Finke, J.H., and Klein, E.A. (Eds): Biology of Renal Cell Carcinoma. New York, Springer-Verlag, 1995, pp. 123-132.

  502. Murphy, W.J., Funakoshi, S., Beckwith, M., Rushing, S.E., Conley, D.K., Armitage, R.J., Fanslow, W.C., Rager, H.C., Taub, D.D., Ruscetti, F.W., and Longo, D.L.: Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes. Blood 86: 1946-1953, 1995.[Abs]

  503. Musso, T., Badolato, R., Longo, D.L., Gusella, G.L., and Varesio, L.: Leukemia inhibitory factor induces interleukin-8 and monocyte chemotactic and activating factor in human monocytes: differential regulation by interferon-. Blood 86: 1961-1967, 1995.[Abs]

  504. Hornung, R.L., Longo, D.L., Bowersox, O.C., and Kwak, L.W.: Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor. J. Natl. Cancer Inst. 87: 1289-1296, 1995.[Abs]

  505. Franco, J.L., Ghosh, P., Wiltrout, R.H., Carter, C.R.D., Zea, A.H., Momozaki, N., Ochoa, A.C., Longo, D.L., Sayers, T.J., and Komschlies, K.L.: Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice. Cancer Res. 55: 3840-3846, 1995.[Abs]

  506. Hornung, R.L., Longo, D.L., Gowda, V.L., and Kwak, L.W.: Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP). Ther. Immunol. 2: 7-14, 1995.[Abs]

  507. Hamanaka, R., Smith, M.R., O'Connor, P.M., Maloid, S., Mihalic, K., Spivak, J.L., Longo, D.L., and Ferris, D.K.: Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J. Biol. Chem. 270: 21086-21091, 1995.[Abs]

  508. Esteva-Lorenzo, F.J., Janik, J.E., Fenton, R.G., Emslie-Smith, A., Engel, A.G., and Longo, D.L.: Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma. Cancer 76: 1219-1223, 1995.[Abs]

  509. Murphy, W.J., Raziuddin, A., Mason, L., Kumar, V., Bennett, M., and Longo, D.L.: NK cell subsets in the regulation of murine hematopoiesis. I. 5E6+ NK cells promote hematopoietic growth in H-2d strain mice. J. Immunol. 155: 2911-2917, 1995.[Abs]

  510. Ghosh, P., Komschlies, K.L., Cippitelli, M., Longo, D.L., Subleski, J., Ye, J., Sica, A., Young, H.A., Wiltrout, R.H., and Ochoa, A.C.: Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J. Natl. Cancer Inst. 87: 1478-1483, 1995.[Abs]

  511. Li, C-C.H., Dai, R-M., and Longo, D.L.: Inactivation of NF-B inhibitor IB: ubiquitin-dependent proteolysis and its degradation product. Biochem. Biophys. Res. Commun. 215: 292-301, 1995.[Abs]

  512. Longo, D.L.: The REAL classification of lymphoid neoplasms: one clinician's view. In DeVita, V.T., Jr., Hellman, S., and Rosenberg, S.A. (Eds.): Cancer: Principles and Practice of Oncology Updates, Fourth Edition, vol. 9. Philadelphia, Lippincott-Raven Publishers, 1995, pp. 1-12.

  513. Bacon, C.M., Tortolani, P.J., Shimosaka, A., Rees, R.C., Longo, D.L., and O'Shea, J.J.: Thrombopoietin (TPO) induces tyrosine phosphorylation and activation of STAT5 and STAT3. FEBS Lett. 370: 63-68, 1995.[Abs]

  514. Tian, Z-G., Longo, D.L., Funakoshi, S., Asai, O., Ferris, D.K., Widmer, M., and Murphy, W.J.: In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts. Cancer Res. 55: 5335-5341, 1995.[Abs]

  515. Tortolani, P.J., Lal, B.K., Riva, A., Johnston, J.A., Chen, Y-Q., Reaman, G.H., Beckwith, M., Longo, D., Ortaldo, J.R., Bhatia, K., McGrath, I., Kehrl, J., Tuscano, J., McVicar, D.W., and O'Shea, J.J.: Regulation of JAK3 expression and activation in human B cells and B cell malignancies. J. Immunol. 155: 5220-5226, 1995.[Abs]

  516. Zea, A.H., Curti, B.D., Longo, D.L., Alvord, W.G., Strobl, S.L., Mizoguchi, H., Creekmore, S.P., O'Shea, J.J., Powers, G.C., Urba, W.J., and Ochoa, A.C.: Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin. Cancer Res. 1: 1327-1335, 1995.[Abs]

  517. Linnekin, D., Keller, J.R., Ferris, D.K., Mou, S.M., Broudy, V., and Longo, D.L.: Stem cell factor induces phosphorylation of a 200 kDa protein which associates with c-kit. Growth Factors 12: 57-67, 1995.[Abs]

  518. Spence, S.E., Keller, J.R., Ruscetti, F.W., Czarra, K.T., Gooya, J.M., Funakoshi, S., Longo, D.L., and Murphy, W.J.: Engraftment of SCID mice by human bone marrow hematopoietic cells cultured in vitro: an in vivo model for human gene transfer. Leukemia 9: S43-S47, 1995. [Abs]

  519. Funakoshi, S., Beckwith, M., Fanslow, W., Longo, D.L., and Murphy, W.J.: Epstein-Barr virus-induced human B-cell lymphoma arising in huPBL-SCID chimeric mice: characterization and the role of CD40 stimulation in their treatment and prevention. Pathobiology 63: 133-142, 1995.[Abs]

  520. Kwak, L.W. and Longo, D.L.: Modern vaccine adjuvants. In Chabner, B.A. and Longo, D.L. (Eds.): Cancer Chemotherapy and Biotherapy: Principles and Practice, Second Edition. Philadelphia, Lippincott-Raven Publishers, 1996, pp. 749-763.

  521. Janik, J.E., Miller, L.L., Longo, D.L., Powers, G.C., Urba, W.J., Kopp, W.C., Gause, B.L., Curti, B.D., Fenton, R.G., Oppenheim, J.J., Conlon, K.C., Holmlund, J.T., Sznol, M., Sharfman, W.H., Steis, R.G., Creekmore, S.P., Alvord, W.G., Beauchamp, A.E., and Smith, J.W., II: Phase II trial of interleukin 1 and indomethacin in treatment of metastatic melanoma. J. Natl. Cancer Inst. 88: 44-49, 1996.[Abs]

  522. Dunn, B.K. and Longo, D.L.: Lymphoma occurring in association with other diseases. In Wiernik, P.H., Kyle, R.A., and Dutcher, J.P. (Eds.): Neoplastic Diseases of the Blood. New York, Churchill Livingstone, 1996, pp. 963-997.

  523. Beckwith, M., Fenton, R.G., Katona, I.M., and Longo, D.L.: Phosphatidylinositol-3-kinase activity is required for the anti-Ig-mediated growth inhibition of a human B-lymphoma cell line. Blood 87: 202-210, 1996.[Abs]

  524. Wang, J., Medeiros, L.J., Longo, D.L., Mansoor, A., Raffeld, M., Duffey, P.L., Jaffe, E.S., and Stetler-Stevenson, M.: Use of the polymerase chain reaction technique to determine c-myc expression in follicular center cell lymphoma. Diagn. Mol. Pathol. 5: 20-25, 1996.[Abs]

  525. Kopp, W.C., Urba, W.J., Rager, H.C., Alvord, W.G., Oppenheim, J.J., Smith II, J.W., and Longo, D.L.: Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer. Clin. Cancer Res. 2: 501-506, 1996.[Abs]

  526. Taub, D.D., Longo, D.L., and Murphy, W.J.: Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues of human peripheral blood lymphocytes-SCID mice. Blood 87: 1423-1431, 1996.[Abs]

  527. Taub, D.D., Ortaldo, J.R., Turcovski-Corrales, S.M., Key, M.L., Longo, D.L., and Murphy, W.J.: Beta chemokines costimulate lymphocyte cytolysis, proliferation and lymphokine production. J. Leukoc. Biol. 59: 81-89, 1996.[Abs]

  528. Schwarzenberger, P., Spence, S., Lohrey, N., Kmiecik, T., Longo, D.L., Murphy, W.J., Ruscetti, F.W., and Keller, J.R.: Gene transfer of multidrug resistance into a factor-dependent human hematopoietic progenitor cell line: in vivo model for genetically transferred chemoprotection. Blood 87: 2723-2731, 1996.[Abs]

  529. Kwak, L.W., Pennington, R., and Longo, D.L.: Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts. Blood 87: 3053-3060, 1996.[Abs]

  530. Taub, D.D., Turcovski-Corrales, S.M., Key, M.L., Longo, D.L., and Murphy, W.J.: Chemokines and lymphocyte activation I. chemokines costimulate human T lymphocyte activation in vitro. J. Immunol. 156: 2095-2103, 1996.[Abs]

  531. Murphy, W.J., Tian, Z-G., Asai, O., Funakoshi, S., Rotter, P., Henry, M., Strieter, R.M., Kunkel, S.L., Longo, D.L., and Taub, D.D.: Chemokines and T lymphocyte activation II. Facilitation of human T cell trafficking in severe combined immunodeficiency mice. J. Immunol. 156: 2104-2111, 1996.[Abs]

  532. Levitsky, H.I., Montogomery, J., Ahmadzadeh, M., Staveley-O'Carroll, K., Guarnieri, F., Longo, D.L., and Kwak, L.W.: Immunization with granulocyte- macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J. Immunol. 156: 3858-65, 1996.[Abs]

  533. Taub, D.D., Anver, M., Oppenheim, J.J., Longo, D.L., and Murphy, W.J.: T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J. Clin. Invest. 97: 1931-1941, 1996.[Abs]

  534. Funakoshi, S., Longo, D.L., and Murphy, W.J.: Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. J. Immunother. 19: 93-101, 1996.[Abs]

  535. Curti, B.D., Urba, W.J., Longo, D.L., Janik, J.E., Sharfman, W.H., Miller, L.L., Cizza, G., Shimizu, M., Oppenheim, J.J., Alvord, W.G., and Smith II, J.W.: Endocrine effects of IL-1 and administered in a phase I trial to patients with advanced cancer. J. Immunother. 19: 142-148, 1996.[Abs]

  536. Chertov, O., Michiel, D.F., Xu, L., Wang, J.M., Tani, K., Murphy, W.J., Longo, D.L., Taub, D.D., and Oppenheim, J.J.: Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J. Biol. Chem. 271: 2935-2940, 1996.[Abs]

  537. Longo, D.L.: The case against the routine use of radiation therapy in advanced stage Hodgkin's disease. Cancer Invest. 14:353-360, 1996.

  538. Longo, D.L.: Autografting for Hodgkin's disease. In Carella, A.M. (Ed.): Autologous Stem Cell Transplantation: Biological and Clinical Results in Malignancies. United Kingdom, Harwood Academic Publishers, 1996, pp.347-353.

  539. Murphy, W.J. and Longo, D.L.: NK cells in the regulation of hematopoiesis. ImmunoMethods 9: 344-351, 1996.[Abs]

  540. Longo, D.L.: Chemotherapy alone in the treatment of patients with early stage Hodgkin's disease. Ann. Oncol. 7 (suppl 4): 85-89, 1996.

  541. Newton, D.L., Pearson, J.W., Xue, Y., Smith, M.R., Fogler, W.E., Mikulski, S.M., Alvord, W.G., Kung, H-F., Longo, D.L., and Rybak, S.M.: Anti-tumor ribonuclease, combined with or conjugated to monoclonal antibody MRK16, overcomes multidrug resistance to vincristine in vitro and in vivo. Int. J. Oncol 8: 1095-1104, 1996.

  542. Fisher, R.I., Magrath, I., and Longo, D.L.: Lymphomas: a clinical approach to the less common entities. ASCO Educational Booklet 301-322, 1996.

  543. Rybak, S.M., Pearson, J.W., Fogler, W.E., Volker, K., Spence, S.E., Newton, D.L., Mikulski, S.M., Ardelt, W., Riggs, C.W., Kung, H.F., and Longo, D.L.: Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. J. Natl. Cancer Inst. 88: 747-753, 1996.[Abs]

  544. Murphy, W.J., Taub, D.D., and Longo, D.L.: The huPBL-SCID chimera as a means to examine human immune function and activity in vivo. Semin. Immunol.8: 233-241, 1996.[Abs]

  545. Weiler, S.R., Mou, S., DeBerry, C.S., Ferris, D.K., Ruscetti, F., Keller, J.R., Longo, D.L., and Linnekin, D.: JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor. Blood 87: 3688-3693, 1996.[Abs]

  546. Kenny, J., Fischer, R.T., Lustig, A., Dintzis, H., Katsumata, M., Reed, J.C., and Longo, D.L.: bcl-2 alters the antigen-driven selection of B cells in mk but not in m-only xid transgenic mice. J. Immunol.157: 1054-1061, 1996.[Abs]

  547. Gause, B.L., Sznol, M., Kopp W.C., Janik, J.E., Smith II, J.W., Steis, R.G., Urba, W.J., Sharfman, W., Fenton, R.G., Creekmore, S.P., Holmlund, J., Conlon, K.C., VanderMolen, L.A., and Longo, D.L.: Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. J. Clin. Oncol.14: 2234-2241, 1996.[Abs]

  548. Ortaldo, J.R., Mason, A.T., Longo, D.L., Beckwith, M., Creekmore, S.P., and McVicar, D.W.: T cell activation via the disialoganglioside GD3: analysis of signal transduction. J. Leuk. Biol. 60: 533-539, 1996.[Abs]

  549. Linnekin, D., Mou, S., DeBerry, C., Weiler, S., Ferris, D.K., Ruscetti, F., Keller, J.R., and Longo, D.L.: JAK2 is constitutively associated with c-Kit and is phosphorylated in response to stem cell factor. Acta Hematologica 95: 224-228, 1996.

  550. Longo, D.L.: Lymphoma. Editorial Overview. Curr. Opin. Oncol. 8: 343-345, 1996.

  551. Longo, D.L.: Immunotherapy for non-Hodgkin's lymphoma. Curr. Opin. Oncol. 8: 353-359, 1996.[Abs]

  552. Curti, B.D., Ochoa, A.C., Urba, W.J., Alvord, G., Kopp, W.C., Powers, G.,Hawk, C., Creekmore, S.P., Gause, B.L., Janik, J.E., Holmlund, J.T., Kremers, P., Fenton, R.G., Miller, L., Sznol, M., Smith II, J.W., Sharfman, W.H., and Longo, D.L.: Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: Results from a phase I trial in cancer patients. J. Immunother. 19: 296-308, 1996.[Abs]

  553. Longo, D.L.: Hodgkin's disease. In Perry, M.C. (Ed.): The Chemotherapy Sourcebook, Second Edition. Baltimore, Williams & Wilkins, 1996, pp.1345-1359.

  554. Gause, B.L. and Longo, D.L.: Treatment of relapsed Hodgkin's disease. Bailliere's Clin. Haematol. 9: 559-572, 1996.[Abs]

  555. Beckwith, M., Jorgensen, G., and Longo, D.L.: The protein product of the protooncogene c-cbl forms a complex with phosphatidylinositol 3-kinase p85 and CD19 in anti-IgM-stimulated human B lymphoma cells. Blood 88: 3502-3507, 1996.[Abs]

  556. Hiddemann, W., Longo, D.L., Coiffier, B., Fisher, R.I., Cabanillas, F. Cavalli, F., Nadler, L.M., DeVita, V.T., Lister, T.A., and Armitage, J.O.: Lymphoma classification--the gap between biology and clinical management is closing. Blood 88: 4085-4089, 1996.[Abs]

  557. Sznol, M., Carter, C.L., and Longo, D.L.: Principles of chemotherapy interactions with biological agents. In Schilsky, R.L., Milano, G.A., Ratain, M.J. (Eds.): Principles of Antineoplastic Drug Development and Pharmacology, New York, Marcel-Dekker Inc., 1996, pp.223-240.

  558. Conlon, K.C., Anver, M.R., Longo, D.L., Ortaldo, J.R., and Murphy, W.J.: Adoptive immunotherapy involving recombinant human M-CSF and R24 anti-melanoma antibody induces human T-cell infiltration into human melanoma xenografts. J. Immunother. 19: 317-323, 1996.[Abs]

  559. Fenton, R.G., Steis, R.G., Madara, K., Zea, A.H., Ochoa, A.C., Janik, J.E., Smith, J.W. II, Gause, B.L., Sharfman, W.H., Urba, W.J., Hanna, M.G., DeJager, R.L., Coyne, M.X., Crouch, R.D., Gray, P., Beveridge, J., Creekmore, S.P., Holmlund, J., Curti, B.D., Sznol, M., and Longo, D.L.: A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma. J. Immunother. 19: 364-374, 1996.[Abs]

  560. Raziuddin, A., Longo, D.L., Mason L., Ortaldo, J.R., and Murphy, W.J.: Ly-49G2+ NK cells are responsible for mediating the rejection of H-2b bone marrow allografts in mice. Int. Immunol. 8: 1833-1839, 1996.[Abs]

  561. Usui, N., Matsushima, K., Pilaro, A.M., Longo, D.L., and Wiltrout, R.H.: Antitumor effects of human recombinant interleukin-1 and etoposide against human tumor cells: mechanism for synergism in vitro and activity in vivo. Biotherapy 9:199-208, 1996.

  562. Longo, D.L., and Arun, B.: Cervical adenopathy: A clinical approach to diagnosis. Consultant 36-11: 2345-2352, 1996.

  563. Kwak, L.W., and Longo, D.L.: Lymphomas. In Pinedo, H.M., Longo, D.L., and Chabner, B.A. (Eds.): Cancer Chemotherapy and Biological Response Modifiers Annual 16. Amsterdam, Elsevier Science Publishers B.V., 1996, pp. 376-440.

  564. Longo, D.L.: Oncology. In Joyce, M. (Ed.): Encyclopedia of Science & Technology, 8th edition, vol. 12. New York, McGraw-Hill Publishing Company, 1997, pp. 369-376.

  565. Ochoa, A.C., Zea, A.H., Ghosh, P., and Longo, D.L.: Signal transduction changes in T cells from patients with cancer. In Herzenberg, L.A., Weir, D.M., Herzenberg, L.A., Blackwell, C. (Eds.): Weir's Handbook of Experimental Immunology, Fifth Edition. Cambridge, Blackwell Science, Inc., 1996, pp. 110.1-110.6.

  566. Kwak, L.W., and Longo, D.L.: Biological response modifiers. In Magrath, I.T. (Ed.): The Non-Hodgkin's Lymphomas, Second Edition. London, Arnold, 1997, pp. 699-714.

  567. Sausville, E.A., and Longo, D.L.: Growth factors and growth factor inhibitors. In Teicher, B.A. (Ed): Cancer Therapeutics. Experimental and Clinical Agents. Totowa, N.J., Humana Press, 1997, pp.337-370.

  568. Longo, D.L.: Lymphoid neoplasms: molecular biology. In Bertino, J.R. (Ed.): Molecular Biology of Cancer. San Diego, Academic Press, 1997, pp.1015-1030.

  569. Curti, B.D., and Longo, D.L.: A brief history of immunologic thinking: is it time for yin and yang? In Adam JA, Bellomo N (Eds.): A Survey of Models for Tumor-Immune System Dynamics. Boston, Birkhauser, 1997, pp.1-12.

  570. Curti, B.D., and Longo, D.L.: The cancer patient. In Parrillo, J.E. (Ed.): Current Therapy in Critical Care Medicine, Third Edition. St. Louis, Mosby-Year Book; Inc., 1997, pp. 368-373.

  571. Fenton, R.G., and Longo, D.L.: Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes. J. Natl. Cancer Inst. 89: 272-275, 1997.

  572. Taub, D.D., Murphy, W.J., Asai, O., Fenton, R.G., Peltz, G., Key, M.L., Turcovski-Corrales, S., and Longo, D.L.: Induction of alloantigen-specific T cell tolerance through the treatment of T lymphocytes with the phosphatidylinositol-3-kinase inhibitor, wortmannin. J. Immunol. 158: 2745-2755, 1997. [Abs]

  573. Funakoshi, S., Taub, D.D., Asai, O., Hirano, A., Ruscetti, F.W, Longo, D.L., and Murphy, W.J.: Effects of CD40 stimulation in the prevention of human EBV-induced B-cell lymphomagenesis. Leuk. Lymphoma 24: 187-199, 1997. [Abs]

  574. Funakoshi, S., Taub, D.D., Anver, M.R., Raziuddin, A., Asai, O., Reddy, V., Rager, H., Fanslow, W.C., Longo, D.L., and Murphy, W.J.: Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice. J. Clin. Invest. 99: 484-491, 1997.[Abs]

  575. Saxton, M.L., Longo, D.L., Wetzel, H.E., Tribble, H, Alvord, W.G., Kwak, L.W., Leonard, A.S., Ullmann, C.D., Curti, B.D., and Ochoa, A.C.: Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity. Blood 89: 2529-2536, 1997.[Abs]

  576. Bosco, M.C., Rottschafer, S., Taylor, L.S., Ortaldo, J.R., Longo, D.L., and Espinoza-Delgado, I.: The antineoplastic agent bryostatin-1 induces proinflammatory cytokine production in human monocytes: Synergy with interleukin-2 and modulation of interleukin-2 receptor g chain expression. Blood 89: 3402-3411, 1997.[Abs]

  577. Tiberghien, P., Brion, A., Deconinck, E., Racadot, E., Herve, P., Milpied, N., Lioure, B., Gluckman, E., Bordigoni, P., Jacob, W., Chiang, Y., Marcus, S., Reynolds, C., and Longo, D.: Clinical Protocol: Use of donor T-lymphocytes expressing herpes simplex thymidine kinase in allogeneic bone transplantation: A phase I-II study. Hum. Gene Ther. 8:615-624, 1997.

  578. Uchiumi, T., Longo, D.L., and Ferris, D.K.: Cell cycle regulation of the human polo-like (PLK) promoter. J. Biol. Chem. 272: 9166-9174, 1997.[Abs]

  579. Correa, M.R., Ochoa, A.C., Ghosh, P., Mizoguchi, H., Harvey, L., and Longo, D.L.: Sequential development of structural and functional alterations in T cells from tumor- bearing mice. J. Immunol. 158: 5292-5296, 1997.[Abs]

  580. Guo, W-X., Burger, A.M., Fischer, R.T., Sieckmann, D.G., Longo, D.L., and Kenny, J.J.: Sequence changes at the V-D junction of the VH1 heavy chain of anti-phosphocholine antibodies alter binding to and protection against Streptococcus pneumoniae. Int. Immunol. 9: 665-677, 1997.[Abs]

  581. Murphy, W.J., and Longo, D.L.: The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation. Immunol. Rev. 157: 167-176, 1997.[Abs]

  582. Smith, M.R., Wilson, M.L., Hamanaka, R., Chase, D., Kung, H-f., Longo, D.L., and Ferris, D.K.: Malignant transformation of mammalian cells initiated by constitutive expression of the Polo-like kinase, Plk. Biochem. Biophys. Res. Commun. 234: 397-405, 1997.[Abs]

  583. Taub, D.D., Key, M.L., Longo, D.L., and Murphy, W.J.: Chemokine-induced human lymphocyte infiltration and engraftment in huPBL-SCID mice. Methods Enzymol. 287: 265-291, 1997.

  584. Ershler, W.B., and Longo, D.L.: The biology of aging: the current research agenda. Cancer 80: 1284-93, 1997. [Abs]

  585. Longo, D.L.: Lymphoma: Editorial overview. Curr. Opin. Oncol. 9: 389-391, 1997.

  586. Bosco, M.C., Espinoza-Delgado, I., Rowe, T.K., Malabarba, M.G., Longo, D.L., and Varesio, L.: Functional role for the myeloid differentiation antigen CD14 in the activation of human monocytes by IL-2. J. Immunol. 159: 2922-2931, 1997.[Abs]

  587. Funakoshi, S., Hirano, A., Beckwith, M., Asai, O., Jorgensen, G., Tian, Z., Hornick J.L., Hu, P., Khawli, L.A., Epstein, A.L., Longo, D.L., and Murphy, W.J.: Antitumor effects of nonconjugated murine Lym-2 and human-mouse chimeric CLL-1 monoclonal antibodies against various human lymphoma cell lines in vitro and in vivo. Blood 90: 3160-3166, 1997. [Abs]

  588. Ershler, W.B., and Longo, D.L.: Aging and cancer: issues of basic and clinical science. J. Natl. Cancer Inst. 89: 1489-1497, 1997.[Abs]

  589. Longo, D.L., Glatstein, E., Duffey, P.L., Young, R.C., Ihde, D.C., Bastian, A.W., Wilson, W.H., Wittes, R.E., Jaffe, E.S., Hubbard, S.M., and DeVita, V.T., Jr.: Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. J. Clin. Oncol. 15: 3338-3346, 1997. [Abs]

  590. Teruya-Feldstein, J., Jaffe, E.S., Burd, P.R., Kanegane, H., Kingma, D.W., Wilson, W.H., Longo, D.L., and Tosato, G.: The role of Mig, the monokine induced by interferon-g and IP-10, the interferon-g-inducible protein-10, in tissue necrosis and vascular dammage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 90: 4099-4105, 1997.[Abs]

  591. Linnekin, D., Mou, S., Deberry, C.S., Weiler, S.R., Keller, J.R., Ruscetti, F.W., and Longo, D.L.: Stem cell factor, the JAK-STAT pathway and signal transduction. Leukemia and Lymphoma 27: 439-444, 1997.[Abs]

  592. Sieckmann, D.G., Martin, E., Guelde, G., Longo, D.L., and Kenny, J.J.: Anti-idiotype monoclonal antibodies specific for the MOPC167 anti-phosphocholine transgene-encoded antibody. Hybridoma 16: 503-511, 1997.[Abs]

  593. Gause, B.L., Sharfman, W.H., Janik, J.E., Curti, B.D., Steis, R.G., Urba, W.J., Smith, J.W., II, Alvord, W.G., and Longo, D.L.: A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma. Cancer Invest. 16: 374-380, 1998.[Abs]

  594. The Editors: The practice of medicine. In Fauci, A.S., Braunwald, E., Isselbacher, K.J., Wilson, J.D., Martin, J.B., Kasper, D.L., Hauser, S.L., and Longo, D.L. (Eds.): Harrison's Principles of Internal Medicine, 14th Edition. New York, McGraw-Hill, 1998, pp. 1-6.

  595. Henry, P.H., and Longo, D.L.: Enlargement of lymph nodes and spleen. In Fauci, A.S., Braunwald, E., Isselbacher, K.J., Wilson, J.D., Martin, J.B., Kasper, D.L., Hauser, S.L., and Longo, D.L. (Eds.): Harrison's Principles of Internal Medicine, 14th Edition. New York, McGraw-Hill, 1998, pp. 345-351.

  596. Ihde, D.C., and Longo, D.L.: Presentations of the patient with cancer: solid tumors in adults. In Fauci, A.S., Braunwald, E., Isselbacher, K.J., Wilson, J.D., Martin, J.B., Kasper, D.L., Hauser, S.L., and Longo, D.L. (Eds.): Harrison's Principles of Internal Medicine, 14th Edition. New York, McGraw-Hill, 1998, pp. 360-362.

  597. Longo, D.L.: Approach to the patient with cancer. In Fauci, A.S., Braunwald, E., Isselbacher, K.J., Wilson, J.D., Martin, J.B., Kasper, D.L., Hauser, S.L., and Longo, D.L. (Eds.): Harrison's Principles of Internal Medicine, 14th Edition. New York, McGraw-Hill, 1998, pp. 493-499.

  598. Fenton, R.G., and Longo, D.L.: Cell biology of cancer. In Fauci, A.S., Braunwald, E., Isselbacher, K.J., Wilson, J.D., Martin, J.B., Kasper, D.L., Hauser, S.L., and Longo, D.L. (Eds.): Harrison's Principles of Internal Medicine, 14th Edition. New York, McGraw-Hill, 1998, pp. 505-512.

  599. Ruscetti, F.W., Keller, J.R., and Longo, D.L.: Hematopoiesis. In Fauci, A.S., Braunwald, E., Isselbacher, K.J., Wilson, J.D., Martin, J.B., Kasper, D.L., Hauser, S.L., and Longo, D.L. (Eds.): Harrison's Principles of Internal Medicine, 14th Edition. New York, McGraw-Hill, 1998, pp. 634-638.

  600. Longo, D.L.: Plasma cell disorders. In Fauci, A.S., Braunwald, E., Isselbacher, K.J., Wilson, J.D., Martin, J.B., Kasper, D.L., Hauser, S.L., and Longo, D.L. (Eds.): Harrison's Principles of Internal Medicine, 14th Edition. New York, McGraw-Hill, 1998, pp. 712-718.

  601. Fauci, A.S., and Longo, D.L.: The human retroviruses. In Fauci, A.S., Braunwald, E., Isselbacher, K.J., Wilson, J.D., Martin, J.B., Kasper, D.L., Hauser, S.L., and Longo, D.L. (Eds.): Harrison's Principles of Internal Medicine, 14th Edition. New York, McGraw-Hill, 1998, pp. 1105-1111.

  602. Raziuddin, A., Longo, D.L., Mason, L., Ortaldo, J.R., Bennett, M., and Murphy, W.J.: Differential effects of the rejection of bone marrow allografts by the depletion of activating versus inhibiting Ly-49 natural killer cell subsets. J. Immunol. 160: 87-94, 1998.[Abs]

  603. Little, R., Wittes, R.E., Longo, D.L., and Wilson, W.H.: Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J. Clin. Oncol. 16: 584-588, 1998.[Abs]

  604. Zea, A.H., Ochoa, M.T., Ghosh, P., Longo, D.L., Alvord, W.G., Valderrama, L., Falabella, R., Harvey, L.K., Saravia, N., Moreno, L.H., and Ochoa, A.C.: Changes in expression of signal transduction proteins in T lymphocytes of patients with leprosy. Infect. Immun. 66: 499-504, 1998. [Abs]

  605. Dai, R-M., Chen, E., Longo, D.L., Gorbea, C.M., and Li, C-C.H.: Involvement of valosin-containing protein, an ATPase co-purified with IB and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IB. J. Biol. Chem. 273: 3562-3673, 1998. [Abs]

  606. Yoe, J., Gause, B.L., Curti, B.D., Longo, D.L., Bagg, A., Kopp, W.C., and Janik, J.E.: Development of rheumatoid arthritis after treatment of large granular lymphocyte leukemia with deoxycoformycin. Am. J. Hematol. 57: 253-257, 1998.[Abs]

  607. Asai, O., Longo, D.L., Tian, Z.G., Hornung, R.L., Taub, D.D., Ruscetti, F.W., and Murphy, W.J.: Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J. Clin. Invest. 101: 1835-1842, 1998.[Abs]

  608. Srivastava, R.K., Srivastava, A.R., Korsmeyer, S.J., Nesterova, M., Cho-Chung, Y.S., and Longo, D.L.: Involvement of microtubules in the regulation of bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. Cell. Biol. 18: 3509-3517, 1998.[Abs]

  609. Tian, Z-G., Woody, M.A., Sun, R., Welniak, L.A., Raziuddin, A., Funakoshi, S., Tsarfaty, G., Longo, D.L., and Murphy, W.J.: Recombinant human growth hormone promotes hematopoietic reconstitution after syngeneic bone marrow transplantation in mice. Stem Cells 16: 193-199, 1998.[Abs]

  610. Spence, S.E., Keller, J.R., Ruscetti, F.W., McCauslin, C.S., Gooya, J.M., Funakoshi, S., Longo, D.L., and Murphy, W.J.: Engraftment of ex vivo expanded and cycling human cord blood hematopoietic progenitor cells in SCID mice. Exp. Hematol. 26: 507-514, 1998.[Abs]

  611. Nguyen, B.Y., Clerici, M., Venzon, D.J., Bauza, S., Murphy, W.J., Longo, D.L., Baseler, M., Gesundheit, N., Broder, S., Shearer, G., and Yarchoan, R.: Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients. AIDS 12: 895-904, 1998.[Abs]

  612. Longo, D.L.: Solving the puzzle of follicular lymphoma. Cancer J. Sci. Am. 4 (suppl. 2): S1-S4, 1998.

  613. Chase, D., Feng, Y., Hanshew, B., Winkles, J.A., Longo, D.L., and Ferris, D.K.: Expression and phosphorylation of fibroblast-growth-factor-inducible kinase (Fnk) during cell-cycle progression. Biochem. J. 333: 655-660, 1998.[Abs]

  614. Curti, B.D., Ochoa, A.C., Powers, G.C., Kopp, W.C., Alvord, W.G., Janik, J.E., Gause, B.L., Dunn, B., Kopreski, M.S., Fenton, R., Zea, A., Dansky-Ullmann, C., Strobl, S., Harvey, L., Nelson, E., Sznol, M., and Longo, D.L.: Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. J. Clin. Oncol. 16: 2752-2760, 1998.[Abs]

  615. Longo, D.L.: Lymphoma: there's something happening here. Curr. Opin. Oncol. 10: 375-376, 1998.

  616. Longo, D.L.: Interferon toxicity worse in retrospect: impact on Q-TWiST? J. Clin. Oncol. 16: 3716-3718, 1998.

  617. Murphy, W.J., Welniak, L.A., Taub, D.D., Wiltrout, R.H., Taylor, P.A., Vallera, D.A., Kopf, M., Young, H., Longo, D.L., and Blazar, B.R.: Differential effects of the absence of interferon-g and IL-4 in acute graft-vs-host disease after allogeneic bone marrow transplantation in mice. J. Clin. Invest. 102: 1742-1748, 1998.[Abs]

  618. Hasenclever, D., Diehl, V., Armitage, J.O., Assouline, D., Bjorkholm, M., Brusamolino, E., Canellos, G.P., Carde, P., Crowther, D., Cunningham, D., Eghbali, H., Ferme, C., Fisher, R.I., Glick J.H., Glimelius, B., Gobbi, P.G., Holte, H., Horning, S.E., Lister, T.A., Longo, D.L., Mandelli, F., Polliack, A., Proctor, S.J., Specht, L., Sweetenham, J.W., and Hudson, G.V.: A prognostic score for advanced Hodgkin's disease. N. Engl. J. Med. 339: 1506-1514, 1998.[Abs]

  619. Chen, E., Hrdlickova, R., Nehyba, J., Longo, D.L., Bose, H.R. Jr., and Li, C-C.H.: Degradation of proto-oncoprotein c-Rel by the ubiquitin-proteasome pathway.J. Biol. Chem. 273: 35201-35207, 1998.[Abs]

  620. Murphy, W.J., Funakoshi, S., Fanslow, W.C., Rager, H.C., Taub, D.D., and Longo, D.L.: CD40 stimulation promotes human secondary immunoglobulin responses in huPBL-SCID chimeras. Clin. Immunol. 90: 22-27, 1999.[Abs]

  621. Woody, M.A., Welniak, L.A., Richards, S., Taub, D.D., Tian, Z., Sun, R., Longo, D.L., and Murphy, W.J.: Use of neuroendocrine hormones to promote reconstitution after bone marrow transplantation. Neuroimmunomodulation 6: 69-80, 1999.[Abs]

  622. Longo, D.L., Duffey, P.L., Kopp, W.C., Heyes, M.P., Alvord, W.G., Sharfman, W.H., Schmidt, P.J., Rubinow, D.R., and Rosenstein, D.L.: Conditioned immune response to interferon-g in humans. Clin. Immunol. 90: 173-181, 1999.[Abs]

  623. Srivastava, R.K., Srivastava, A., Cho-Chung, Y.S., and Longo, D.L.: Synergistic effects of retinoic acid and 8-Cl-cAMP on apoptosis require caspase-3 activation in human ovarian cancer cells. Oncogene 18: 1755-1764, 1999.[Abs]

  624. Srivastava, R.K., Mi, Q.S., Hardwick, J.M., and Longo, D.L.: Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc. Natl. Acad. Sci. USA 96: 3775-3780, 1999.[Abs]

  625. Text Atlas of Lymphomas. Armitage, J.O., Cavalli, F., and Longo, D.L., authors. Martin Dunitz Ltd., London, 207 pp, 1999.

  626. Feng, Y., Hodge, D.R., Palmieri, G., Chase, D.L., Longo, D.L., and Ferris, D.K.: Association of polo-like kinase with alpha-, beta- and gamma-tubulins in a stable complex.Biochem. J. 339: 435-442, 1999.[Abs]

  627. Hirano, A., Longo, D.L., Taub, D.D., Ferris, D.K., Young, L.S., Eliopoulos, A.G., Agathanggelou, A., Cullen, N., Macartney, J., Fanslow, W.C., and Murphy, W.J.: Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 93: 2999-3007, 1999.[Abs]

  628. Bartlett, N.L., and Longo, D.L.: T-small lymphocyte disorders. Semin. Hematol. 36: 164-170, 1999.[Abs]

  629. Miller, L.L., Korn, E.L., Stevens, D.S., Janik, J.E., Gause, B.L., Kopp, W.C., Holmlund, J.T., Curti, B.D., Sznol, M., Smith, J.W. II, Urba, W.J., Donegan, S.E., Watson, T.M., and Longo, D.L.: Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Blood 93: 3250-3258, 1999.[Abs]

  630. Woody, M.A., Welniak, L.A., Sun, R., Tian, Z.G., Henry, M., Richards, S., Raziuddin, A., Longo, D.L., and Murphy, W.J.: Prolactin exerts hematopoietic growth-promoting effects in vivo and partially counteracts myelosuppression by azidothymidine. Exp. Hematol. 27: 811-816, 1999.[Abs]

  631. Srivastava, R.K., Srivastava, A.R., Cho-Chung, Y., and Longo, D.L.: Synergistic effects of retinoic acid and 8-chloro-adenosine-3',5'-cyclic monophosphate on the regulation of retinoic acid receptor b and apoptosis: involvement of mitochondria. Clin. Cancer Res. 5: 1892-1904, 1999.[Abs]

  632. Srivastava, R.K., Sollott, S.J., Khan, L., Hansford, R., Lakatta, E.G., and Longo, D.L.: Bcl-2 and Bcl-XL block thapsigargin-induced nitric oxide generation, c-Jun NH2-terminal kinase activity, and apoptosis. Mol. Cell. Biol. 19: 5659-5674, 1999.[Abs]

  633. Srivastava, R.K., Sasaki, C.Y., Hardwick, JM, and Longo, D.L.: Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. J. Exp. Med. 190: 253-266, 1999. [Abs]

  634. Longo, D.L.: Lymphoma treatment: you have to admit it's getting better. Curr. Opin. Oncol. 11: 319-321, 1999.

  635. Bendandi, M., and Longo, D.L.: Biologic therapy for lymphoma. Curr. Opin. Oncol. 11: 343-350, 1999. [Abs]

  636. Bendandi, M., Gocke, C.D., Kobrin, C.B., Benko, F.A., Sternas, L.A., Pennington, R., Watson, T.M., Reynolds, C.W., Gause, B.L., Duffey, P.L., Jaffe, E.S., Creekmore, S.P., Longo D.L., and Kwak, L.W.: Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Medicine 5: 1171-1177, 1999.[Abs]

  637. Longo, D.L.: Follicular lymphoma. In: Foley, J.F., Vose, J.M., and Armitage, J.O. (Eds.): Current Therapy in Cancer, 2nd Edition. Philadelphia, W.B. Saunders, 1999, pp. 321-329.

  638. Janik, J.E., Miller, L.L., Kopp, W.C., Taub, D.D., Dawson, D., Stevens, D., Kostboth, P., Curti, B.D., Conlon, K.C., Dunn, B.K., Donegan, S.E., Ullrich, R., Alvord, W.G., Gause, B.L., and Longo, D.L.: Treatment with tumor necrosis factor-a and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients. Clin. Immunol. 93: 209-221, 1999. [Abs]

  639. Kaufman, D., and Longo, D.L.: Hodgkin’s disease. In: Abeloff, M.D., Armitage, J.O., Lichter, A.S., and Niederhuber, J.E. (Eds.): Clinical Oncology, 2nd Edition. Philadelphia, Churchill-Livingstone, 2000, pp. 2620-2657.

  640. Arun, B., Curti, B.D., Longo, D.L., Stevens, D., Alvord, W.G., Gause, B.L., Watson, T., Kopp, W.C., Janik, J.E.: Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. Cancer J. Sci. Am. 6: 21-24, 2000.[Abs]

  641. Chase, D., Serafinas, C., Ashcroft, N., Kosinski, M., Longo, D., Ferris, D.K., Golden. A.: The polo-like kinase PLK-1 is required for nuclear envelope breakdown and the completion of meiosis in Caenorhabditis elegans. Genesis 26: 26-41, 2000.[Abs]

  642. Kenny, J. J., Rezanka, L.J., Lustig, A., Fischer, R.T., Yoder, J., Marshall, S., Longo, D.L.: Autoreactive B cells escape clonal deletion by expressing multiple antigen receptors. J. Immunol. 164(8): 4111-4119, 2000.[Abs]

  643. Kalechman, Y., Longo, D.L., Catane, R., Shani, A., Albeck, M., Sredni, B.: Synergistic anti-tumoral effect of paclitaxel (taxol)+AS101 in a murine model of B16 melanoma: association with ras-dependent signal-transduction pathways. Int. J. Cancer 86(2): 281-288, 2000.[Abs]

  644. Dunn, B.K., and Longo, D.L.: Molecular biology and biological markers. In: Hunter, C.P., Johnson, K.A., and Muss, H.B. (Eds.): Cancer in the Elderly, New York, Marcel Dekker, 2000, pp. 69-121.

  645. Murphy, W.J., Longo, D.L.: Growth hormone as an immunomodulating agent. Immunol. Today 21: 211-213, 2000. [Abs]

  646. Mi, Q.S., Zhou, L., Schulze, D.H., Fischer, R.T., Lustig, A., Rezanka, L.J., Donovan, D.M., Longo, D.L., Kenny, J. J.: Highly reduced protection against streptococcus pneumoniae after deletion of a single heavy chain gene in mouse. Proc. Natl. Acad. Sci. USA 97(11): 6031-6036, 2000.[Abs]

  647. Kenny, J. J., Derby E.G., Yoder, J.A., Hill, S.A., Fischer, R.T., Tucker, P.W., Claflin, J.L., Longo, D.L.: Positive and negative selection of antigen-specific B cells in transgenic mice expressing variant forms of the V(H)l (T15) heavy chain. Int. Immunol. 12(6): 873-885, 2000.[Abs]

  648. Raziuddin, A., Bennett, M., Winkler-Pickett, R., Ortaldo, J.R., Longo, D.L., and Murphy, W.J.: Synergistic effects of in vivo depletion of Ly-49A and Ly-49G2 natural killer cell subsets in the rejection of H-2b bone marrow allografts. Blood 95: 3840-3844, 2000.[Abs]

  649. Longo, D.L., Duffey, P.L., Gribben, J.G., Jaffe, E.S., Curti, B.D., Gause, B.L., Janik, J.E., Braman V.M., Esseltine, D., Wilson, W.H., Kaufman, D, Wittes, R.E., Nadler, L.M., and Urba, W.J.: Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. Cancer J. Sci. Am. 6: 146-150, 2000. [Abs]

  650. Kenny, J.J., Lustig, A., and Longo, D.L.: Positive selection of low affinity autoreactive B cells. Curr. Top. Microbiol. Immunol. 252: 39-45, 2000. [Abs]

  651. Sasaki, C.Y., Lin, H., Morin, P.J., and Longo, D.L.: Truncation of the extracellular region abrogates cell contact but retains the growth suppressive activity of E-cadherin. Cancer Res. 60: 7057-7065, 2000.

  652. Sredni, B., Longo, D.L., Catane, R., Shani, A., Albeck, M., and Kalechman, Y.: Synergistic antitumoral effect of the immunomodulator AS101 plus paclitaxel (Taxol). Association with ras-dependent signal transduction pathways. Exp. Hematol. 28: 1496, 2000. [Abs]

  653. Longo, D.L.: Lymphomas: complexity, not chaos. Curr. Opin. Oncol. 12(5): 379-382, 2000.

  654. Alexandroff, A.B., Jackson, A.M., Paterson, T., Haley, J.L., Ross, J.A., Longo, D.L., Murphy, W.J., James, K., Taub, D.D.: Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol. Immunol. 37(9): 515-526, 2000. [Abs]

  655. Tiberghien, P., Ferrand, C., Lioure, B., Milpied, N., Angonin, R., Deconinck, E., Certoux, J-M., Robinet, E., Saas, P., Petracca, B., Juttner, C., Reynolds, C.W., Longo, D.L., Herve, P., and Cahn, J-Y.: Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97: 63-72, 2001.

  656. Longo, D.L.: Hodgkin’s disease: chemotherapy. In: Rakel, R.E., and Bope, E.T. (Eds.): Conn’s Current Therapy 2001, Philadelphia, W.B. Saunders, 2001, pp 429-435.

  657. The Editors: The practice of medicine. In: Braunwald, E., Fauci, A.S., Kasper, D.L., Hauser, S.L., Longo, D.L., and Jameson, J.L. (Eds.): Harrison's Principles of Internal Medicine, 15th Edition. New York, McGraw-Hill, 2001, pp. 1-5.

  658. Adamson, J.W., and Longo, D.L.: Anemia and polycythemia. In: Braunwald, E., Fauci, A.S., Kasper, D.L., Hauser, S.L., Longo, D.L., and Jameson, J.L. (Eds.): Harrison's Principles of Internal Medicine, 15th Edition. New York, McGraw-Hill, 2001, pp. 348-354.

  659. Feng, Y., Longo, D.L., Ferris, D.K.: Polo-like kinase interacts with proteasomes and regulates their activity.Cell. Growth Differ. 12(1): 29-37, 2001. [Abs]

  660. Henry, P.H., and Longo, D.L.: Enlargement of lymph nodes and spleen. In: Braunwald, E., Fauci, A.S., Kasper, D.L., Hauser, S.L., Longo, D.L., and Jameson, J.L. (Eds.): Harrison's Principles of Internal Medicine, 15th Edition. New York, McGraw-Hill, 2001, pp. 360-365.

  661. Longo, D.L.: Approach to the patient with cancer. In: Braunwald, E., Fauci, A.S., Kasper, D.L., Hauser, S.L., Longo, D.L., and Jameson, J.L. (Eds.): Harrison's Principles of Internal Medicine, 15th Edition. New York, McGraw-Hill, 2001, pp. 491-497.

  662. Fenton, R.G., and Longo, D.L.: Cell biology of cancer. In: Braunwald, E., Fauci, A.S., Kasper, D.L., Hauser, S.L., Longo, D.L., and Jameson, J.L. (Eds.): Harrison's Principles of Internal Medicine, 15th Edition. New York, McGraw-Hill, 2001, pp. 509-517.

  663. Sausville, E.A., and Longo, D.L.: Principles of cancer treatment. In: Braunwald, E., Fauci, A.S., Kasper, D.L., Hauser, S.L., Longo, D.L., and Jameson, J.L. (Eds.): Harrison's Principles of Internal Medicine, 15th Edition. New York, McGraw-Hill, 2001, pp. 530-547.

  664. Perry, M.C., and Longo, D.L.: Late consequences of cancer and its treatment. In: Braunwald, E., Fauci, A.S., Kasper, D.L., Hauser, S.L., Longo, D.L., and Jameson, J.L. (Eds.): Harrison's Principles of Internal Medicine, 15th Edition. New York, McGraw-Hill, 2001, pp. 650-653.

  665. Armitage, J.O., and Longo, D.L.: Malignancies of lymphoid cells. In: Braunwald, E., Fauci, A.S., Kasper, D.L., Hauser, S.L., Longo, D.L., and Jameson, J.L. (Eds.): Harrison's Principles of Internal Medicine, 15th Edition. New York, McGraw-Hill, 2001, pp. 715-727.

  666. Longo, D.L.: Plasma cell disorders. In: Braunwald, E., Fauci, A.S., Kasper, D.L., Hauser, S.L., Longo, D.L., and Jameson, J.L. (Eds.): Harrison's Principles of Internal Medicine, 15th Edition. New York, McGraw-Hill, 2001, pp. 727-733.

  667. Fauci, A.S., and Longo, D.L.: The human retroviruses. In: Braunwald, E., Fauci, A.S., Kasper, D.L., Hauser, S.L., Longo, D.L., and Jameson, J.L. (Eds.): Harrison's Principles of Internal Medicine, 15th Edition. New York, McGraw-Hill, 2001, pp. 1131-1135.

  668. Murphy, W.J., and Longo, D.L.: Alternative strategies other than growth hormone for the treatment of immune diseases. Trends Immunol. 22: 15-16, 2001.

  669. Janik, J.E., Miller, L.L., Korn, E.L., Stevens, D., Curti, B.D., Smith, J.W., 2nd, Sznol, M., Conlon, K.C., Sharfman, W., Urba, W.J., Gause, B.L., Longo, D.L.: A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. Blood 97(7): 1942-1946, 2001. [Abs]

  670. Srivastava, R.K., Mattson, M.P., and Longo, D.L.: Cytoskeletal involvement in apoptosis. In: Mattson, M.P., Estus, S., and Rangnekar, V.M. (Eds.): Programmed Cell Death Volume I Cellular and Molecular Mechanisms, Amsterdam, Elsevier, 2001, pp. 237-267.

  671. Westin, E.H., and Longo, D.L.: T-small cell disorders. Curr. Treat. Options Oncol. 2: 225-235, 2001.

  672. Murphy, W.J., Koh, C.Y., Raziuddin, A., Bennett, M., and Longo, D.L.: Immunobiology of natural killer cells and bone marrow transplantation: merging of basic and preclinical studies. Immunol. Rev. 181: 279-289, 2001. [Abs]

  673. Westin, E.H., Longo, D.L.: Lymphocytic lymphomas and Hodgkin’s disease. In: Austen, K.F., Frank, M.M., Atkinson, J.P., and Cantor, H. (Eds.): Samter’s Immunologic Diseases, 6th edition, Philadelphia, Lippincott Williams and Wilkins, 2001, pp. 359-379.

  674. Luo, Y., Long, J.M., Spangler, E.L., Longo, D.L., Ingram, D.K., and Weng, N.P.: Identification of maze learning associated genes in rat hippocampus by cDNA microarray. J. Mol. Neurosci. 17: 127-134, 2001.

  675. Luo, Y., Long, J.M., Lu, C., Chan, S.L., Spangler, E.L., Mascarucci, P., Raz, A., Longo, D.L., Mattson, M.P., Ingram, D.K., Weng, N.P.: A link between maze learning and hippocampal expression of neuroleukin and its receptor gp78. J. Neurochem. 80(2): 354-361, 2002. [Abs]

  676. Hu, L., Rezanka, L.J., Mi. Q.S., Lustig, A., Taub, D.D., Longo, D.L., Kenny J.J.: T15-idiotype-negative B cells dominate the phosphocholine binding cells in the preimmune repertoire of T15i knockin mice. J. Immunol. 168(3): 1273-1280, 2002. [Abs]

  677. Yang, F., Li, X., Sharma, M., Sasaki, C.Y., Longo, D.L., Lim, B., Sun, Z.: Linking b-catenin to androgen-signaling pathway. J. Biol. Chem. 277(13): 11336-11344, 2002. [Abs]

  678. Wilson, W.H., Grossbard, M.L., Pittaluga, S., Cole, D., Pearson, D., Drbohlav, N., Steinberg, S.M., Little, R.F., Janik, J., Gutierrez, M., Raffeld, M., Staudt, L., Cheson, B.D., Longo, D.L., Harris, N., Jaffe, E.S., Chabner, B.A., Wittes, R., Balis, F.: Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 99(8): 2685-2693, 2002. [Article]

  679. Mi., Q.S., Rezanka, L.J., Lustig, A., Zhou, L., Longo, D.L., Kenny, J.J.: The M603 idiotype is lost in the response to phosphocholine in terminal deoxynucleotidyl transferase-deficient mice. Eur. J. Immunol. 32(4): 1139-1146, 2002. [Abs]

  680. Longo, D.L.: Genetic abnormalities in lymphoid malignancies. In: Vogelstein, B., and Kinzler, K.W. (Eds.): The Genetic Basis of Human Cancer, 2nd edition, New York, McGraw-Hill, 2002, pp. 785-801.

  681. Ghosh, P., Buchholz, M.A., Yano, S., Taub, D., Longo, D.L.: Effect of rapamycin on the cyclosporin A-resistant CD28-mediated costimulatory pathway. Blood. 2002 99(12): 4517-4524, 2002. [Abs]

  682. Szocinski, J.L., Khaled, A.R., Hixon, J., Halverson, D., Funakoshi, S., Fanslow, W.C., Boyd, A., Taub, D.D., Durum, S.K., Siegall, C.B., Longo, D.L., Murphy, W.J.: Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood. 100(1): 217-223, 2002. [Abs]

  683. Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.D., Muller-Hermelink, H.K., Smeland, E.B., Giltnane, J.M., Hurt, E.M., Zhao, H., Averett, L., Yang, L., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Powell, J., Duffey, P.L., Longo, D.L., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Montserrat, E., Lopez-Guillermo, A., Grogan, T.M., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T., Staudt, L.M.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(25): 1937-1947, 2002. [Abs]

  684. Longo, D.L.: DR's orders: human antibody kills tumors by direct signaling. Nat. Med. 8(8): 781-783, 2002. [Abs]

  685. Raziuddin, A., Longo, D.L., Bennett, M., Winkler-Pickett, R., Ortaldo, J.R., Murphy, W.J.: Increased bone marrow allograft rejection by depletion of donor NK cells expressing inhibitory Ly49 NK receptors for donor class I antigens. Blood 100: 3026-3033, 2002. [Abs]

  686. Espinoza-Delgado, E., and Longo, D.L.: Non-Hodgkin's lymphoma. In: Laughlin, M.J. and Lazarus, H.M. (Eds.): Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Totowa, N.J., Humana Press, 2002, pp 83-99.

  687. Shack, S., Wang, X-T., Kokkonen, G.C., Gorospe, M., Longo, D.L., Holbrook, N.J.: Caveolin-induced activation of the phosphatidylinositol 3-kinase/Akt pathway increases arsenite cytotoxicity. Mol. Cell Biol. 23(7): 2407-2414, 2003. [Abs]

  688. Artz, A.S., Ershler, W.B., Longo, D.L.: Pneumococcal vaccination and revaccination of older adults. Clin. Microbiol. Rev. 16(2): 308-318, 2003. [Abs]

  689. Ferrucci, L., Guralnik, J.M., Cavazzini, C., Bandinelli, S., Lauretani, F., Bartali, B., Repetto, L., Longo, D.L.: The frailty syndrome: a critical issue in geriatric oncology. Crit. Rev. Oncol. Hematol. 46(2): 127-137, 2003.[Abs]

  690. Longo, D.L.: Radiation therapy in the treatment of Hodgkin's disease--do you see what I see? J. Natl. Cancer Inst. 95(13): 928-929, 2003. [Journal]

  691. Yano, S., Ghosh, P., Kusaba, H., Buchholz, M., Longo D.L.: Effect of promoter methylation on the regulation of IFN-g gene during in vitro differentiation of human peripheral blood T cells into a Th2 population. J. Immunol. 171(5): 2510-2516, 2003. [Abs]

  692. Sharov, A.A., Piao, Y., Matoba, R., Dudekula, D.B., Qian, Y., VanBuren, V., Falco, G., Martin, P.R., Stagg, C.A., Bassey, U.C., Wang, Y., Carter, M.G., Hamatani, T., Aiba, K., Akutsu, H., Sharova, L., Tanaka, T.S., Kimber, W.L., Yoshikawa, T., Jaradat, S.A., Pantano, S., Nagaraja, R., Boheler, K.R., Taub, D., Hodes, R.J., Longo, D.L., Schlessinger, D., Keller, J., Klotz, E., Kelsoe, G., Umezawa, A., Vescovi, A.L., Rossant, J., Kunath, T., Hogan, B.L., Curci, A., D'Urso, M., Kelso, J., Hide, W., Ko, M.S.H.: Transcriptome analysis of mouse stem cells and early embryos. PLoS Biol. 1: 410-419, 2003. [Abs]

  693. Longo, D.L.: Immunology of aging. In: Paul, W.E. (Ed.) Fundamental Immunology, 5th edition, Philadelphia, Lippincott Williams, and Wilkins, 2003, pp. 1043-1075.

  694. Sredni, B., Weil, M., Khomenok, G., Lebenthal, I., Teitz, S., Mardor, Y., Ram, Z., Orenstein, A., Kershenovich, A., Michowiz, S., Cohen, Y.I., Rappaport, Z.H., Freidkin, I., Albeck, M., Longo, D.L., Kalechman, Y.: Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res. 64(5): 1843-1852, 2004.
    695. [Abs]

  695. Westin, E.H., Longo, D.L.: Lymphoma and myeloma in older patients. Semin. Oncol. 31(2): 198-205, 2004. [Abs]

  696. Takahashi, K., Reynolds, M., Ogawa, N., Longo, D.L., Burdick, J.: Augmentation of T-cell apoptosis by immunosuppressive agents. Clin. Transplant. 18 Suppl 12: 72-75, 2004. [Abs]

  697. Yuan, J.H., Feng, Y., Fisher, R.H., Maloid, S., Longo, D.L., Ferris, D.K.: Polo-like kinase 1 inactivation following mitotic DNA damaging treatments is independent of ataxia telangiectasia mutated kinase. Mol. Cancer Res. 2(7): 417-426, 2004. [Abs]

  698. O'Farrell, T.J., Ghosh, P., Dobashi, N., Sasaki, C.Y., Longo, D.L.: Comparison of the effect of mutant and wild-type p53 on global gene expression. Cancer Res. 64(22): 8199-8207, 2004. [Abs]

  699. Ferrucci, L., Corsi, A., Lauretani, F., Bandinelli, S., Bartali, B., Taub, D.D., Guralnik, J.M., Longo, D.L.: The origins of age-related pro-inflammatory state. Blood. 105(6): 2294-2299, 2005. [Abs]

  700. Kusaba, H., Ghosh, P., Derin, R., Buchholz, M., Sasaki, C., Madara, K., Longo, D.L.: Interleukin-12-induced IFN-g production by human peripheral blood T cells is regulated by mammalian target of rapamycin (mTOR). J. Biol. Chem. 280(2): 1037-1043, 2005. [Abs]

  701. Sakatani, T., Kaneda, A., Iacobuzio-Donahue, C.A., Carter, M.G., Witzel, S.D., Okano, H., Ko, M.S., Ohlsson, R., Longo, D.L., Feinberg, A.P.: Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science. 307(5717):1976-1978, 2005. [Abs]

  702. Longo, D.L. Radiation therapy may improve survival of premenopausal women with breast cancer involving axillary lymph nodes. Postgrad Med. 117(4):6, 2005.

  703. Taub, D.D., Longo, D.L.: Insights into thymic aging and regeneration. Immunol Rev. 205: 72-93, 2005. [Abs]

  704. Longo, D.L.: Closing in on a killer: anemia in elderly people. J. Gerontol. A Biol. Sci. Med. Sci. 60(6): 727-728, 2005.

  705. Ershler, W.B., Sheng, S., McKelvey, J., Artz, A.S., Denduluri, N., Tecson, J., Taub, D.D., Brant, L.J., Ferrucci, L., Longo, D.L.: Serum erythropoietin and aging: a longitudinal analysis. J. Am. Geriatr. Soc. 53(8): 1360-1365, 2005. [Abs]

  706. Sasaki, C.Y., Barberi, T.J., Ghosh, P., Longo, D.L.: Phosphorylation of RelA/p65 on serine 536 defines an IkBa-independent NF-{kappa}B pathway. J. Biol. Chem. 280(41): 34538-34547, 2005. [Abs]

  707. Gulmann, C., Espina, V., Petricoin, E. 3rd, Longo, D.L., Santi, M., Knutsen, T., Raffeld, M., Jaffe, E.S., Liotta, L.A., Feldman, A.L.: Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin. Cancer Res. 11(16): 5847-5855, 2005. [Abs]

  708. Longo, D.L.: Radiation therapy in Hodgkin disease: why risk a Pyrrhic victory? J. Natl. Cancer Inst. 97(19): 1394-1395, 2005.

  709. Ferrucci, L., Guralnik, J.M., Woodman, R.C., Bandinelli, S., Lauretani, F., Corsi, A.M., Chaves, P.H., Ershler, W.B., Longo, D.L.: Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am. J. Med. 118(11): 1288, 2005. [Abs]

  710. Rezanka, L.J., Kenny, J.J., Longo, D.L.: 2 BCR or NOT 2 BCR - receptor dilution: a unique mechanism for preventing the development of holes in the protective B cell repertoire. Immunobiology. 210(10): 769-774, 2005. [Abs]

  711. Rezanka, L.J., Kenny, J.J., Longo, D.L.: Dual isotype expressing B cells [k(+)/l(+)] arise during the ontogeny of B cells in the bone marrow of normal nontransgenic mice. Cell Immunol. 238(1):38-48, 2005. [Abs]

  712. Lee, G.D., Longo, D.L., Wang, Y., Rifkind, J.M., Abdul-Raman, L., Mamczarz, J.A., Duffy, K.B., Spangler, E.L., Taub, D.D., Mattson, M.P., Ingram, D.K.: Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin. Cancer Res. 12(1):198-205, 2006. [Abs]

  713. McHutchison, J.G., Manns, M.P., Longo, D.L.: Definition and management of anemia in patients infected with hepatitis C virus. 26(4):389-398, 2006. [Abs]

  714. Feng, Y., Yuan, J.H., Maloid, S.C., Fisher, R., Copeland, T.D., Longo, D.L., Conrads, T.P., Veenstra, T.D., Ferris, A., Hughes, S., Dimitrov, D.S., Ferris, D.K.: Pole-like kinase 1-mediated phosphorylation of the GTP-binding protein Ran is important for bipolar spindle formation. Biochem. Biophys. Res. Commun. 349(1):144-152, 2006. [Abs]

  715. Ferrucci, L., Maggio, M., Bandinelli, S., Basaria, S., Lauretani, F., Ble, A., Valenti, G., Ershler, W.B., Guralnik, J.M., Longo, D.L.: Low testosterone levels and the risk of anemia in older men and women. Arch. Intern. Med. 166(13):1380-1388, 2006. [Abs]

  716. Ershler, W.B., Longo, D.L.: A report card for geriatric oncology: borderline pass, improvement needed. J. Gerontol. A Biol. Sci. Med. Sci. 61(7):688, 2006. [Abs]

  717. Maggio, M., Guralnik, J.M., Longo, D.L., Ferrucci, L.: Interleukin-6 in aging and chronic disease: a magnificent pathway. J. Gerontol. A Biol. Sci. Med. Sci. 61(6):575-584, 2006. [Abs]

  718. Longo, D.L.: Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure. J. Natl. Cancer. Inst. 98(18):1263-1265, 2006. [Abs]

  719. Zou, S., Sinclair, J., Wilson, M.A., Carey, J.R., Liedo, P., Oropeza, A., Kalra, A., de Cabo, R., Ingram, D.K., Longo, D.L., Wolkow, C.A.: Comparative approaches to facilitate the discovery of prolongevity interventions: Effects of tocopherols on lifespan of three invertebrate species. Mech. Ageing Dev. 128(2):222-226, 2007. [Abs]

  720. Lustig, A., Weeraratna, A.T., Wood, W.W. 3rd, Teichberg, D., Bertak, D., Carter, A., Poosala, S., Firman, J., Becker, K.G., Zonderman, A.B., Longo, D.L., Taub, D.D.: Transcriptome analysis of age-, gender- and diet-associated changes in murine thymus. Cell Immunol. 245(1):42-61, 2007. [Abs]

  721. Sredni, B., Geffen-Aricha, R., Duan, W., Albeck, M., Shalit, F., Lander, H.M., Kinor, N., Sagi, O., Albeck, A., Yosef, S., Brodsky, M., Sredni-Kenigsbuch, D., Sonino, T., Longo, D.L., Mattson, M.P., Yadid, G.: Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models. FASEB J. 21(8):1870-1883, 2007. [Abs]

  722. Berner, V., Liu, H., Zhou, Q., Alderson, K.L., Sun, K., Weiss, J.M., Back, T.C., Longo, D.L., Blazar, B.R., Wiltrout, R.H., Welniak, L.A., Redelman, D., Murphy, W.J.: IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat. Med. 13(3):354-360, 2007. [Abs]

  723. Chen, G., Ghosh, P., Osawa, H., Sasaki, C.Y., Rezanka, L., Yang, J., O'Farrell, T.J., Longo, D.L.: Resistance to TGF-beta 1 correlates with aberrant expression of TGF-beta receptor II in human B-cell lymphoma cell lines. Blood. 109(12):5301-5307, 2007. [Abs]

  724. Ferrucci, L., Guralnik, J.M., Bandinelli, S., Semba, R.D., Lauretani, F., Corsi, A., Ruggiero, C., Ershler, W.B., Longo, D.L.: Unexplained anaemia in older persons is characterised by low erythropoietin and low levels of pro-inflammatory markers. Br. J. Haematol. 136(6):849-855, 2007. [Abs]

  725. Stote, K.S., Baer, D.J., Spears, K., Paul, D.R., Harris, G.K., Rumpler, W.V., Strycula, P., Najjar, S.S., Ferrucci, L., Ingram, D.K., Longo, D.L., Mattson, M.P.: A controlled trial of reduced meal frequency without caloric restriction in healthy, normal-weight, middle-aged adults. Am. J. Clin. Nutr. 85(4):981-988, 2007. [Abs]

  726. Hayun, M., Okun, E., Hayun, R., Gafter, U., Albeck, M., Longo, D.L., Sredni, B.: Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model. Leukemia. 21(7):1504-1513, 2007. [Abs]

  727. Brodsky, M., Yosef, S., Galit, R., Albeck, M., Longo, D.L., Albeck, A., Sredni, B.: The synthetic tellurium compound, AS101, is a novel inhibitor of IL-1beta converting enzyme. J. Interferon Cytokine Res. 27(6):453-462, 2007. [Abs]

IRP Home     What's New     Contact Us     Accessibility     Disclaimer     Privacy     Site Search     Site Map     NIA Home    
NIH logo-link to NIH Home Page DHHS logo-link to DHHS Web Site FirstGov logo-link to FirstGov Web Site
Updated: Thursday October 11, 2007